var title_f12_23_12656="Adolescent HIV cases by race and ethnicity";
var content_f12_23_12656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Diagnoses of HIV infection and population among adolescents 13 to 19 years of age, by race/ethnicity, United States, 2010 - 46 states",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 484px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HIV: human immunodeficiency virus; %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. HIV surveillance in adolescents and young adults. Available at:&nbsp;",
"     <a href=\"file://www.cdc.gov/hiv/topics/surveillance/resources/slides/adolescents/index.htm\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.cdc.gov/hiv/topics/surveillance/resources/slides/adolescents/index.htm",
"     </a>",
"     (Accessed on August 20, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12656=[""].join("\n");
var outline_f12_23_12656=null;
var title_f12_23_12657="Lenograstim: International drug information";
var content_f12_23_12657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lenograstim: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1979247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Euprotin (ES);",
"     </li>",
"     <li>",
"      Granocyte (AR, AT, AU, BE, CH, DE, DK, ES, FI, FR, GB, HR, HU, IE, IT, LU, NL, NO, PT, SE);",
"     </li>",
"     <li>",
"      Leumostin (AR);",
"     </li>",
"     <li>",
"      Myelostim (IT);",
"     </li>",
"     <li>",
"      Neutrogin (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Colony Stimulating Factor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To reduce the duration of neutropenia and associated complications in patients with nonmyeloid malignancy following bone marrow transplant or following treatment with cytotoxic chemotherapy; mobilisation of peripheral blood progenitor cells for harvesting and subsequent infusion; treatment of severe chronic neutropenia",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Severe chronic neutropenia or following chemotherapy: SubQ: 150 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Bone marrow transplant: I.V., SubQ: 150 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution: 13.4 million units [105 mcg]; 33.6 million units [263 mcg]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10403 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12657=[""].join("\n");
var outline_f12_23_12657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979247\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979242\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979245\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979241\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821109\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979244\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10403\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10403|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_23_12658="Patient information: Invasive aspergillosis (The Basics)";
var content_f12_23_12658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/43/22195\">",
"         Patient information: Coughing up blood (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/5/92\">",
"         Patient information: Heart transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/59/25521\">",
"         Patient information: Neutropenia (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Invasive aspergillosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/invasive-aspergillosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H97977895\">",
"      <span class=\"h1\">",
"       What is invasive aspergillosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Invasive aspergillosis is a condition that can cause fever, cough, and other symptoms. It is caused by infection with a fungus called &ldquo;aspergillus.&rdquo;",
"     </p>",
"     <p>",
"      Invasive aspergillosis usually only happens in people who have conditions that weaken the body&rsquo;s infection-fighting system. This system is called the &ldquo;immune system.&rdquo; These conditions include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Neutropenia &ndash; This condition happens when you do not have enough of a type of white blood cell called &ldquo;neutrophils.&rdquo; Neutrophils help your body fight infections. Getting treatment for certain diseases, such as some types of cancer, causes neutropenia. Some diseases can also cause it.",
"       </li>",
"       <li>",
"        A stem cell transplant or bone marrow transplant &ndash; The risk of invasive aspergillosis is higher when:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        People get medicines before a transplant to get the body ready. These medicines cause neutropenia.",
"       </li>",
"       <li>",
"        Some people take high doses of steroid medicines after a transplant. Doctors give these medicines if the transplant is attacking the person&rsquo;s own cells. This is called &ldquo;graft versus host disease&rdquo; or &ldquo;GVHD.&rdquo; The steroid medicines that treat GVHD can make it hard for the body to fight infection.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An organ transplant &ndash; This can include a heart, lung, or liver transplant. The medicines you take to keep the transplant healthy make you more likely to get infections.",
"       </li>",
"       <li>",
"        Taking high doses of steroid medicines &ndash; These are not the same as the steroids athletes take to build muscle. Doctors give these steroids to treat certain diseases. People who have an organ transplant usually have to take steroids. But people with other conditions sometimes do, too.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Invasive aspergillosis usually affects the lungs. But it can also get into the bloodstream and spread to other organs. These include the heart, brain, and digestive system. Invasive aspergillosis is a serious infection. It can even cause death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H97977910\">",
"      <span class=\"h1\">",
"       What are the symptoms of invasive aspergillosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms in the lungs can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Chest pain &ndash; This can be a sharp, stabbing pain that gets worse when you breathe in.",
"       </li>",
"       <li>",
"        Being short of breath &ndash; You might feel like you cannot get enough air or have to work harder than usual to breathe.",
"       </li>",
"       <li>",
"        Cough &ndash; Some people cough up mucus or blood.",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Symptoms in other parts of the body can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stuffy nose, fever, and pain in the face",
"       </li>",
"       <li>",
"        Eye pain, vision problems, or bulging or swollen eyes",
"       </li>",
"       <li>",
"        Seizures &ndash; These are jerking or twitching movements a person cannot control.",
"       </li>",
"       <li>",
"        Rash with spots &ndash; The center of the spots might be black.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H97977925\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam and learn about your symptoms. He or she will also do tests to look for signs of the fungus that causes invasive aspergillosis. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Tests on a sample of mucus that you cough up",
"       </li>",
"       <li>",
"        CT scan &ndash; This imaging test uses a special X-ray to create pictures of the inside of the body.",
"       </li>",
"       <li>",
"        MRI scan &ndash; This imaging test uses powerful magnets to create pictures of the inside of the body. Invasive aspergillosis sometimes spreads to the brain. Your doctor can order this test to check if he or she thinks this is likely.",
"       </li>",
"       <li>",
"        Bronchoscopy &ndash; In this test, a doctor uses a thin tube with a camera on the end (called a &ldquo;bronchoscope&rdquo;) to look inside the lungs. He or she can take samples of fluid and tissue from the lungs. Another doctor will look at the samples for signs of invasive aspergillosis. You might have this test if other tests do not show for sure that you have aspergillosis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H97977942\">",
"      <span class=\"h1\">",
"       How is invasive aspergillosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to kill the fungus that causes aspergillosis &ndash; These are often given through an &ldquo;IV,&rdquo; a thin tube that goes into a vein. Some people can take pills by mouth.",
"       </li>",
"       <li>",
"        Taking less of any medicines that make it hard for the immune system to work correctly &ndash; You can do this if your doctor thinks this is safe.",
"       </li>",
"       <li>",
"        Doing surgery to take out infected or dead tissue &ndash; Doctors sometimes need to do this if aspergillosis affects the sinuses. The sinuses are hollow areas in the bones of the face.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Depending on your situation, you might take medicines to kill the fungus for several months or even years.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H97977957\">",
"      <span class=\"h1\">",
"       Can invasive aspergillosis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. If you have a high risk of getting invasive aspergillosis, doctors might give you medicines to help prevent it. But the medicines can cause side effects, so you might not take medicine unless you are at risk.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H97977974\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/43/22195?source=see_link\">",
"       Patient information: Coughing up blood (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/5/92?source=see_link\">",
"       Patient information: Heart transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/59/25521?source=see_link\">",
"       Patient information: Neutropenia (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/23/12658?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83434 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-C2C11C53A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12658=[""].join("\n");
var outline_f12_23_12658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97977895\">",
"      What is invasive aspergillosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97977910\">",
"      What are the symptoms of invasive aspergillosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97977925\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97977942\">",
"      How is invasive aspergillosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97977957\">",
"      Can invasive aspergillosis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97977974\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/43/22195?source=related_link\">",
"      Patient information: Coughing up blood (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/5/92?source=related_link\">",
"      Patient information: Heart transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/59/25521?source=related_link\">",
"      Patient information: Neutropenia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_23_12659="Penciclovir: Drug information";
var content_f12_23_12659=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penciclovir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/20/33091?source=see_link\">",
"    see \"Penciclovir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/19/7475?source=see_link\">",
"    see \"Penciclovir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Denavir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F207427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F207404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Herpes simplex labialis (cold sores):",
"     </b>",
"     Topical: Apply cream at the first sign or symptom of cold sore (eg, tingling, swelling); apply every 2 hours during waking hours for 4 days.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F207417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/19/7475?source=see_link\">",
"      see \"Penciclovir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Herpes simplex labialis (cold sores):",
"     </b>",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F207405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Denavir&reg;: 1% (1.5 g, 5 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12990456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply only to herpes labialis on the lips and face. Apply sufficient amount to cover lesions and gently rub into the affected area. Avoid application in or near eyes since it may cause irritation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F207391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of recurrent herpes simplex labialis (cold sores)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F207433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Denavir&reg; may be confused with indinavir",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F207425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Dermatologic: Mild erythema (50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Application site reaction (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%, postmarketing, and/or case reports: Erythematous rash, local anesthesia, local edema, oropharyngeal edema, pain, paresthesia, parosmia, pruritus, skin discoloration, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F207394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to the penciclovir or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F207379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunocompromised patients: The effect of penciclovir has not been established in immunocompromised patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Should only be used on herpes labialis on the lips and face; because no data are available, application to mucous membranes is not recommended. Avoid application in or near eyes since it may cause irritation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13376203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies following intravenous administration.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F207407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13376204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F207397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Denavir External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (1.5 g): $115.32",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F207388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction in virus shedding, negative cultures for herpesvirus; resolution of pain and healing of cold sore lesion",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Famvir[extern.] (CH);",
"     </li>",
"     <li>",
"      Fenivir (BG);",
"     </li>",
"     <li>",
"      Fenlips (IL);",
"     </li>",
"     <li>",
"      Keyou (CL);",
"     </li>",
"     <li>",
"      Vectavir (AT, AU, BB, BE, BM, BS, BZ, CZ, DE, DK, EE, ES, FI, GB, GR, GY, HN, IE, IT, JM, NL, NO, PL, SE, SG, SR, TR, TT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F207378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In cells infected with HSV-1 or HSV-2, viral thymidine kinase phosphorylates penciclovir to a monophosphate form which, in turn, is converted to penciclovir triphosphate by cellular kinases. Penciclovir triphosphate inhibits HSV polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F207393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Topical: None",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alrabiah FA and Sacks SL, &ldquo;New Antiherpesvirus Agents. Their Targets and Therapeutic Potential,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1996, 52(1):17-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/23/12659/abstract-text/8799682/pubmed\" id=\"8799682\" target=\"_blank\">",
"        8799682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9746 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12659=[""].join("\n");
var outline_f12_23_12659=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207403\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207427\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207404\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207417\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207405\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207390\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207375\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990456\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207391\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207433\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207425\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207394\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207379\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299836\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207384\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207386\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376203\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207407\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376204\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207397\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207388\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038722\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207378\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207393\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9746\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9746|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/20/33091?source=related_link\">",
"      Penciclovir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/19/7475?source=related_link\">",
"      Penciclovir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_23_12660="Infant humeral fracture healing";
var content_f12_23_12660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Infant humeral fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 339px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFTAggDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UoorUlaUzqUBLBsBR1LfT15oAy6K6vxBoOq+GtUj0/XrCW0vPLD+XMgVihHBHbHbv0NZUhdichlUtnHfngD8qAMmitDezZdwRuGAAOnQ4/nSMx3qMBckLwMjjrgfWgChRVkbhGSuScEEgemBSM+4gADGBkHuf8mgCvRVoNyue/HPt/jTCxb+I4IHHrigCCirK7TGxcktjPX/AD2/lSKfm+Q54HH60AV6KubXkC7Dlc8bj0pDC20Y4bggDOeRQBUorQihLKQuVJXPJ6D1/lUsVsP4gwUgA8evP9P50AZVFb9rbyhlKZLBuu7I4z+fSt2yvLm2dFUlhwCx4B+npQBwdFfQHhHxi8L+VcRp5gwoYDAz/jXrei+KbedVVwuMALz2zQB8SUV+kWh3kF1bR+XIu4DnDc1uRurspU8jOSe/rx2oA/MGiv1FjZQpyo4b5gK+Nf2zDu+KOmEgD/iTxdP+u09AHglFXLQ4ifIzk457+3412d18OPGFton9sT+H9Q/s3yRcG4SPcojI3buOQuOc9gc0AcBRWkEBjBz/ABd+zAf/AKzSRDDRlcMDnLDpmgDOorULA4XAV2JweeT9PSg+WAxUnJP3uuDn3oAy6K1WYtlUXJ5AUt0/xqKMtsGW+Y/d4oAz6K1ozxk5K8kkccelOQkKygKX3YyeuM9qAMeitsJuYj5hGDjjjPFWUjwApXEgPQ8igDm6K6po2jkAGdrr93Hep0WNMHI355I5I60AcdRXaPGu7KFeO3v2qzbxCQjCFs+vb60AcFRXpEcBdQFjB5yQBTPK5Ys+B0+n59aAPOqK9BMILhgoIZcE+tQyRBg2QFPTrQBwlFdi1u7SBSyqMY69AKfLBsG2JCSMbiBQBxdFegW1mUB6Bm524JIPcUy6tgFZgCG9MYoA4KiuteLcFBJjIHBGce9TCNWUBzk9z680AcZRXZvbBWY78E/wjmuZ1cFbvBxwo5HegClRWxpB/wBEkU7iu7LAdMcV1eieAfFHiXTW1DQ9Guru13lBL8qrIw6hNxG78M0AeeUVryuY5GSXcHj4YEYwenNRsx3MSR8vXB4P0oAzKK1A+1sYJJHXOOK09OeIOroMMCBk5yooA5iivTrO6jtJN7qjMvITqM9uP1qW3updRuGlnLO8hCnJztH49MUAeWUV9NeCtPRfKaVgWb5UYnv/ALXtX0n4P0a10zTkKxAyuPmYjk8//XoA/NKiv1H8pEjdcAKTjHTn/IqvOoKSEjjPJP4UAfmBRRRQAV6J8JG0WHx/pF74lvY7TSrKU3jmX+IxqWSMDuS20Y9M153WmvMahkKhhkZPHX9eDQB7J8bvFvhvxx4d0jW9Ov7mbWLW4mtbiG+jWKdoXYyxttRmXYm4qOfwrxlyxZm8zLKNpAXnjnOPanrskOdgTrye59P1/wA4pE4VQqbQQQT6+nP1H6UARKuFBPDZ9MjB9aVvlXruOd39alz+52x4YN8pYrwT/k/rTUJyoCr1wrN3Xtn04oAhZyAcE5IA246fSmHZxnkAg8dMf5FWNuxjlSoXAJY565/yPxqBCpXhQX756daAGcqckHdyMnmnru4IXJBwcLn/ACaeArFWwpEjbSce/wCnFKFRVbLAg5xz0wOD/n1oAgCn1YA8dOvtSrsCjoCvXOSf5VbMR2rkAKeeTx6Z/OljjbcN4HljnC9D2/PgUARwxnnPIJBz685/pVyG2A4MRRehG7IPYHpV6ztgYiHRWZ/XjBPNaMULLICxA3A8KvGO/WgDMitVZZApLngg5z+HtzVm3tiIdoyACflx36f5/GteOyGf3fOfb9ferQsQcHLEdQc8YI9utAGKIdoUmLLAcYPTn3qxBb/MQNwX0xgYznA962I7TaNo45zsbkken8qtLamPZgg88+3vQBQisx5a4bDAZB989K2tH1O4tSVkyEHOW659BTYoG8xBgE9sHp/h3qxLaBzvxuCfxEZ/X9KAO40LxVNEqGOUR54KnnA6GvSdB8ZSHCzxsYn5O0g57dK8LsY5JcQ7MyDqApxj/CunsYLqGFHU+UQOV/8ArUAfQOka9FfRB8jJ+8Cf1x+Ir5O/bHkjk+J2mtFtI/siLJXoT501ei2+r30ZZcg7T82D+VeJ/tC3kt741snmXay6fGn5SSf40AedWgkZNsbNndkAdvevqu48XeEP7KS6m1bQ0jk8LppU8trLOdT3+X/qkXaY9u7Az1684r5Vs/MVNyKSMkcdOneplPIVDjkjIHJ/z60AI27cvzY7A+hOecCnIScADg8bsdDzz/8AXpEyhIjHzZ+Y9QfTmmF8gfK3zEYwPT0NADw52nDdBjgc/rTIyVCkHAJ7dvbNPZQQVwcBRxnJGB/+qnIgCx85Of4fegBCAy7gRjnqenfApuMksoBbdnaR2xT/AC1DqG3dMEDsRUu350SNmxnIw3Xjr0oAigVsEFeXXAwMcfhU0EJkl+6ofOBz+dMXKy7lbdjgZ44z7VbjiwyJtBO7t396ABV2uqqM8de1SiHC5PymT5sirCxuFjIdfu4APuP8aRl2Oo3MzFcdOtAB5TthwvQjlW6+/tU0Q3KAME5JwV/+tTQpYqcqh3Ebc9RV21VUXa8mPwxmgCAL5rruU4BOd2SRUkMDNOECgDGeuD+tW5IfnUJ94DGav29gE27xl1GRjmgCktuScbT5YPIJ6+lTm0c/eBCBfT7tbEVuvl4bJHQAHj+VOW3O3aSeuD0z+dAHPsgYjgkr6Aj9aiYqAWKkAH3rop7H91ujA+Xquev4VhSMqFgd27nJ9KAM5oydpYfKTgkZH6GlEZ6KRyffpVl1B4AJYcg56VWO5XZt+GJyTnigDqdJtRLECVwPccUt7pqeU0Ui4BGRx3qHwxeNIpiZgDg7eM5roiPlCHOwHk0Aedz2jRyqeQFPVmO3PSnJbHA2ZbJxgE4x/hXYeItLZD50SoqMBllFY0cPlhTsYsTyAOvuaAKUdt8g3b855JNcb4mjWPUyFGAVBxjpya9NjthtdniYtnnB6mvOvGahNWXaScxA8jnqaAKmlsfLdegznd3HSvZtXGl+NfCXgv7J4r0zQ5NDtfsl1b30jwvG4bPnRbVO8sMHjnIFeOaS8QgKS85fOPy71NcF1JKqTtJwcH+XFAEFyR50wSRpSHx5uSN3PX15qAPtdzgD1yAOfrUrhGLNxsVeMtjvQ0asQvB5/iz1oARE81Q2CTksQp4H+Na8Vv8Aucy7sAYGO9V7CIhjj5TjcNorptI0p70jdlY8jLYGSaAKWn2jzbW6x5A56j6fWuw8PaeS6gBm3H+I4Ga6Xw98OvtSIXvoSCApUKSVP+cV6n4X+EkOwSS6iM4+UKgNAGB4Vs2gv7RdoO1g2Mce+Owr6ItijW6bRgbc1z+heDdO0YHZvncjlpOmR0wK6LkDKnjt/wDroASQqFBboDVOX/VsjYLA/n9atyAHaOQOn0qrc4AYgY+XJ59j/wDroA/L6iiigArWHytgjIUnlj6881k1rqV8yQsodSeADkZxwKAISFQqvLrgZ9D0qbcnmnBclxx24xz+XNSFVCEhlZRhiN3CknoPbnr7UrD51UhS2Aw4498/XAoAgSRVjXZyXJ7/AIc/pzUcJAKSMvILAAnrj196m6EbcblGfk6E46frQ/zbmUgO3UL/AA4HfNADV2IWL7TlAF9jUbKpfkoDncd2O/f3HHT3qfy3YH7hUhic8DscfnSEZDbgG3YLHHQY5xQBCyB5FjPUdcD9aY33uu5Q2QfYn/GrIieSXKqNuATtyAB0qeBCu1BuzjbyvT3oAggQyxPvC5+8SMZJP8u5/GtK3gAQoQ4z1IPPJ9fyNT2loZS7MvQ+ucjp/Kr8cIRSwU7ehwMen+fwoAjityG2Bsg4yD19cfnWlBAuCXAUAjhcknj/AA7VJZRANGcAj72SOMVoBEZFXHzDqRyCaAEtYzkttKLwAPb/ADmr62udxUbRgcBun1/WltYxEr5Uu33AVyDz61s28QXduGS2OFoAy1tXbB78Y/LipbZC4YqAnGDt7Z9q1EtiVLAYXAxgcj6/pU5tG3KVyGUYI6Aj8aAMwWpKlcY6cjk/jWjY2nmzLCCwBXA2etWLe1OQDE2QOn8vrWzpkcdvE8hbcCRj6n+VAE1hpSjy1tlbzD6nLH6V0+naYskzYRcKO/GT71HpiJ+6QAowPfvW9ZxN5qmMgDgsc856/jQBiX/h6Rp2kiQsigE7eMV84ftDxCLxtaL8wJsEJz6+ZJX2dbRB4FRdpVhwe5P4f54r5O/a4iji+JOnCJFUHSYido6nzpuaAPH7I7YG6HLAAEcZ6ZP51L1bepMgz17gDjFMsV3Qk8H5uF9Tx+VTKihAuCUz8pB5Pt+tAEZ+Vm2cbuOD6cVJGEKKCu7Htx+NMZd2duQyknHXv/8AXpY4y7Ke45BA4Ix3oAi2fKo+ZTkggdT9anVCSWAHzDa3PA5qQRD5guc55JGTnrg1ZjhLR4bCMBznOTmgCsIf3gkUAYx7/ripUhbKFuM8EE8GrXlZDDyxkjoBxipY4AqHrkDjA56DvQBWiiJHzHdkk4A/p/WrEEG1gG6HBL46DtTkTG53yME4BHUCp4gwIVgAuM/dyQfwoAI4y4SMjAGB16d6kjtyyDIGVJBJ68+1WIwFwOVYD5c9896fEpGRjPbr19snpQBW+ygAk8EAbhnOfrVhY1L5wd2R0PFWoomkkCgNluMAZOfavQvCHgk5W61GEoxwQjDp9aAMLw9oUsv76eI4xwp/+vWxJpvkwMf+WhP3QMk/413sdilqJAqowzwCOQPpWRqESeYy5OSMZHGP6UAcTJbmNsAhmP3uACvsaaIWU7M7ScjI7VtX+1AcDIUjlhgEVSuYwIy3zbB0G3FAFLBjfsx6Y/8Ar1z2pILeRvl3Z7NzxXRyEkElcNnAwOAKx9X2s+A2CAB06UAYDLkfKpAB4G7BH4VBt8xSzccdzz9TWg4G9uMBcZ781AQyuyeWcEevBoANNMltcK0cmWDbt2ea9T0m2XUbKOeT7xXBUDt6Y9a860y0Ms4QEh16bRwPrXrnw7t2lkW1fG7GRu7jNAGgdEW70+RdisMDAxkfzrg7vRp4JmRxgrnBC4Br6Q0Lw8zI6zLGydnXjFc/4v8AB7xxPNHCg2klcLnrQB4I1uIWPmY2gZJHHP8AhXlXj0Y10AMWHlDkj3Ne8azZNFAHWNyhB+fb1PfFeFfEEY1yPluYFPIx3agDM035rYouCxf7vqMCpFRQr5Lr2HBPHpRpIBtDxkiQkYGT0FSSqRgbsqO6L1NAFOQLvOFG7HOT/WpEyzjCZxj5ie3vRGMyP0brhenvxVy2Ee0MU4JweeB6c0AX9Nh8yRVKBSx2nae/vXqnhjS9ypHFGhGAST1yO9edaThL6IhUKddp449K9l0ya2t7aEtIEUAHk/Nj8KAO40S0ljPAZmODlTxmvVvDFtcxafH5jbnPzFun4CvFdP8AEe11axhMjIdokY4A+grtNG1zVtTv4LcXxiR+pRQMf5xQB6s3Tp0qJgBySQBzxUenRGK3VWd3JH3nOT9amYAjPccUAQTNkAHqD1zUMzkxmTpkdT2/D8alcjMgOQD0+tQSqEiZVO4qv4UAfmBRRRQAVrRSEMWwGY4PHTPX/DmsmtuJnZo0wHihIA/2h7etAAi5ZSCCV+6WGQT1P4YIpQSB88Q3bMkZzgZ/zikQ7/nPJbJGw4yen4dRVlcFW7tjGD1J/wD15FAFUKWV1aPBTIA/iJwf1pgBd5HU4AG/BXktjufxq1ht+3gzn0BBGO/XrxTLdVEw6DIOR1J4oAj8oQvtC4B/Tp/gadBAH4HLFguVPXv/ACqaJZAUVgu7b1HGQAOPzzU0caK4cBshug6DqKAG29uqF8j5Sp42/wBavw2jsQ0n3V6ZIHbimwQuTGroVAXjd1/z0rVsrdAQCoO0bef6fpQA+zgMcRJwoI7Lz34960RABGSybs9N3HFWraH5EYqQ7E5B7Vb8lRnA446jp6f1oAz44AZFUMB0wT71fWDy9hQB1zyu3p+NWnRTAxQR8sCwJFTJEFJdlcZAUbeRn8aAG2+GHlqCBznnjFaNsqkq2QT9TUKw7yDFnAzwB+dXrOGTLDyznocen1oAmgXKjCZ9eeO/Wrnl5fCdTjOOfyNLHazqMpC68dD7j1qSKGeM/OpBxnGe3qaAHhd2QAQnHpn/AOvT4o3iLq2eR1wPy96UIX2oGVvl59TVgoXiKOoDj5lPB49/woATT7+S2YM2SD2x/n0rptL8SxRxqJUKqo2jIBzn19q52OFnlO8DbkDG0Y9fxqWONVlGRjp17H1oA9Z0SeO6QqjlgwwOMZ/L0r5U/a/XZ8S9NHB/4lEXPr++mr23Qbi6tb2IRTENuB2ZG0ivEP2u7gXXxI0uQKFJ0eLOD386agDxyyBaFsKCVbPJ4PtVr7uMqoCsXAHPTufzqtYgeQxIyd3A/KriLtjC8KxGR6j+XagCKONt7YBXnkHn8qmhw3yyAjABIx39ajXarZJUhhtLemRmrkCKHWNTuUKcexFADI0Bd1USZznAPX1/QVdiTA8zLM57HntTYohIqbidpAIbHcVo2Fm80zFEPPAJPt2oAhhjll8oYLIPmyOx9MVbFnKB8+M45H972zXbeGtCjng3OQSDgDHXjp1rdPhm3jQTFJPn4CnBFAHly6e6spXknOFxxUq6VLsZjKAcEkV30+jrbswQgrnGB1NVv7Pj3KCqp6BscevSgDjFtnjZcA4A9OCKtaZpt3fXUUENuzOenzZ/yK7LStBfVL5YYE3HAOCOMV6fo+h2fh+2UlEa5yCT6fgaAMHwj4Ii0ZEubv8AfXZ+YLx8ufeuwa1RpRnd5hPHPHFMFypnwp+ckZIXAI9/Sp53CK4VsucADPTNAFd4SiFpGCnnGBnNc7qrZdV44znHNdFLCyW4muXIZuQoIP4Vzmv3EKIrBfLAHOT3/LmgDldXt/lbIwADtOehrn5JykIJO5l77ufyqbVr/wC8UO1RnocCubS8UzElw/cA55PpQBsNcGVJMY3kYU+v41jXu6eVGMgbAwwB6D60yTUST5Zj4xnjnFRxSsZBnqec7etACMHXp904xjNJEh3KgcYDH5a0Y08xCwU5z096SGMNIAifKD0x3oA0fC9nvv23LncM8LnFeqeArUp4hs1KlYmbBxwa5jwlYgShtoyBweM1614K0xY9ahuHYHaOGx2+lAHqsMcduiIoxgY4FLdW8d1A0UnQjFU5hJKN67gahF19jiQOwLFvqTQB578RPDcgj3W8KmEDGFx8vv8Ayr4/+MNsbXxWiNjcbZSQM8He/wDhX6IskF3BtlCSqRgk4Oa+Iv2t9Ig0b4l2UNqWMcmmRy4P8OZZhj9KAPKdI2fZmOSX38LnjGBzUs+5jJtwuBknHb14IpujJvs5MKS288jtwOafcDBCmRR3VuuaAKkaMXyWXIz0GR7VqRPvI3EYbHPWoIoy3JADDnls5FaEMYAYKo+ZercEDHBoAv6dEVZW6ruzwucnsa9Asid4ZshlG0Hpj8a5HR4wkaeZknhef/rV21gEaEBEcEEZAGc+1AHSaGdrFVKlsZGRt+nP5V6h4CkiTVA21t2NpJbgevNch4R0Ce9WFxGM5yquPuivatI8O2tkiOigSEDJI6fSgDYgLADcD35wOnapTg+h/rTCHVCPvEDjtmqgu1+0eSwIPGD6HFAFjbge30681UnQbMFux57nn/8AVV4fMeSM9agmiVl+fJ4YCgD8t6KKKACtgxMjKxxt4yRxgYyc9++ax63i2LcgBsMp29OOPf2xQAiBhGibQARnIbtxyc/56U6JA/m7eMkHBbrwaduJVt+QCo7dzj/9dSDMpEnyjYxPB6DAxQBCQ5GAQShGOecc4+uOKBG6krlAHPBOc4OOMVIuyLyoh82FwQeuM5PHvU9tFKEb5F2qcDdgE/T+VACJCTtkdm4ABCjOOnX361ahh8qUMSd3Kntn/OaswRFAjKOWGQTzjgVfjjErMVwvfk5xQBWtLZgEXDZ69P1z09a37C03vnIPQN835UlvAzs20YwQWJbvxjitmBSB8qtsAHegBq2q7Du3bgo4GAScVPb2+7O/hsZ/zzVqEKYhk7kyAQMrx6fWpcKzkfMVP3cjOR7+9ADoLUCQEjjH8WPyq1aWXmzAoMgnlscUi5wFyAB198dq6Hw3bs5kLLuVTwoFADbewKrsgRdknBcc5P8AjVuKxZF2ksADu5PGT6f/AF66SzsiHDfeI4U4xk/54q4unKwCHJHG4Y5+n6ZoAwYbZw43MMHgDGRj1q59mJYjKnnH1Na5sW+z5Ayo55A4HoPelmi8oBQoBzjJPO32oA5m604Rt5sCjac8ZwMVnGIMNzI53Y4zyDn/AArr2j+eRCv7tc4AOAqg9vXPX8Kx9Utgj7uMNkq3Oc/X60AVYYlPMkeWBAGeCPTj+tXIYE3fvBlWwuc8n1qtAMxAbW+b5iVOcH6+lXLBfJiydgORgjA2gd6AL2mWxJiREPDcLt69OM18/wD7WMfl/ETTF5x/ZERAPp5s1fTekiPzwXcFge3fJHevnD9sX/kpumdMf2PFgg5486agDxnT2KW7HaShbDcewqeR3j2lznJ+VgMk+3tUGmgGJtx4Jx9OnNXEVSdx5J28/WgAtEdup2YJJOc5NaixkIWUjcG5waqW8RERy2PlIPPfOa1LC2efy1jJP0OTnPUf4UAS2ML3EqgEBRyRwcf4V3MPh+axt4JXj/cSKGGw5zUOhaOkVzBEofLsN2OtfQF3oFvNoUVsQqq0fysOqmgDyXT5IrZE8rg7uhP559q0dZ1XypIsFTuXk46Gr2teFbmxkULhrcry+TuzXG3dlcfa3Qp5gye2MGgC5a3s93P8pDJ3ytb+naDJqE7FiEibqXPH4VR8P2UUYHnIucDknFdDNrZ8sQ2yrHF06YOaANvTIItGiFvpyqwx8zgZI46CqM7ySzEF33lhj+9VeIyykMn3s7RyR+P1q1DGEj3yY3HI3t94e9AFm3uWSP8AergH3GT9ana6htoxIdsaAdWxx9K5PW/FtppEbIR5sxHABrzLXfFGoanw7eVEegXjP40Aei+I/GdtBKEhkWVxkrt4A+vauB1rxI10+6SRvl7Lx/8ArrmpmLMST1HGcmq7PGy4UBixA2gf1oAnur6WVSpbaDlsLxiqES/PlGIA6hu5p0pKNtPzAdEPepbMlmXcduOOmDQBKgfdukAYDvVuELt3A/XA6e9QuAqcZZj/ABYNTRFFw3IbPIx1oAvW+XQgLnPTnP6ip4Q0Uq5ZgM9VNQ2c2UwDhmyematFy8hAfqOo6nHbigDuvDs0rGEMoC44yP8AP8q9c8GLFFLGypunY8EkkAV5B4OH+pkDjJGNvt9K9W8PO0U8Zg3ZB+8BwP8ACgD1NZQ1uWfbkDnHY1wPiK8X7STudU6Nj19vSteW+KQyM0+0j5mwcgiuOuXimmdwdzdc53bhn+dAG5oOpuZ1ghlLoeTITwMdulfMn7YOf+Fl6ZukEpOkRfMP+u01fSvhSGK5vmiXZgEEIORjrxnvxXzl+2dEkPxQ0pI12oNGiwP+209AHkGjM39nuvzbDIeAM84FPn2iTIGdwBxtJ59M9qboe17GRC207yevbA6VO6MwB6xA5J6ZP4UALAvmODHCwx0UD7xx+prYsIC0rqkRQsMBeufbPpWbZxyZwCWOACzema6nQSovYfMywDAEHgjnp/WgDpPCnhq4u3XegUgD5j/Q17H4Z8LwWPlnYJX+83INYGjOIjGUKqEHYbjXdadcGR45S65xjJHA46UAdDodxBbEqVjjdTwo6Ae3vXaWkxmjDMCrH+E15iLjyJN7yfvEPUEHP1/wrVsdezIVbeMjG7pigDvi64yDkD0rE1+X7PLFLGB83BOcZrE1HxE1m7s0ymLB5HAX65rldQ8UnVnVWdQoYkFT1xQB36aqFlSNmLScDAHvWmlwJomXvtPArzCDWGjwAMqORu71saNrLsZAX3Kxwp28jPagD886KKKACtwKxJYg5xtAxk4HU4/KsOtnzCnOGDfMCTyDgcn9OlAErDe7bR842hcewB6f560RhN+5SqjBQ/Nwe/8ALNBUs52ZyF5xxx14P6fhU8UB80KW2Bh+Y46H/PWgAs4t7g7hnIVsDBx+P4VtRoIcMgBUg844x3zmmW0aKxZipKnO0cbcdsfjVqKJ5IgR91uhbH+e9ADguEyoAJGFBHX/ADxVmFB5ozGzKc52DqfT+VTWNg+cspLDGcDv2rctbJgsZiAORkhhx70AVrdHVWJiKqwyMjP41sWW8vhcbicjJ6DFWJIA0bNIOR0x1plqqxunBG3vjrQBMIZCQFRSoJPze/0q0kZIwIwHYdFIpEYLEQrDAOPu4FSiYAEbeccYxn+VAFhLEMgAkAGOfr6V6B4Q0QwWXmSnJc9+461w+mbru9t4ASdzAD889K9o02zWC2iQ4wD8vsB1oAktdOgTeuApIBHp7D9KtfZIYkPQHAJGOc56/wD16sBSFYqOQBuC+3SmsFyGflT8uMdQOaAI1hUIGbGMgMWA6VXvLeOVcsANvp1x3H1qzCRvZcnqOe2O3ao5QGChzlgvIHIz0wfwoAzZIoiQ/faMqpGOg/xNZOp2ETRZDudrYHPQ5rV1DCI4JxuYkcdufyrFuLtBAg3ZKjP60AU1063iJIBIJG48fiat2mn2ymJSzAueCnGfr61TidJCGVv4snnAI9+KvwA+XEoADB+gPJz/APr6UAaOmrHHNE+4EKCNhwMc5z7jvXzX+19MZ/iVpjkg/wDEniGR/wBdpq+i4TlXyCpIDc9+2K+Y/wBqF3fx/p/mKFxpkYUA5482XFAHmektsgY5XG8cd+nBq4rERZEYChSTtPbris/TU3REsMru5H5VqRxZUKR8uRjtntQBaiBQHd94kEduOtdn4btykBkj4kzjJ7D1964+EA5DE8DBGOo6ZrrPD7ymRYow6l8Hpkn1NAHovgm3EuqwS3GAwOWPc/nXrwukupfKV3EYxjHOMf8A168k8H2krXTyupY53AEY7V6P4eunEj45RsKf7v0FAG745WAeHi0DqMKck9vevDbiZoIzIEwA+S2c9+nt2r034nao1vpgjQgs643MchhXicEj3UwSYbUHIXoD6fWgDWfWNziLGzLYBU810ekxzXzLljIg6ALgA1z2nQ6fA4ed0eUZ4PUil1Lxotmphsowgxt8zGO/p+dAHaXuq2ukWeJJVafHC5yCfWvKvEPja+u5Xh83YCSuFrL1nxClwkoiaTzD98sT0z1FcnIzFgpMhAyQ3B/GgDYnuXmceaSXHPJ5zUayiVQXXBzkDpg/0qisgePBDZIyABk9unf8akEqrIwZtzDA6Z78UASSA7BhtxyQR9KSQqFf5ijDseo/WoDINpaNiW9D16803cWKjGX+8O/AoAfI5kCndiN8AZ5P/wBarFkS0DBSCR0K1SlYsowPLJb5eenvmrlupVQx4OMZHQ+tAE6ZBIYljjPc4qZQVwCvHbNCOrsMsM+p5wafjLHzOvueMUAXECKNqcZ+92FWVBfaRuZF6gcflVS3XdGOd+OBk8flWkp8zZCGcHADAdKAO58HhooklZd3QDd2r0jQFaIg7+CeMcD3rgfDUC/ZYVw4cn5cLxz716FYw74gpkG9Rzxk59aAF1KVF/dgsc55XkisqWVPKjcrtfGGyMfl2NXJrSWdtwZfM6ZVeeKvWWhmeRfNeUqvGAfu0AdP8OrREW4uDjf933FfMP7an/JVNM/7A0X/AKPnr658MWcVhaPHFtLFyWI9TXyL+2kc/FPTP+wNF/6OnoA8f0JWNjIQGIDnvx0FWnmdT1yCM7fXH/66r6A3+hugXkydc8dB1q1MxGWQLjr16H/OaAFsmLSF9nDd+M5Hoe9b2lyZuNyoxcnJGcj6ZrFthwFEaheq/Ng5x0rYs0ZXTYRkfeBPJHsPWgD27RovMjgdWA3IDk4wvtnsa6y0JQRlGYj0HrXD+FNk9jDJjqgzhiPw+tdZZyrC+JBkgZODkCgDWZmZzkgqRzzzTBKVKjcTgcDNZ8t9H/DkleRnNRXNwrhREQTIuOR2oAyPGetrA8ds0uQwycHII9+1YGm6kUUZcKRnC7u/X+tc942v2bXrgD94kXyr+A4H51k2epMWC/I3zbuT2x6/WgD1KHUmKIVdmLc9sjrzj8K0rfU2jXKS9s/MvTPv3rzC01d0jEmcFSeT0Occ1rWWuJKhDMDsHI7d/wBKAPm6iiigArZVThi7EImTk88n+dY1dKnzkHlsndtJAAweM/mKAGRxh5g6qcHuD046foK07aA4IfG7OcnHfHb+vtVWwV2kHyDdnrjjJ5yfbP8AKujih+UvIy4GCNp6e/8AL8DQBDYW4DoowzHuTjJJ4qyYzCWHzMfvZbB3fT+dWbeNjgRggd2xkZ9M+pqZoPMm2dVz1bAwB6YoAlsN+1l2kKWIZiQTj/8AViujt4mCLtIjwDgqcggdf6VRtbUARRQKdzEANnAOema2bi2uNOn+zSoElzhiDkY7YI4/KgBIJAWKPIDkZ4HFSbQ5Hy/KOhHGQar3CCNF3kEHgDHf61Vt5+WPmuQR65x7CgDSaJWUjPyr0AHvTM+Wwyw3Nnnpx6VLZzK6/KzAnPBGMj0qeC2Fy6JGWZWO0Dqc/T0oA6b4e6Z5+oPcE7kiHGOR17fjXq9qWU5OezZ5POf8e1Yvh/S49G0qOJV2OflZhyfx/wA9q19x3KSRx1B6cn+fNAGglypctkD5sDI6+/vSMchMc7TjJwcVnXMo2ZxgRnkE9++P1/KkNyPKP+3nlDz259OnP50AW9yRSoGPQg9PqP8AGq97L5UOFGHZTn39/wCuaoSXy5eQMDGxwrZ5565rW8PRx6zNJcsmbeM4AzgN/wDW60Ac9LbXWoSMlvFI8eTggZOM/wCRVWfRL9N7yWzlQOcLkAe9etIqxgLGqqo7AYFIQCCuB1oA8Unja3iO/OV6EfdA561PbSIyKuWOCTgH/CvVNU0m11K3dLiMKxBw4GCBXnGrWB026ZH4yTs2/d/L8aAJIXVih5cFiQRwQODmvmT9qAg+PtPwScaXGOe372WvpKFjuVvlCkAKMnp6H/Pavmz9p0o3j3T2QEA6ZGTnrnzZaAPNtJOIWzkLuPzZ6HFacHzRKzO2AeCR19qydMYLbyZDdeo7fQeta0QIIXGCevo3PNAGnpsCyTIBjaSAMnJwOx/zzXpGjww2ckQhXeSvQgnBrznToGnnijUEAsD1/P8ArXpWg28MsybxxGuACM0Ad34ftlQGUNhsEKvQ/wD166Xw3draibYCx4JBGCtcn9peCBFkVQ2AAAO3r+VdV4eYzoVYoEdeT3H4UAcZ8QdWN7eBXRWToFBriUNtbymaQF1QfK3TmtzxfZywag6FTjJw2OvPasO6sXVBJIhAIBI5B/KgDK1C5a+lwibOwAHP41m6nYELvYBRjGQeSa39FtDLcsyhQ3O1TxU2paeVgeSbYFAztzyD9KAPPpmLsAY1Rgf4T29xVRlMUjKRtxnJ65/wzWlqIKSZAwDggoc55/Ss2WX5yASehxkdcUAPhBIwGJYA/L0xz3qYMY0BGAQuTz61QDkIcICD3ODz/SpN7YYOpA3ZJPUUATt8uwDAB6Dg5/woUoVCMCGxjAPWqZYKVGcgccc4Pekjl3j92NzE8kAEDFAFlULyK2MlCAAeQKvRIqqSwYnPUjpWTCSZNwz8vOMY/TvWtuQEZ3KRzj0/KgDRgjGV2/xck8mraw+Tu+Ub/wDd3cVRs8A/MQSegxWhasxJ8sZ65ycYH0oAtRRknORgjGVq/Bb4dXJZhnt1+tUw2CA44yASR/L2rW0tY5nQBv4ucd/agDudDgAiijkGGxuBBxk9uK9C02TFoQxIZQckenp7VwmiEIQpCZDdABwPWunt2kAPz/u/4Qpxke9AGpYpGZAFzuByVzk+vWul0LS/NdnbPkk9c/e9q5/QYTNcGONQWcgFuxFelWkAt7VIwBhR0oAIY1jXCqFA4I96+M/20SD8U9Mxj/kDxf8Ao6evsW/nWGF2LADBzz7V8Vfta3P2r4k2D/8AUKiHX/prKf60AeY+H/LNsyt95pCBz04FW5gMsBkEHkL9Ki8ONjT32H94JSQPwAqzLtEjEcryPlAOKACJQ20urEjqQcZ9vpWvYpsKorjrjtzWPbv3BVtp9MHI/lzWvaysDHIqod2M5XGfegD1Lwi5GkwEfKRwSD0NdegKyK5lKhF5A6gelcJ4FuP9CMY4Ak+ZgcAdxxXcW04DHCnGPlTGT9KAEub1TMWwxUHad3Ud+afJdnzIwo2ZBYgfrXMXk7C5I+UMTnBH1/qa0dOkZ4ZZy5aXymOS3HQ9PegDybxFeGfUrlpJAHZieTyec/41nzXLLIwXII+brgDvj9fWo9VP72SUEM287SRn9fWs1pskrIeR8xJ6n2/SgDTfUW3lc7dq8Y7E9P8APtT4NTMB2bjsYn5C2D37+nWsBpjI2cAKcnI4x7U2STzB+7AyBjbjBBHf3oA5uiiigArp0tzuUhtjhRgHk8Af49K5iusUPuJAwDlR78cfXigDR0qz3BpCdrAYJPHat6CNE+dADnkhsEdvw7VR0NA0Dls5OV+uD2rajTcNowTjnnqMg8+/agCWKLEIMjBdoz/9ap7GGS5nZy52Dr1wfw+lSwoGkRXVuc4Pbnpya2NNCxxNwcA55GMcUAPW1URZAAkUDGfWpxbySEEtn5RznoB29qIkZZlK4x6DrnitKEh93yttJPJUYz70AZ0sSyLtUAbeWWs42wdmDKgwTjPU10DxYjJLY3jI8s/gc1mXEDD5nAGOCvQsDQBVgxGQ5RzyRjOQK7n4fwPeal5siKqR85655rh1hUMwG47uCP73v9a9l+H1kLLTg+0Ank5GMigDr5Coj5UgsORnpjrn86qzqCr7AGbP6d/yNJLPEW2bx5mMEjnGapO7DY27CbsDAPzZ70ANuJH2NuVQckZx1zXNXWomFCjyOsIOSM/5FbF/MhQh32qDw2emPpz3FeP+P9akd2trRiYxkFlI+v8AjQBrX/if7Xdm2hYoqt83zdenHvXvfgREj0CJoip3nce/UV8V2N1Ml9FuPGR9Rz/9evtzwdEYfC+lqyneYFYnp1GefegDWlkWNWZ8lQAcev8AnilRt8e5QSp6AY/z0pl7F5tu6AHOMjDY59abagC2UK27A2n1JoAmZg6kjOAe3Oa5TxdAJRuwoGcMOuf89hXVKFORkH5vWsDxEufNVRk4GCP1/kKAPPIibfHzFucnA3AjHUfiTXzj+0uS3jrTySD/AMSyPB9f3kvWvphl8tmVHEbBscen5d/Svmv9p4k+PNNBAG3Sol4/66y0Aea6W+ICvYvn9BWxZszbip+UZBXv06isjSMGBlzyXxjH0xWxCQ2OSCCcd9vFAGvoOftavtJ29l9cnA/KvVvDludgk8kfNyTwMH0zXl2gJm6D7xgHHH04r1Hw9cIIyikBum00Abske7cu3B7szc+vSt7Qp/s8ZyhMgUjIHB4rHjhRpQ24iTAO3OcH3robHyLeMvMxb5fxB/l1oA5y7QahK4kZg2fk3ZyPbFZOo6JLLGzGTdsUn5RyKveItUitzGYQiDcSNvf8a5vUPEbfPH5ax5GA26gDLt7l9LutrqAG9+DUPiK+Q2rGNiFxkKcD8qyNR1NGYkEM2OO3PeubvNUefduBABA4XOP8igBk8oZ2Y71LfdOc/jVWULlm3DcFwvZj7n86jYIrb1YdTjA7ehHpULPuK4HyADPsKAIy+0fMCOcZ3HnrUguQqspGS2CBnvVZwQSHwccEg9vf3yafCu0ZOSPfqOepoAl4KHeCPQr/AEoExiIfdu49eD9aXaQjcDHLY9qieNjlcgcY4PH40AXLcRuyndjHTsea0BlXUI4GRjBHP4VStI9kYJJ/PsBV5gNqkNls455yfrQBatiijGCcHvzWhFcCNsDHA4IwAKx7c5b7wAA7dK07QDfhsMCD83XBoA0LYmZS7OSh64PTv+NdJoUbm7iwm9Bzxzn8RWHYj5cKnOOSP55rrfDkDqrOzEjOBx0oA7HTxi5GBwRlsnJzXRq5wBsKcDDN1NYOmrNJcKiHcpOeorZQxvj5yrA7VB7/AICgDsfB0Ya7VmY46DAA5ruT0x6etcJ4RkS2mj35ZmO3cx6V3rcjAOfpQByXiu5ZI2RWK45IyeR/kV8aftKTGfx7aMzq5GnoMr0/1ktfcOraYl2yu5Ykf7WMV8X/ALWMAt/iNp8aoEA0qPgf9dZvzoA858Nqv2GViBkuRnPsO1WZwwUAKN244YN3qt4bQtYy7XOfM5UDnGBzVibDMdy/NknPfigCGJSzEEbG6gZByfWte2kESAsw5U9QMj/61YbuUHmlhvzk4zye1XIy7/MoJA+XI4H60Ael/D25Ek8kIcErztBAP512lxckebtchepB9fSvM/h9J/xP0ieM5kQEkdSfb2ru9WVozIg3lXOB7/UUAZc0m+5l3B1QPhTuwa6K1YRaFqagFikTHOeDmuXSF5QrOGYjJDgjBya2p5P+JDfgkBEiCsAMj2560AeR6iwMrbjwGIIHH4/zrGn3MuRllOcZ7ep/LFac/C+YA24kr93OOe3p3/OqF4ykBgQxBxgLjOf6f4UAZs0jRxqJCuMg4HJ9c+9QpdOXYIVHoCMf/q9akuIsElWUMvIIUAc5/Ec1X3oSAS2cc/X2oAo0UUUAFdUHEWeMMoxyODjJ49K5WuriIC79m1V4A5PzAnrQB1Wgon9nMWBQsRwRjBPUfWtq1iMERIOQeh6cHtWToan7AFLAck46gnPX061pwDLAnJA6jsf85/SgDUtE+cqG68YB6VpQRrvdGHJweCenr7Gs+FGOTHt2d88Y+nvV+1VmThWLHq0Z/wA+tAGvboAiFzz1Yp6Cnz4Ugt8pcFhuPHX9KrxlwyMWIYE/dAORmiZnZQgILE557n2oAcHcqQ+3cADgHGe39arSncyszxnA7nH51ZjbESCTG4enUdsZrPZJHuCHGUbgAjk0Ab/hjTnvr0DbmMHt6/55r1iRBb20cEe1cZXOCR/n/GsHwRpn2Cy8wou7BDZOQau3155k5X5+RuPv0/8Ar0ANuJnS7UBiAG555xj39qs/aEcLG2doP48VnO+dpLjknnHU9hXP+Kdci0m0L5HmD+FeucUAV/GutfZrWWGNlWRgfuDnHrXk1zKXVC7Fo24bJ7H19Knv9YbUZHmlcB2JGDn8Kyrpg8LbVk553AUAV4YDJrloLZtxMiKeg79+Olfd2mR+Xp9onTbEij06Cvh/wXGsviTT/tAzH5y5UjPGfWvty/1K106xFzduIrcYwx4/SgCyoKdSTxj68VDGGjZQvKgcjGK8k8Y/Hzw/oreTp1rPfyAZJ27FHP51qfD34o2PiwuJDHCz/c56f7J/SgD0xSSATzg8YGa5rxNOVnaPeVOMhQcYPTJroopE2gHI3cn/AD6VwfjHUfs+tZUpwBkZGeKAMiYJ9oZQzB1fHI6D/wCuK+Zf2m+fH1kcnnTY+vb97LX0VPORMJJmb5jnAb6da+cv2k5DJ45sGIYf8S2MAMMf8tJaAPPNKQm0kYEAhueeccVrIBGUeMMN/Dc5A5rI0hdyMH+6WAHOM+348Vu6ZE3lpjDA5BVuuc5xQBuaQx8tRjnbkj1Pv+Art9On8pUIHU43dvx/xrkLOIxhDhOAdxPU+1bWluGkbD7QF43ZPWgDrI9TKICM4JwrZGfStpNbaPTLhpDlguMk/wD1q4EMwUKn3QcgHkjBqZ7lmt5oWLEP6jkYFAHOeIdcmlu5A0ufRe3/ANYVgyX8sjZJbYeCe1Nv2f7TJtZthbBwcc1TZihVWGyMA9e4680ATjcTlmVgTVWV8B1DfMvUAcCkdyd23C7scZqtLP8AK2TuOM8dvWgBXlweRggZ/TqBTOCG256/kMdgartMzqW25JwOOSMdPwpvmtK5JPLHOOh+n9KAHEleMHnABABx6UokALEEqp6Z7/5zUUm5gcncdu4HGOP605XJAAGVOOAeeKALSP8AKoDZTOMkdPQU0sGDIkmGHXAPNRLMWTbtG3pux/nmnAlOhGG+ViO/pQBdjOYg0YwQcCr0dwxjbzG2nsMfrWZCZCrAngkcgVZjmdlwgJJOAP60AXo2AXaNpJOSQcYrR0wAYZuRnoODWMrl2CsoHsec+1aVgzPu3RgAcAMOg9aAN+zk2SKeTz1HpXfaCM26hyR3Azkn/CvP7FAXTyiBk5wDzmux0+aSL5CSrdOmMfWgDubQESK25kTsT1NbEDEygB0wxwOP881ydvcsRh92DzlRWjYvJJcKYlJb+Ek/0oA9M8KWU19MJChiSI43eorvgMKMDoKzfDdn9i0mFGXbIw3P9aw/Gnif+yNsSY+b7zGgDZ1C/SAmKMEucjPYcV8UftVo6fEm1Mkxm3adGykjGB5svFfTlprovxII343Da2M4Ga+ZP2q8n4hacSMA6VHge3mzUAee+GFzaSHcB85HpngcVbvGYDkDcM4B/qareFtv2OTcePM6Y9hVq+BlOSc55255GD+tAFHeG2McbV4B29fpxU0Mh8whsgd88YH86qTZ8zdkBRyQPX3p8DKS4QZHXr178+1AHYeBr0x+IrbLfMW25AA4PSvVNdXbcLniROoJJ/GvG/DVwkeuafKzhCZRk9PpzXtetos0pnx2ARuMn8KAMUxgsDuADDIULgfX/PrUmoKB4W1EjPGOO5I/zmpJgm5WdtiDPyqOM9DjJqv4gkaDwjMDICjygYz6c5oA8qlWUEqoyB9xTnt1OOxxWdOuEO8nA5z0BPX86tzSOSA7sr5KEY7nrj3rOuZWxsWQhfvAkgAGgCjdlCVyecnOPTtUDNk794U4zlQRjPfHpippQCAhXKrjJORn/PH51VUKzsGwR02qc4HXigClRRRQAV0sDkFcou0DGeQcjpXNV0MJOQExJlSGyc455P15NAHeaIGTTVf5kBJ75xx0FaljnIzGWZuw4/L1PSsTSJWg09MHcuScd/z78GtjTWEgVt+cYJySSB70AbsBRcIMFug55q/YpEShCqB0UK3fvWLb5Zk3IVIPcVraT804DsfvcDHPvQBqY3Ox2nOTgLxz680yRhIoLEcHv3r0abwxBPpyz2sSiTywxUDgtj/61c1feH7oorGLYy4B+XIFAHMyS7j8gGB3Pf8AzmrXhu3OparsJXy4/mOOCT2qfXdMNnGoQHBAz2APX+tdZ4P0hLK0Ryv+kMNzHB6daAN+4dYLaOJCDuUgheMc1l7zLgqRtHqMD6/X2p93J5jnacKOBnsM/wAqqqxUFwW2LyTnpj09qAEurxba3mmcjH3gfWvFvF2svqGpSGV9sWeAO4+tdD8QPEBbMCnJ5BH48g46V5pcyqdwJLZ4yDxQA+SYxOHU85OcHj/9f+ND3iOu3gqOMHPB9BWVdsBKUbBJPbp68VnvMQVA3CTO7gEnrj+VAHdeC5Vm8VaanKlpguAckj2r6b+NuqQ6Z4e0+1lJTzm2+2AO5r5b+Ej/AGrx/okbhSXuFAJGD16V7J+1VqhjvtItony4UuQDxQB4J4rst9/KySK245GGwMZ//XUXhHXpNE1IMsjmzYgSLjkj0qle3McsO4syE8bs5PWubeXEq7Y3RTwPzzQB93fBTxDJrenXQM7zRR4MYLBiv0PWue8Uag99rsxlC4LsMZ4wBjNc/wDsm3IOla6octIoQsOnr69Kn1G+SS7vbgNhvOZeecDPr9fyoAlW+lW+/wBYCw5GM8n1rwb9obI8bWYLbj/Z6ZOc/wDLSSvXTKbiZZQSPQDscjqPpXjHx3bf4vtDzj7CmCTnP7yTmgDlNBAaE8jIfOM9eB/nPtXQ6eGEgV9hJySxbvx+Vc5omPs8m48GQAiunt3jQHcqcj5QPp29aAOg051hT97koynAJxgdq0LR0QHZn1FYFtdLhvMYMmPwHHTFWba7ZSxTa2RwOp/GgDeLh8Rq/IGQcVWugBD5m8urfeyeSR71Fa3MbbCD8+cEMPWpb3aIgoywwSTnofagDidUUpcykZIIyB1+vArMJd42xnIHQ9fxrW1QKt0GV84PPy1hXTKeYyAgHB6YoAiknk34AwxHHHUev60k2duBkHaR0wMf5H60OcAJu27F2nB5Oeef0/Oq9zI7kBlycc9wDj8qAEEjOiEDDdwABnHYUsjhgpYMpJwcLjHNRuCoHGGJHBB6DvmpCQBjeQuOSelACI7FtgLMTzknA/P8uKas218R5HY56/h/9enl0fYp5cN3GOvpSqoEpMe084xnJ+poAHAZXVkyxwx9MVJ8qBgi7mbg46AdiahKqRkux28bTngipS4V24y4A4Xp/WgC1CCwXlSo4Gw1LCAGVQ2WGSQ/NV0RxGAznbnKkYyc9vepAy9Ffgc9O/pQBfgZWOVODuHIOAM1oWrqgwOM8DmsiOdlcpjIAyMH/P5VbhcJIN6HqMe4oA6OzmcFXDfKOcnsPXNdJYanFsCHLE8gnn8a42GfcFIkITPGP61q2bqMAEjB57E0Ad5Z6khRQu7bu5zx/wDWrq/DEol1uyEQA3OFYNznmvOdNdpJPL5x1OT2rvPCJij1SxZm2hZAThun9KAPpVB8q9RgYryL4lrJcam8aAu68AJ2+tes2rb4V+lUtT02K6DP5SF8YbjkigDwvS9NvIr2PyZ2RSRuVRg/iTXif7TrbvHWmcSDGlRD5+v+tlr6g8R6rpfh2NkYqb5ukaD5h9SO1fI/x41abWfGVvcTqqlbNI1A9N8h5/M0AYXhZQ2nSAEg+ae/B+UVauQBEquuHGBx1NVPCyA6fIxIGJTz07DvVicZYY3KzHKjr+NAGZKQDhTg5xk/w+49KYjESBFYHAwRjpUsxz8hKkDG4YxnPSoMgljJHkdQeoJ9aANjT32XEJYsPLYbccAV9G7FfQrI8ZkQck5zx6V8y2zAOxUrjoOcD/PFfS3g1pNR8F2Txnc4QDn+lAGO0IE2Bkjgr24J9PrVDxqm3wfu2lGeTaBggHjHXoeorUuCPtZ8xsANhWPIFZ3xQkx4Zt42UIGYnrjH+cfpQB5G6nd87KCTw3fufz/pWZcAq7khdrAlsEA8dcVoSEg9ASBu6n5hgVnXAQtnOF27vXB59e1AGdPzyz4H3ScHG3pnPeq2XztYgjsvqccZqxPIN3zFucnj5eahX+MsNvBOPX/DpQBRooooAK2wpBPkqoXCkYznBPH9axK6C0jaW5iyvqDg9vT65oA7O1R0tIemQM/TPGPyyc1p6MSkrJHIAoGSMYzz9azpBIir5YONoKx9/wDIrT0xBKykcDg4A9exoA3Yd4XaTwox64Hp/Ortizx7HAII5yT26/jVARMkYTGBxu/x960LdZFQrjc4XaPf/wCtQB714bcTaRbyE43rnjnp16/55qaKAyTsrYKkkNk9+P8A61VPBLk6NbjILBemD1PGK2FiIuORhVbaMD6/4UAcR4ztxBDO7AYTGeOuKr6JqglsVQMGYLwRyTx/MZrd8ZQltLm3KuGUZbpxz/nFeWaLftbXojdxGmDnjjr2oA7gZlZCSHU5OCMYx9ax/FmrJpukPkMG+6u3gnjP5VsC5hFkJ0YFjyQTXkfj3U/7RvDFwYo+CAeKAOS1O7e4mkkJy8jdR054/rWRPM+SOcg9cflV+RgpIJYIflGCOPeqczGKEqzjZ0AGDx7igDOuywYbGJZlxt4IPr9DWPczy7WceWFI2gjjB7j3rVupPtAYDp1Bz0FZNzswQD2DYPTn/I6UAd9+z5A178WNDzub96X7fwg8/pXWftU6l53xG8rIP2eBFVT0zj9DWb+yjbfafipFKsaZggkcevYf1NYn7Ql0bj4p6w+WbbMEAB4wAKAPPbuZ5JtqnCqMArzuqOGRvMV2BDdVweDkHmo2Q/KULMygLx0B61owJbQyRtNukDgYRF6YoA+jP2QTI8XicsTjCAgjgH5uKraal/qGv6hbOohjSdgN7YHXrXQ/snS/8STxEFiESqykOV5PB5+leJa5qGpf8JRc3CXDZS4JVV6demPyoA98g0WC3UBdspLAEngZx2r56/aDtPsfja1jKbCbFCR/20kr6E8A3s2rWkE97uRwMnHT8RXiX7VIjHxC08RDH/Eqi3cEfN5suaAPM9GUNbuDgEv1PTtWvCNoOUCgDsc4HQfT/wCtWboO1bORpEyu/Gc89B/9atmCTKYXaT1Ug96ACKRsMQuMdQBkn6CrKOybWBIAOAcH+VRLGFlGMEKQRk46j9asMpClcHOM5NAEsGpSZUAHAbBIwDVx9QSa2LySNxk9OtZWAiMpVS3X3pr4dPlyDkHAB4agCPUpBKS3G3r1wfx4rn5tyvgD5M9QM5zWzOJEZQwySegBPFZV4GZSdxB6HHBNAFQHaMkDap5YkE/59qgbbtUlsHPzL0qdtu47SAOCdpOf/wBVVy/JAI45B20ASIrGHAwWUEkMffpilXnj7oAycc449aImYnDsh+bcRn270u1eoCE8Z57UADLkkgjOBxnOM88Um5WkJHKkd+x9eKOEkUENgcseSVHahSAA/XpwD0/z1xQAq/IW3sRxgj+Zp4kPlqyrgrwGB7UIzbNrbTns3B/xpzLhScLs3dM/yoAcHdAA2DnJHFCMS4BUjONoB4/+tUiskagbdqHnBOevepF2HoRhcbTjGaAHwsnnqSXVwN3PQ+taEJG4EFsk8Dp1rOhwhJypyxzir0YJc+WRz2HJFAF1AEJJCkMxHXoPpW1YEKqk8nvj+tYURO8nkZ45XvW5YSSgBG4JOMBsg0AdRpJFxKGwmBwSvBzXqXw00ltX1uJghNvbkFzgYPtmvNNMi8qGNPlRieTjGf8AGvpf4X6PHpHh2NmVQ8/7w7RgH0oA7YKAm1eABj2rB1/WI7NRErbS2ctzxx2qDxr4hOg6UZY1DSMcKD0H1ryseJ2vphJPLjdzgdKAKXinSZMzXlrIJd+fUk56/nXzV8WVZfEluHXafsq8f8Devr23gvLyKOS0gEyMdoLEdPc184/tUWLaf8Q7CKSNEdtMjc7e+ZZef0oA4bwqyrpcu5Sf3pzg9OF7VNex5DtEwCoDjggUzwoCdGnAIx53IzyeF6VNeRk5wCAwLE+hxzz37UAZc3VyikgDr71ApABEwPJznNTz9uGL9euCPrUbozsSQSCckdxigCaAAvhsAvyM8n+VfSHwgZZvBrxrkshYc9q+dbJFXDBdzddp6/XFe9/AeQXWj6hbFmGwk/L06dRQBJexobyRo2Gz75Gz8qzPiNIkvh20cx7UU5GT1/D8P510eqxQQ3j/ALxvK6HpzXPfEld3h6zZtqttDbRyR14A+lAHjkzMrsuAQGBIA5AOeP61l3JYSBwDyPvKOp+n5Vs3LoOTjGOoPJP+fpWXdkKwb58jgDPQ9+fT/GgDNmjO0FzkhicdM/8A66j+VcJuG5iM5HX86nkbc+WADEY55xnvUHlHeuMjaP4l60AUKKKKACuo0jJ1GFpRkbiR2GAOn1zXL12WjEf2nCxXjcQqt3x/KgDp5HUTtvO7b2Xn14rT044QbHzkYGAASOax5iRclYxhc4OQc4z0rX0hA8uQRjqdozgYoA6CP5VDbW29eTyO/wDn6VdABiOMhh27GszzHEfl4GCMgr/nirtspWGPKuCME47j0oA9o+HUwXSY8lm2jdlv4vT6da6iZgJtvzY985Oe/wDOuJ+Hszvpy/eAHBz1xyP8K66RvMuArblGAAxPrQBS8VqDY3RGduwsue/414Fq8nkXrDGAGOQP05Fe+6vI9zaMmCAwIDd8f5FeAeLE8nVJIzu3AnOew7UAT6h4inj01Y0Yl/rwPr+dcVfTSzguDuZvfv8A59KsT785JZsDHP4ZrPugcYOQO/PbvQBTZgANu5VbI/Sqsx3rIqjLnnngVdZSSzBT8w42/wA/5VQlU7GwMnHJzzQBm3o8oM5zwRnIxkgismRQ3zuwVuVBJz3/AMK25oWn2gEhie3PFdr4L+Fd/qsq3msH7Fp745YZaQd8D39aAOs/Y509m8YavdBV2w2gQN/tFv8A61WPF/wrjufFeqaz4kvlihnuHeOCFhvbnIr3T4U+HNJ8O6BPHo9oYA335v4pMDqTXlfja2me5muLu4aRyW25HC80AeBeOrXTLTUWg04P5anABHBx0+tctHOEz5W2MYyCBknpXUeOLZZL3dvK7mHbnA/z1rji2F3FtrA4246cUAfVf7Jc0knhrxSXdmCbVUE8/cb/AD+FeOXVoRrdw7kLGZj0bGcGvYf2SVC+AvFEoOcy5442jYTg15NqERl1Rg52/OW3Ae9AHp/w91ERXUcAmyjMM5OcD2rz39rAY+Imm4AGdJiPHT/WzV0fha3khvo51P3cY579MVxf7Scwn8cae27cRpkQY5zz5ktAHB6CB9mds7Tvx06jHNaiK4lK/K23A+lZegRhoCSNwDklT6ADn9a2Lch4yFOOACR3Pt+BoAlgyqjP3emQckn04qwrsSAOnT5TjHufWordVEwBDAL97uT6Z9OlXBGc/KyHHXsPagCAyZLH92Wx8w6j/wDXTDIGR3y27pgHn3/Gp2Aw2QOuRk1CwCoQwOO4C/yoApXTsQT2yNwH+eazbi3M9s2eMMQAOMfWtG4YxoTjgjpjPOfX61Un3K8ufmODyD196AMZo2jBLFs9PX/PFMkYZwDuGOSDz71YnO0MHYcDceOueOtVZOcgAdOB6++KAHHGxmBBfpnrxT4suGVmC45yO/41Cqkx7gQFUnmnycluhYDvk5FADmQEvnkEZAH9akOFdkCA5AJ9qrNJk7eQo7HH+fWnrJtKlgHyOAOv4mgCZizLz0GDk9eKNh8kkHOD0JwaYjnOFPI/hUVIZPMjLNGT2UAZ/OgByLlAzn5+oJOB+FSKRGwUcKec45b2zUYDLnzAGXrwRwPSh5FkACjheBv6/wD16ALZwOQMgjGQfunNWbdyVZdpYLwC2OT7ms+FsKSp64BNWEd1ZgDiPIGM5OaANWPA+XBBB4we1aemoZZVIP3ecbuaxI3PmrjHT5j6VtaQ20A4ODxux/KgDv8ARBunhC8ZYDpz19a+rtFO3TLZXHKqARnkcd6+U/C7Mbm2wx3bwV/PpX1toluFsoXkGZGUFvbjpQBw/wAVbG8v1t7e1jYjBYsD0rzyx0IWc0ctwfM2/hj6V9A6pbxz2redjC8g46V4v4w8V6RpnmW+mQC5mXjc543f1oA9E8NXdv8A2fFtYLGoIG/qtfK37Y9xHc/E/TXicOBpEQJHr501aWo+K9WupGMtw0agn92CRx+FeS/E3UZdS123lnkeRktVjBY54DMf60AN8KjdpTofumcnGMg4UVdnXLMBg46MM9RVTwkWXS5iu7PncY7cLVu6YkncFXLHvjOPp04oAyp8Bi24K3XJ6/hUBII2zAtjkd8D8+P/AK9Wp33oMspGeh571ASxZlPKdMgZye1AE1vtypAIZTgEc9Oor239n2dhrWoW+QUaLzOT1rxS0JjKvglSTkdlzXq/wKudvi1wu3aYGByO+c8UAdp4l+fVp03Y64+UYYZzgH/PSsb4r/L4YsCo4YDOM/L7/rXQeIFD6pMhUblPTb0+ornPisxj8PWoAU7VwueOR0GaAPFJw6zMgcEk/MCcHJ5z9apXIfG75iSckk9ecdqvzyYlJfo2M7MAA+/vWZIxI25IY/MDjrz2oApuWRVDYVcnJGMZ7jH4ikEedoVOA2CF/rTpDtZnXb93GMEc9D/OmgfOjFh8wABUYxQBQooooAK63SGC6hHKXKs/JyMZFclXXafKqTweYVAyVOeuM4FAHSgMZN3JIc5Jz+JzWnpDsHVARtPB2jqcmsw/u5SQT8wHXkcj+dXtKk8p97jL5zntQB0iyMMgqPLAznFXbdvuj5tueMjAaseK4L7CCAzHaR0HPUfkDWrZtvyg+7nAIOaAPVPh9IWsMIuV5HpuxjNdRO+xty8kncFP8Ixj19a5L4fgLbyKCP3cgO5uCc+g9OK6kgvKzAgAKT16Y9f0oAnd1mtHAJJGWGT3P1rwr4jw/ZdWYsWG9d6tjHavbLVkkYoUA4J6/hXlfxhjAW2k25ZQQTgevX60AeVSTkBxuxzgr1z6f0FQSyjZ8wwQQCv8vr3qOSTcoJ6nHzf3Rziqs0r7RjJBAHPU0ASu+1SN2QCSPf2q/oWg6hr135Gn27sQSrv/AAqPXNaPhjQE1GX7TqH7uzX5jt7jGBxXo1jqJtY/sGiwrDbFdpKDkn3NAE/hnwLpPhqNbm/X7VqBG4K2dqH1x36V1FqZNQuEMhPlhxtHT8Mf561i2CyyYkmkMkjZGDW7o/F9AIvmO7OOvPrQB6vo8SwaPt2kKQeO2K838U6RbXSvwF5JyDyfw9TXpCgpoz7iAdjdRgH/AA4rzrWRKxVj6cYz34/OgDw/xt4Fe5VzEpKrkh8V4rf2J068MMhYMhGeOM5xn9K+r/Eky21uzyDa23btPSvAPE9iZ9QM0MYKtkMD356/XigD3X9lmMxfDLxNPt3K1wxGMckJ1x+NeUXT+ZqE7pE3D54PrXunwK0w6R8GdTdj88xlYZHT5f1ryzwZZR6jqz26486RiAH70AbPhHTbrUCkVlFI7LzsCZx+NeV/tDW8tt42tI7gESfYEyD2/eScV9seFfD9toGmpDbKDNgb5cYLe1fJf7Yahfifp4X/AKBMZPGP+W01AHlGhNi1YZA+c/U8DituNAHxgbR1Ud8dD71keH1UWZkbBIlOB6cD/GtiNR8qLISduRg9CKANK1gZlDM68jrn9PzqxFGDKo2AsByuCd1NsrdmaMKCXweAp/IVf2mKR0ZSrAYBHX6cUAZ5gBUPsDEE4wcc56flVaWMx8uu3PygH+daEnzAmNhn36VWaLCurliEwA2aAM+eEAMSRjHABxkZ7e9ZV38ix8ckkge2eldEyRMNuFcjnJOD0rJvtu0P8oTqM+lAGBcEli2CSD0PfjrVZm8zYO4GzlepzVuYBQSQxO7n39qqs/yIpyBnKj3oAiEasGAlUAEAcdaXYy/MHye59OfWnAgnYuNvLA4zmoX29AGx15oAkYlWJddxz/nmmpKQ4J5xxx3FAZdhAzk9vemlfnGCvzc8dqAJi4+V0HzZwR2PFCHgZyTzw3QH+lQodm1u54A/rU4w23HykDAbJGaAF5AxIw54GQOfenuRgHhiOdwHT/61NLxrg4LZ7Z5JoRUwxKAcY4OBmgCZC7njHPoMc1aQSNnOAeOB0rPbCZAdioHb+L3FW7ORtgYNgg/NnrigC6IPnU9Gbkk9vwrotITLpgHg/N65rChn3HJztB4HXPvW1p8yfIseWTdnc3U0Ae5fBvQv7T1Tz5h5sUByfl6n+VfSds2LdAOAB37V5X8K7eDRvA9tKF/e3B38d61viH4ifSNCUpJtkn6YOMCgCPxt4taK5+yWxxHyGZeprxPxVp5ZzcQZ8kgls9jW1BqL3oK7/MlJyCTnj61r2Gj3F+jK8R8sg4BPFAHjD5EbqfLyOnc5rznxu2dYXnOIgP1NfTWp/D97Rd8Cl48EnC5YY9a+fPi9aLZeJ4Ilx/x6qx4x/G//ANagCt4RDHTXUN96c8Zx/CKtX2cFdpXLZGRjPAFVPCGP7Onyu4eYcj8F71cv9krjA4IznII/+tQBlzJsy0e7bkgAr09eKrR7NqnPDZwc4PNWZ2bYwC/OTyxI/SqzsAFBKs44JHAHp1oAuWUTfNuQHHcnnp2969K+DB2eNoQ33PLYDA6EjJrzWBpBJmIZ29VHOffmvQPg4+zxnal12/KzEN3OORQB6frF3HJrU4jQ7wfvngYJrkvi3Jt0+yhJ8zAOAOep9PrWxq9xHJrJkj+XLYODnHOAM1z/AMYPmhsjvIyvJHGBQB5DP1APJ5YgHjH+f8iq8i7g3lAA5wM88e3txV6WTbgc7R8p449/pWddysfmbaFxwBwRQBUkTlhwM4yVPQ/SgbSDkrxuyeTj8Kc2QULITkZyBj8ajG3YVLEnnkdBj2+lAFKiiigArp4iqTpyoIYMCVzjvnFcxXTxSD5AXJyME4yFHH6UAdIkpfDABgeNwHQVftZSQMYO4c85x1HHt/hWam4Rp0VehK9OTWhA7onJDdjg4z/SgDZiyQEwQgBzk+tadhIdzk/3sDtnj9a56BxtRN7bSQGPv2rUs5mKJsZVGdpwcdP8mgD13wK3+ikuQGJJ454/z/SuxaVSEKgFjxxwV56/59K43wMrf2Tl9uT1INdODuIHK7emzr14+lAEzTIjBUC7iD1GP89K4r4j2a3Gls6jdtwOucnFdbM+JVJYbfvZ9frWXq0YurGeEKfm+UEjr6UAfNV3tWQq+Ac4ULxj61b0HTYr2QNIAAGLeuRir2qaC66lIGL43HCbf511/hnQ0EaokZEfHOfzoAbptq7xi3hVtvQY6fTNdNp2mtB+7iU4wJDn/PtV+ztvKjJQdMKMnIHatKIFVX515AJPsKAKKxy7iMHgY4GP89K3fDceJWlYfOV+XB9v6f1qDYdxVWBdgMZH5GtvQIwt1bSPgkA8rwCOM59+lAHblPL0EhiNxTn2NcvMrSFVCrjG1T646/1rsZkzYFSO3B/l9awjDmQtgFdvCgYBzwaAPKPiNDuk8tDw+SABiuCs/DjMrsRtk656j8a9413w4LgG5f52C/KCOhyawI9DAjKsoAyRlhnbQBveE4za/CRwQuGik6LnI+leReDLI2ni6zmWQFBKAfXk+le7Na7PADREFQYcEdMZzx/n1rg/Cujrb3cc7MVIcDHcjOf8KAPYBtC9xjoM5r42/bKBHxQ00ksc6PEck/8ATabp7V9kbsFS27D8YznB+nrxivjb9slg3xP0wg5H9jxen/Pab0oA8k0In7HKq53M/wDD17f/AFq6DSRun+f7xO49PWue0I/6NJhVJ3E579BXZ+FrczXaKoDLkYI7kf8A16APQPCmjNfSII12AfxEZ/8A1V2GueCT/Z/nJbM+37wcVt/DexRb6BlBAA5RwB/KvW3tEeF45FVlIIbI6UAfIWpaQYDJ5cYCgHjFc7InByxHXnOOPSvb/iD4WfTTcT2fMbE4IGCBXit4z7myOQcH1B9TQBRkUrGWZtkhyeCOlZd5GZIwXdSCMlQM5Na0xDxHI3H2I4rMutiINx4zggf560AYFyokicxjtg5HNZKlmGB1B4Gc1sXaYSQdF/mfesuSPkt0IHINADCF++hxjnP9KCVLDEY2kk9e1IylsnJPt0x60jDAwOR6j60AIQBnqPY0E5IwAo604xHdhwR2yTSBCp6fQ460AOyYyACc4POOaFHHzEjHbvQxUsX8w7uoPPJp74VCSQzHjqTQAoYFNjnkd8Ekj8KlwCSQRuzjHaokJZFUZz0wen1qYMo2hj83RiOcDtQA4EKrtHjI+Xnv61ZgXKsGwyjAYsOOlQjdtG6Pp0HSp7eRSFZuhyfQ9MflQBbhixg9V65/pXQaMha4jDLuwwBbjHNc/bnKhlDcYG0dK6Xw/HI95CkasCWGB1PWgD6v0Vz/AMI1p0NqC2FXCgcrxVP4qaDf6jZ2UhI8kDB3dRXa+BtF/s/QLRpkTz2QM2D7VoeKGtIdGmmv1Hlx/MOec0AeMeG9ETTJB5i7+cFm6AV3K3um2SZmkSLAGeeleR+MvHrl2i02NYlGQH6GuNh8Q3EtwTdz793JLE4FAHtWu/EGLayWdqpAyAZOAfwr5W+MtzJd+LkllIJNsuMdANz8V6ws0U8SmNwcDj5gOa8e+Kkol8RwlQoxaoDg5/iagBnhBiNNmALj943AHbaKt3O8AhQOfl9Mc1T8Ibf7NmLkgCU8g+y1oPjLkjexG7qOSKAMm62uFZBwOvGOnXHpVIISwwPmLHAIwPyP8qu3BUxqDuCnnAPQ9/p0qrCWV2AblTlTjqPQ0AXITsUqHUHI69f/AKwru/hK4/4SkTP8qLC7N65xXBW8TN88hKocZIOf/rV33wxikhl1O4VBhYGXLNyD0NAHQS36vqIDNt3OQG69/wCuaofFJQs9s7Al2QKOfb/ColIa8BLDdnoO3/16d8TUJjtWZjkKON3TjFAHmV0gZyz5Cr6n9P8APrWeybZGXcCT1xwT6f8A6qvXaHyg2GZgc5C9vb0qhMeSshAZj8x9/X9TQBBJkRBmJGR/Fzz9e9RFgGLcYHBwMZNLKcMwyd3PTnB/xo5DAgZGOexNAFSiiigArpo1dZNzyAF/4iO3oP0rma6mVsxjKssgznJ6gE9PyoA2LKVXtUA5IO7JHH/6v8K07ZgXKMScA444Hv71i2nllC0jMrZ+4Dx6H8P8auwSAEFPmKkDPOAPSgDZRk2nzcdj3wP8a1bVo1RPN+feSwVeM+tYkU24LtYYIGeAcc9fatnS223NujKrLuyvqOxoA9f8NJ5OnW+3ABUEDpgcf/XrcSbfEmRjd8nTnrXPaHcs8EWyQ7VICsw6Y9R9K6a3iXagAzk4zjocUAXTEHYhlAY4GcdR2z+dQSQICHY7srjOBweoq1li+Mu2VyG7en+TTpY2ZTDGv3zgbgMjjrQB5p4q0fdeedGGIY4YDr9au6fGsVoIcnKHBGM+39K7a704Sxjzh19gMenNczLZPHMqkfODjJ44/wA4oAdCE3uFA4XpzUgkRnyo6YGKWK38stsBGAeOnGeDViGyHDOfkxzx1J96AI7UmS43kYU88DArpfDoBnibaME4x1+h/wDrVjx2yRqeWCkbNuBnkZrrtAtzujXCMUyflOflPegDqpGzbDaMZ5GBnFUooG3fPESueB75zn9P1rS2/u0CnPbnimOFcn75xwAOQDigCheRpKhAXdnkKQcYx3rJmg8yJ/3IAPAx3A7n2ro5R6A4YYJz1x/ntVOe3VpDtyGfB65HGMUAE9uW0kw7dg2jqOnTj6Vi2WnmMOWjxjHYdjmujmGYYsLsHoD+P4VXgVYztckpgZz06/yoAsiPhfl5/u7uPrXxp+2WCPihpmV2n+x4vTn99NzX2ehXO7LLsxxn+lfGX7Z2f+Fpabww/wCJPFjd/wBdp6APHNEcJC4ABcsRz9BXUeGr77PqNtI6lUJAZD064OK5HTC4gfnCZP54FbULjckjK4XhuD1HP+FAH1t4MuoFjt5wyGOQAhu4GO/0Oa9SgmSe3HlFWU9wevuK+avhVrxv9Nks5WUyIcLgdwOOK9H0DxDLY3SR8FQdpAPB+lAHS+O/s6aepmY8/K2TjAzXgHjHwv5ObixYSQv/AAgd/wAK9+8ZrBq3hSf7MQJUww98V47YXjxTyRXCl4vVun5UAeRTRlXkO1gVBzx04qhcsQSACAevp/nivWvE3huG/smubVtsvJ+QYDe1eWarYT2sjrcqyYO7ngD2HrQBh3ca8DkF8jH0rKurXALDJA7Mfzx+lbGwYKfKGLce1VJuSWZSxzgY4GQKAMkxgDnBJ5wDg0yT8T0PIxVyaL5SpHzucjK9OPWqmTtPO455GOc0AICTg5XkEYPNNVjggkkY+tKzIUJCnPQUKqlWzkEd+v4UAA2kEHAJPFPVCxKbwQB+FIY8EkZ3L13f0pqHbj+L2HrQBIAFwQFGD60qqJACoJ29R1NIQqxgnOTzzjmlWXawJzwedvHGKAJopCM+a5YdAeT9DVyElnDMq7duBz0NZ6qvymMkknOAau2xC7gAHGec9frQBpwgPsUBgNueO9e6fATwcuqSf2leKXiiOEH973rxGwVpGiV1wcgAHIJr7K8AaWvhzwjpcDRN5043HB5OecUAd/q2q22jaSbi6cIsa4Udye2K8N8UeKrzXzMk8qiEH5EXoB/jVn4n67cz63FZuwFtGMFSf4q5u0tRczMETcG4DAdfrQB5prkJi1B1Yknrn3rLHB+dsMOor23U/h5d6pbLNHbJGVXuOD+FcuPh+6OzORhSRtA5JoA43SrwiQLtLK3OccZriPiSSdeiJGAbdSPpuavWxbQWExSW3AcDlW715V8VLgXHiOFgFGLZRx/vOf60AJ4QCNpMysp/1xyV6kbV4q45Ty2KKhBwBjuao+DgPsLkrnMpA5HPyjitC5wyb2jCEYACn60AZMwR12sPnV+x4x0qIIwdnAyV4IB7VIxXO5WOVOcsuM+tAXJ3KXRc9AR8w7//AKqALVsEyN+EXbkrjgk/0r0rwbEdO8IXN05XErGP3wP6ZNeawoYZA7LzkEKxBI9K9Nudtj4dsLdVZHWMOyMOpPPOaAK9uCJi6OqlicADg4Gev4Uzx7Kl1p8EyBshwASPQVDZNklzuJC4wowB/nIpNUma58OzYODG4xnk56ZP/wBagDzybGA2emAHznINZ0ygZZssMEfj1ArRvFBVmjC7doy2epHoKz5yVf5U4xg7iO3Xn0+tAFJlDDbjoAF2/wCelJgp0UKOhB6nHb8aViSSQV6Z6DpTQS3zFmODjPXHPUetAFSiiigArpJ8pG5LlxuI47Duf1Brm62zPvCeYuc9ARg8cA+woA0LNZMyIWHoM8dM4P8An1q9attXjiReG5yD/n+tZlmZVjK4I8w7RnoueT/QVYikHnu7Y27uR/ex7egoA3rO5DHEm45OeOMA4wK6zwray3eoxsg3IvBz2FcZYKZ5WiVg445BxtPbn869o+G+jNBZ75l+d1yTjhfY/rQB2nh6wAjTgYJB44B+g7en4V1MVuEjI27mzkEdOh/rVfRLPCKOAzDt2A6/rW3GCFVMLhm6evfOf89aAI/LwhkIAIHA9Ox/nToLUmaOPaCUXO3PJIqeMfvFR8HjDADGSP8A9dT2kflgMpYKSAvHqeo9aAIJbQPE4XcQMjHr71j63pszFZY4lDqCGI6EY/ma7IZ2gKCCcgkjqaSa3VoSPuyZ4479KAPOjbPHEwIAJxsBPr/+qpWs5ShyWDKmRjHXJ4x3FdHeWvlybwd+Tgg/wrjt+tPhtQ6R4G4bdrcAdB2P4UAZNtp7S+X5ZYS+YDnPVcDrXXaVpyQsrYwy9VxkHjt+VTWdpHBH5jY3Mc9+9W4xwGDMQQB83+etAEjbtjDv64qN0cZIfHA689OtSfK3PbpnFNnbC5ILBf50AQrllcrxg/eA5+nt6UibfMbauXzhcd/85pTy+EZhtBPTNPVnV1ypyx6Y60AEhbbg7Bg5B6YxUUUbM4+f5/UdqcxG8BNxcZA3DnnvTlTC7RgqRy3T8CKAE3MpUEAr0JI79K+Mv2y2LfFHTctuxpEQ5GMfvpq+0D8wCjjtnjj3+tfF37ZbBvilp2M5XSIgc+vnTUAeJ2TbYnIHzepHA6frWhE7FVViAGXB/kP8+9ZcG0Qkk/MSceo6f5/CrKvtcZLdcqMdR2zQB3XgvWBpWrWzF38sbUYvnJB759q96aSLzIp7ZtyMAykHqK+WLd2VxtcN/Hk9h7V7T4B8Qx3+k/ZJXUzwjaGJz+dAHrdnfS3unGKIMWUnkHAHXj3ry3VtVjs9WnsrzfE275GwOPrXS+G9XkttYRLpx5DY2kN+HSuW+M2kotyt7aglDyzADI9/egDQttQZbYOAJUJHPP48UzV7C11u0YGFElUdfT3rz3w/4iubICKXLwhuADyvrXeQ3UGpwJPpjqJsZ9xQB5n4k0O50xwxG9BySo4FYcsL7MuMgHPy9fpXr86pdxNBqkYGe4HNcj4h8KmItPZSDbgnaAST7GgDg5BmNFAOWOFUjpWfdQ7cMrMeh47VsTW+zcshZXJLYx/KqMxcKANvlyDOfUf/AKqAMwQsOq4YHOD6UeZhSgGT3PrUs0eACjsVOcAj6VFIDxgdDkKR2/woART8wQnCHGTjP40snHTscZJ4PvTXXKgkrz6HpTeV7KRnHIoAsL8zqSgLHnk8AelK7EM6FUK8Y2jiq+8hCoYBSelOj5cLuwD+lAFpGj3KwGAvOP7tW7Vecsm3d+npWfCFzkj5jzkDFaMEqE55D47d/pQB1PhGx+2a9psDb23Tqp555P619yaZbJLeRnaTDbRhEPXBxXxh8NCX8YaUEJJ85SqHOCc192abbfZ7cbnLs4BbNAHzz4p0C91bxPOTuWJpcDgkkZ7V6n4I8J2ljawv5QMmPmYjJz710DaZbC7kuJgmByR0xVy01KBy0cQGVGRkbcigC2LaCJDlV2gYOR2+leaePp4IGD2KKBnGRxzj+VdR4jvJzFmEgqT344/xrj57Rbu2aZucZUgc5/CgDwTxPPdXk7uAUbJGQP8ACvG/FSsuqfOxYlB1+pr6T8R6LHFJKWVeQSTg8+nFfP3xJhEHiCNVAA8gH/x5qAJPCig6LMSes5G3HP3Vq/fuI/3gO8scDj/PNUvCBH9lSBl+Xzicg4J+UcVdnkUrwh2LnPcgUAY88fmARqwKs3XHAFPVVVSo+QE7i23/ACasLtcMGwCAce5/zzSwqTsjU7sjccHoKANPRrea8v7OFBuLSYbBHHv9K6Xxff8AnXpjRvkXbHyO2MVQ8M/6HFPevCQ+3y4uPut3NUriUzzlmcs7Nyx/ln65oA2NNDNpzlQ3m5OG55HHf8Krz5MV4iZw4LKobg4/+vjmp4nltraRZvTHI4xnt+FZ89x5Soz7cjOGzzz/APXxQByk0jKRsbDEbAuOh74rNkAyWdSpDEFcE556e3rWzqGVnZvnDqSR0P51kXQbo+CSCeTtAP8AkUAU5sOnLYb73qDmolYYG7HAIHGT3p7EqRtI2nn/AOtUSFd2XOex7j8+tAEFFFFABW9M29jtYE428KOm4/8A1qwa2JsMW+7kqB1ye/IH+c0AWoEKyo/7s8kP7e35ir8SgkszMcdM9eTz+X9KyYZdlzGgjxxxjjAAP+PWt2FywZVG4vkADsevH+f50AdF4TsjdX6t+8ZR0wQcV9G+F7FYbOIYOwbcjv8AifxFePfDayb7cfkwvJ6fofx/nXvmhwvGirIM8jpjGfWgDo7Ky2RLujUN13A8n/ODVubykj7Ku4AjuM+h/rVYXnzBVIZcDPb1xj36imS3abdw4KjuM80AJK7CViMFenHYfX61NABsIY8qAcYPA6AfpVCZwrnjKA7uRwTwB/OtCCbkHIJduNpPf/JoAvQNulVWPPU/X/IqZWLO4U5PHy5xnmqDuquVXcOxJ5xxxz61Kk4byioY9AVA6nHb3oAdcqpwjg8g/exxzj+VS2dsIx843AHg/rVhU25MmAcDAzk1LJtZdxAyBjLdPz9aAEABy2NoHJIOQRT1JAwc8k8f4VE0nykuv3cdDg/5zUKTBgxBwx79+n/16ALj42kEELjgA8/54qLG4YZty4xz2+nrUw+RVGPlB7dqZGW3Fdq7V74/z7UAIitnO3/gJA5+tPiJyuM9Ow47UmVUKvAUE45zTw3OBnHHFADNgk/iyCQwx6UrxDJIY5pQ2CWYA45yB0FNdvLXkgLnOeSM/wBKAEdDnfkE5PDDP6V8Y/tm4/4WjpmO+jRZ5/6bT19oKdyt/EBnP1/zzXxh+2cMfFLTOAM6PERj/rtPQB4Xbldh3KTz6VIowSc7ckZyePzpLbmAjAxu6kZxTMFHO7BGBnryKALiSKI96sg24Xn0z1ra0DV5NP1KJo+m7DDHbuT61zgG7zFDqwxx25qxCzo6BW+ZAfl29RQB73b3iX1nFcQurEDJ9Tj09K3JL2HXfDrwThfMUY78+wrxXwjrRsZY4JSAjdATwPrXosF5mQTWroqr95T0x60AeearbPY3pgZcLng5/GnaffXenzLLaSkMvUA8Gu+8V6NDrGkG8teLiMbiAB+vevL5GAeRX+Xb0znNAHo+k+KIdXhNvdbI7nHBPRj3qxNM1u5jYNJG3IOc15PGSr7t7gg9QRXWaN4i8tki1AExZAVienPWgDQ1jQoNTikkhAWQAY7fpXC6jp01mXScOEBwDznHpXpsqK0vmWzFVIyT2HtVHUYIbpDBOvmSEZDDj8PU0AeVzxj5wQu7jgNjioDEFRgHJPoD0zyfrXVavorWTGRFLDnnFYckeyc7htG3kAZ/WgDKZRlycnB60whixZxnvmrUkZR9yr85PRe/vUWHVgHXYBxwODQAhiG8lTgeh4603JyPm5zjkc0EN97HJOM+hp8CF3BwGA65NAE8UhRShX5gOuMYFadkqyLksqjGDhcZrNEBWUndwep9TWrZIzEBGOQ3YfpQB7N+zz4cN941tbmZA0Nqd3I6mvsN+O4A968e+A2grp3h20uZY8PIDIzNwf8A9VehTa5BfSvBYOJSvDY6ZoAoa1Pc3WuR2RUrARnIP3vfP9K3NNtCgBlRVcdPcdqYtuwlt5G5OMYNaq8gHGKAKd+iiDbxz04rlr6wEUo8tTgjO3OR/wDWrtmQOfmH61FJbRyY3DIHtQB5Rqmim7xB9kLbuFcZGB6/5618tftC6PJonjW0tpkZGewSQBhjgySD+lffkUMUSfKq4Br4w/bQ/wCSp6bjvo8X/o6egDzHwkq/2VKxHzCY8+20cVenjZYXwu49UH9ao+EQP7LlBJAaYjI7fKK0bjuVDepHPTGMUAZjwgAgn5k6jHT8amshuf5WbJAXcOnvj2qKb95J8xXC4A9auWMJZTKw55CpnGCe4oA2i7QwbSxZVI4z90+tW9B0u61C9RI1Z89gOT3qhalVt8NnAOAMckf410GnXn9n2++2cRyNHjcCc5x1oAn8QWSWUr2skkDSpksFfdzjgE1y9wN5IchQRnK9PXpQ12zyF5CxeX58g9OetVrp8jJjBC9Dnp3xQBlXse5mmwpcLyo6+1ZtwCZAdik+pPt3/lWzfbGyGDOu3YD3BwMn8RzWHdArgIfkyVyOwGOP50AZ8kZbkAZPJ+lRqCcgtwM8k1JJGY8jAIB659fX0NRELjg846etAEFFFFABWtPHH5jOzkFmzg/eU9/89qya20AjDtlS0nUsc46c0AMDASIEd+3IPPbv74/Suk02MtNEWcgsAFA/XNc1EWPM6t8ozhfft7df0rr9EIaO3kQpgAYDHn/OM0Aeo+CIpbSdZkk4UAgOPbpx1r1iy1dHXcflIxznv6fjXkWl3Sk7IwFKDOM9q7XS7kmJWnx8uc8Y69R+dAHfW94siJG0q4ByCDn0q2pdpEO4bzkAEZyf8iuTt7lWO5FYvnoR0+v15rQhvGCqOuVIGc5Oe9AG/wDO+xQFDDkt161o70UfM7Rsz7SWHAz3+vFYOmO7yiLcWCMRgHHbjH610FvZTXBU/wADDcQTwTmgBqSbgic5ZsEDPA9j9a1tOt35LfJuP3Rxz6e1O0/T0tkDuN7YGeOBV9nUEdUU9x2/zxQArpjGP4f1FMbbtOeBwTnpnrSmVREXOAvJHuPWsye8Nw6Ki4AIDAt29qACcmXeNrEkZG44yKnt4XZQGBTcPlOOce9PiiBSPceV6nHNWkIWIkk5Ht/KgBygBdrY64wKR1GSfMO4DB6CnDswJI6/L3pXwNuACcgfh3oAhZGZsHAbjIJ/z+dKoLFdp4U8gnNTZHB9ulNLHHBA5wfb/PFADCGZiBgr2J/z7U0kqSgUspGeD3p+dindjGPmB7e/uKduAYAgMCOv+etAELHZhclRkEZHX/Pp7V8ZftnBh8UdMDf9AaLGf+u09fZkz5iIby2brtP8/pXxj+2Sxf4oabnto8Q9v9dNQB4jAV+yujMBkk4zj0pT5W4EPhehQHiqdFAF0bWbe0qluvXHPvUoZN2/zUzk96zaKANZrnGCJVHygADHB9vaux8L+JIIk8m8uI1VRgEuBXnFFAHt+m+LdPspyhvbWSAjDfvhkj8653xidIeRrvTtStGEgyYknBIP0FeZUUAb/wBsiDbldc/7w9u1TpdxlmAuoh2yWHTrXM0UAejaF4nWyHlTXUbxlRzvGRzW3NrGmSRrINSsww6jzFz/ADrx6igD186vpbKyyajatnuZV+nrWBqi6TJHujvLRZdu0FJQePzrz+igDoLhoMH9/E3ph81WeRHZf30a7TleQcVkUUAWzIAWVT8vTOeTzVqwkhUnLquR/F3rKooA6SJ7YhN00AAOT8wrqPDsOi3GrWUcupWVtC7qHeacKqjOTknpXmdFAH3fr3xB8J6L4OuYNH8TaHLcrB5UawX0TN07ANmuL+CnjnQY7mebV9f0yyYAYE95HFu/76NfIlFAH6OH4k+CiDu8XeHyW6f8TKHj/wAeqzH8R/BAQA+MfDf/AIM4f/iq/NqigD9KP+FkeB/+hx8N/wDgzh/+KpP+FkeCOv8AwmPhv8NTh/8Aiq/NiigD9Jv+Fj+BycDxj4c/HU4Of/Hq+Rv2tta0vXfiRp91omp2OpWy6VHG0tnOsyK4mmJUlSRnBBx7ivEqKAOw8IcaVMSFCiY/N3B2r0rSugzk/Mecg/T+h74rL8H4+wyA5w0pHXA6Cr8u1G6sd2SQD2//AFUAU8FWYYXHX0BPapbSRo2ZygKg9zxnjNRvlTgLjLEhV6njv7VPbNgBD82GHyjjaBz+JoA2LYLLu8poyAQGUk/X/GtK9t4RZxBZt7A854AA5/H0/CueRS7RojhS3LAdh1/KpBdTRqQ1yFG7HH8QzjFAE80LIqB0yBHkAHgn8PqPyqjcTxyREEoP4QT1HuR+JpSssznMhlbnCjtg81VmtfL+cpyPu5yMY6Z7UAF1MV2rjb8o78H39qxLvzBgI2A3G09MfX19q0XLFC0x256k9Rnnr3rPnVgqgAkDjI44oAoN/EAM7vu4+XjnNRfxHPBPTAqeSPLMoOXI6E5z/nNVyOSA2Mcg9qAIKKKKACtido0cRJtB5APZc85/WsetObcWMqnYTkY9Bgc0AO2/u3JIYIec545OfxrsfBsudL27DsicjO3JAPr6GuNVwZlYghSc9M5Prmuh8I3gjnaPzCYn5+b3Pp60Ael6TccJtZdxIOwj+Hiu+0l9ttGv32Ck4PUe9eUaRdpFOSwHl8jB7fyr0PQb1pljlWUklhgcfMKAO3tM7iJCoXPPGccc/wBavRBAW2MoGeCegwM4rHtJEMSqSQRgc9Tx0Nals4+5kgk7j8vOOKAOl0Aqhyqck5PP5j+ddhalNhCAgDoB0OK5LQpVc7kB3AFW449PxrqbeUBgFOV6KRQBfOSpHmFSPbnj+dIdrJukwQB25zx2qNpFAkeRgij1GMD3/GqTXDXKOsCMF4y5OCMjtQBFqdy0uIrdMoEGT6c0um24iRWKnJJBI5xVqG1CKF5wq4ORjPHT/PpVgRnBEbEZ7f57UAPQFzkc44O7n/PSgYyCRgg46igcHO4FRzk9+9IwYHdjcxwQMdKAJE3FRu2liMgD/wCvTiCQQo6D6ZNRngEknk5IJ6e1HK7Sz8DjPfmgCRcckbsHt601xyVJAzwOPekG4A5bGQTn+tNWUbQAeeq57j6UALwckg4xg8ccH+VIAADnjHHB6U0AtuLOWzzjGCPwpjhmO9AGI9D+n60ANnI5+Yg4xkDOAf518Xftf7v+Fm6dukMh/smPDEdvOmr7MnI4BPLcgZx0+lfGv7YRz8TdOG0rt0iJeT1/fTUAeF0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHW+E2P8AZkiFfkMxIPodorSMBMZ3Da23C/T/AOvVDwjKqaTMCxyszNgf7oFXrnJCkSNgENs7f560AUY9oJVhgKM4xwD/AIU+FAr5iUM+csOTjHp+FAJ3ndyecHJ6egpiwyExYk+9njOMDkce9AFyR1VmQ/KCOvfnp2/WmQK8kgCjJGMluPm9qc5xGyNhUC89z6Guh0DS2li8+XLBOBnoaAKYtjCmVKsQnzcH/PtUM0reWkSoBGhbzCV+Ynv+GK3L6KQcr8wIxwOh46464H8qw7ljLKYxvbaDjHUjoc0AY18cI4DbX3BsBcjHbP4VmTx7mO1XMmB8mcY/xrW1ENG/zFTg7Tntzx+tZc6yABgCSMgc4GPT+XNAGdOCshU8EjkH0644+lV9u4gD5RjIBqxMoWRgGxJnoev4ev1qEOcg4B5JHqT70AVqKKKACtWZla5EbqCucY39M9ayq0pC21dqlhGQuCuMH09v/rUAJuO1A6bV+4AOnerFtcCCfzFIU9Prgdf5VWWTbArONy7sEHk4Hr+ZoOfNbLBgTxuHXtn+lAHe291vk81SV3Fc5PHf8q6rQ9TZXiCzYiBGcevoMfWvMdLuTJHEmCEQnKk8j2/UVv6Vdncso3Nxlvb0PH4UAe56VqqGEI54xux/P610EV2jvmN+Dghq8ctNawkY3rkDccnhuOce1dbYamqoshkyMY4OBjPf9aAPUtJ1EJLkEnsSp69/yreTXEjfYc8HPB6Dv+HSvMNM1SPj5xuLAFv/AK/0roYrhJ1LAud2AcnBJ9qAOtOove8lmAOG29gM5zXW6dCVjUsU3EDJHP5Vwnhl4p75IpGIQHcgB6jsD+NekxKVVQcA9+Ov1oAaAQMfe7nI6/h/npSYyCT25HPP1qRVGckDPTg/nTdu47gQD06c0AMTCFucrgsTnrn1pU3bXABGeh61IB2OCeRim4GCpYDIySKAGgkkLhlAOORS5CgsflJ+8cYoZR8uMEHsADTSpIORuGfvdDge1ADlbCnYOD0ppJ8vcRuI5wKaytvzvIGOR7/0p7Er32nFADMl4+JBwMqR6+h/OopigwXGVPGCwwTj+VKVZQxy2Mcbvf8AlTAG8vkbGHLYI64oAz7iUmVm5CYw7D+lfHn7XTs/xK08sMD+yowo9B501fXk8wXLNjbnDZ65x+tfH37WD7/iJprAkg6TERx0/ezce/1oA8VooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOz8G4Gkzk85lZQp7natad+6hAr7QV4Hof8APNY3hcsdGlUHGZz0PP3RWnIN6EYVpHA56nr3FAFWCNlnJV+Mkknt6VZghRc5JDYxgDBHfntTSP3O6XHzNklRx17U9SVbhgEIwMDHGOvPegBXh5AU5JHA+vWvQtJtFOm23l7fN2DJU968/Ef+lIrAjBGPQHrXrnhOIHToI2TB4L8Y454z68UAU7zQrn7AGMIBbIXLZ6j0ri7u3e1M88m5ChGOjcZ/xr0/X7iXmKMhfLBKlc8CvMvEs8kSsGBd2B4PGBkc/nQBxGpEryxPBxyeD9T/ACqomAhZ9pd+pY4J9OORirskfmTM25VUHHXgj1FULjjggM3IbnHGPegCrckIq4GM/KQQCQR0BqruVXAwPRvepZEx0DHPIJ5HXgfWmM3z7jkZ6gfwjPFAFSiiigArQuJWMxyxDhymRnFZ9WGunYudqgsc8ZH9aAF++pKg9ckkcnsAKBvkOWZsAgFvQnvTWuXPRVU5zlcj+tKlyUC7Y4wVPUZ5+vNAFiOaSAjAVvRexP8AXNbNnqlvMrQyr5S4C9SfX8xXPi6IfcsUa+wzx+tM88jPyrzgnjrj/GgDuY5SMmNmZFGc46ntjNXrXVZoiubhijgEbs8HNcDbanNBHsCpIMg/Pk8j8att4iuD1t7bpjo3/wAVQB7LomvESFJRnGOcZrtdK1wSIS4Oc9jjHp+tfNkPiu8hzsgtcnuVb/4qtGD4h6vCF2Q2XygAEo3bp/FQB9e/D6VZ9WiKknaeV/XP1FevxsNgOQRj25r4E8O/G/xLoNz59raaTK3YTRSMB+UgrqE/al8bIuBpfhzr/wA+83/x2gD7V3DAIzTMksOcBeoHpXxcf2pvGxIP9l+HOP8Ap2m/+O0H9qXxsQf+JZ4c/C3mH/tagD7PHzLypPqMYBpPlGCmfXg9fWvi7/hqPxtz/wAS3w9z/wBO83/x2lH7UfjYcjTfDoPQH7PNx/5FoA+zS42kxHBzk9DRFICrA5GG5PfmvjE/tQ+NCCP7L8OYJz/x7zH/ANq0jftQeNmGDp3h7/wHm/8AjtAH2g5WM7g3sASePpUDSjcsYIJPXPGfX/PtXxq/7T/jRmJOmeHueuIJ/T/rrTX/AGnPGThQdL8O4HT/AEeb/wCO0AfZcjK6gKMJkYzyT7VBcSZAZiQMdQ3pXx0P2mvGQ66b4eJ9TBNkf+RaRv2mfGTR7Dpvh7b728x/nLQB9RanII/O3cJy+CPu9vzzXyL+0w/meP7VtzH/AIl6dccfvZeKtXH7Q/iyeIRvp+hADusEuT/5Erzjxn4ovfF2qpqGpRW0UyRCEC3QquAzHPJPOWNAGDRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAdl4P2ro8zNxiYgcnrtWtVzmKRUI3rnBwcmuJ0/Vp7CFooVjKM247gfQeh9qsDxDeA52wlh3wf8aAOnHKgqN4BwD26fpRbnfOQFG4HncOMg9cVyo127AHyxf98nn9acfEF0cZjgyDkHDf40AdvbwvPqMLHZE57kda9C03UmtIhHErEg/MBnj/ADz+deGWvii9t50lWO3Yp0VlYjP51rx/EbVo1IFrp+D1Bjf/AOLoA9zgu/tdhJK7AMRj5xnAHWvKPFNyJb+RM5GPLQ54Izzx0rIk+JusvaG3W105EIxlInz/AOhVzk+v3c77pBGec4wcflmgDWCyJltgKFixGCPyqk8Rlk6LhsKfqP51Q/te4/ux59cH/GkOqTM5do4iSMEYIH6GgCeeJWBL7hIeRjkfXFU0yAM4JJySeAD/ADpXv5GAHlxAewP+Na2h+JLbS23S+GtE1F85BvRcN+iyqD+IoA52iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Fracture, shaft of the humerus in newborn. B) Four weeks later, large mass of callus, varus angulation of 45 degrees. C) At age 14 months, fracture remodeled to normal alignment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Beaty JH. Fractures of the proximal humerus and shaft in children, in Eilert RE (ed): Instructional Course Lectures 41. Rosemont, IL, American Academy of Orthopaedic Surgeons, 1992, pp 369-372.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12660=[""].join("\n");
var outline_f12_23_12660=null;
var title_f12_23_12661="Penicillin G procaine: Drug information";
var content_f12_23_12661=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penicillin G procaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/10/32931?source=see_link\">",
"    see \"Penicillin G procaine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/13/35027?source=see_link\">",
"    see \"Penicillin G procaine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F207778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pfizerpen-AS&reg;;",
"     </li>",
"     <li>",
"      Wycillin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F207804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Penicillin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F207781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anthrax:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalational (postexposure prophylaxis):",
"     </i>",
"     I.M.: 1,200,000 units every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Overall treatment duration should be 60 days. Available safety data suggest continued administration of penicillin G procaine for longer than 2 weeks may incur additional risk of adverse reactions. Clinicians may consider switching to effective alternative treatment for completion of therapy beyond 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cutaneous (treatment):",
"     </i>",
"     I.M.: 600,000-1,200,000 units/day; alternative therapy is recommended in severe cutaneous or other forms of anthrax infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endocarditis caused by susceptible viridans",
"     </b>",
"     <b>",
"      <i>",
"       Streptococcus",
"      </i>",
"     </b>",
"     <b>",
"      (when used in conjunction with an aminoglycoside):",
"     </b>",
"     I.M.: 1.2 million units every 6 hours for 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gonorrhea (uncomplicated):",
"     </b>",
"     4.8 million units as a single dose given 30 minutes after probenecid 1 g orally",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neurosyphilis:",
"     </b>",
"     I.M.: 2.4 million units/day with 500 mg probenecid by mouth 4 times/day for 10-14 days;",
"     <b>",
"      Note: penicillin G aqueous I.V. is the preferred agent",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Whipple's disease:",
"     </b>",
"     I.M.: 1.2 million units/day (with streptomycin) for 10-14 days, followed by oral trimethoprim/sulfamethoxazole or doxycycline for 1 year",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F207794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/13/35027?source=see_link\">",
"      see \"Penicillin G procaine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"     I.M.: Infants and Children: 25,000-50,000 units/kg/day in divided doses 1-2 times/day; not to exceed 4.8 million units/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anthrax, inhalational (postexposure prophylaxis):",
"     </b>",
"     I.M.: 25,000 units/kg every 12 hours (maximum: 1,200,000 units every 12 hours).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Overall treatment duration should be 60 days. Available safety data suggest continued administration of penicillin G procaine for longer than 2 weeks may incur additional risk for adverse reactions. Clinicians may consider switching to effective alternative treatment for completion of therapy beyond 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syphilis (congenital):",
"     </b>",
"     I.M.: 50,000 units/kg/day once daily for 10 days; if more than 1 day of therapy is missed, the entire course should be restarted",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F207782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F207783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: Administer every 8-12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 12-18 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension: 600,000 units/mL (1 mL, 2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F207761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Procaine suspension for deep I.M. injection only; do not inject in gluteal muscle in children &lt;2 years of age; rotate the injection site; avoid I.V., intravascular, or intra-arterial administration of penicillin G procaine since severe and/or permanent neurovascular damage may occur",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F207760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderately-severe infections due to",
"     <i>",
"      Treponema pallidum",
"     </i>",
"     and other penicillin G-sensitive microorganisms that are susceptible to low, but prolonged serum penicillin concentrations; anthrax due to",
"     <i>",
"      Bacillus anthracis",
"     </i>",
"     (postexposure) to reduce the incidence or progression of disease following exposure to aerolized",
"     <i>",
"      Bacillus anthracis",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F207811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Penicillin G procaine may be confused with penicillin V potassium",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Wycillin&reg; may be confused with Bicillin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F207802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Conduction disturbances, myocardial depression, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: CNS stimulation, confusion, drowsiness, myoclonus, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hemolytic anemia, neutropenia, positive Coombs' reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site, sterile abscess at injection site, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Interstitial nephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions, Jarisch-Herxheimer reaction, pseudoanaphylactic reactions, serum sickness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F207764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to penicillin, procaine, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F207745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurovascular damage: Avoid I.V., intravascular, or intra-arterial administration since severe and/or permanent neurovascular damage may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolonged use: Extended duration of therapy or use associated with high serum concentrations (eg, in renal insufficiency) may be associated with an increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5720603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Penicillin crosses the placenta and distributes into amniotic fluid. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F207786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5706684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Penicillins are excreted in breast milk. The manufacturer recommends that caution be used when administering penicillin to nursing women. Nondose-related effects could include modification of bowel flora and allergic sensitization.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Penicillin G Procaine Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600000 units/mL (1 mL): $20.33",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F207755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic renal and hematologic function tests with prolonged therapy; fever, mental status, WBC count",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F207766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aquacaine (AU);",
"     </li>",
"     <li>",
"      Aqucilina (ES);",
"     </li>",
"     <li>",
"      Benzetacil (MX);",
"     </li>",
"     <li>",
"      Cidan-Cilina 900 (ES);",
"     </li>",
"     <li>",
"      Cilicaine Syringe (AU);",
"     </li>",
"     <li>",
"      Farmaproina (ES);",
"     </li>",
"     <li>",
"      Fradicilina (ES);",
"     </li>",
"     <li>",
"      Hidrociclina (MX);",
"     </li>",
"     <li>",
"      Intrasept (CH);",
"     </li>",
"     <li>",
"      Jenacillin O (DE);",
"     </li>",
"     <li>",
"      Klaricina (ES);",
"     </li>",
"     <li>",
"      Mudapenil (AR);",
"     </li>",
"     <li>",
"      Pam (NL);",
"     </li>",
"     <li>",
"      Penicillinum procainicum (PL);",
"     </li>",
"     <li>",
"      Peniern (ES);",
"     </li>",
"     <li>",
"      Penifasa 900 (ES);",
"     </li>",
"     <li>",
"      Peniroger Procain (ES);",
"     </li>",
"     <li>",
"      Procain-Penicillin Streuli (CH);",
"     </li>",
"     <li>",
"      Procaine Penicillin. G (FI);",
"     </li>",
"     <li>",
"      Procapen (FI);",
"     </li>",
"     <li>",
"      Provipen Procaina (ES);",
"     </li>",
"     <li>",
"      Retardillin (HU);",
"     </li>",
"     <li>",
"      Servipen-G Forte (CH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F207744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F207763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Therapeutic: 15-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Penetration across the blood-brain barrier is poor, despite inflamed meninges",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: ~30% hepatically inactivated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% to 90% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Renal: Delayed in neonates, young infants, and with impaired renal function",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/23/12661/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/23/12661/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paryani SG, Vaughn AJ, Crosby M, et al, &ldquo;Treatment of Asymptomatic Congenital Syphilis: Benzathine Versus Procaine Penicillin G Therapy,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(3):471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/23/12661/abstract-text/8071762/pubmed\" id=\"8071762\" target=\"_blank\">",
"        8071762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright AJ, &ldquo;The Penicillins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(3):290-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/23/12661/abstract-text/10090000/pubmed\" id=\"10090000\" target=\"_blank\">",
"        10090000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1990, 38(12):1353-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/23/12661/abstract-text/2254575/pubmed\" id=\"2254575\" target=\"_blank\">",
"        2254575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9750 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12661=[""].join("\n");
var outline_f12_23_12661=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207778\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207804\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207781\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207794\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207782\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207783\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207757\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207741\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207761\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207760\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207811\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207802\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207764\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207745\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299842\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207750\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207753\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720603\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207786\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5706684\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323653\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207755\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207766\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207744\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207763\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9750\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9750|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/10/32931?source=related_link\">",
"      Penicillin G procaine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/13/35027?source=related_link\">",
"      Penicillin G procaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_23_12662="Chapter 7A: Exchange of water between the cells and ECF";
var content_f12_23_12662=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 7A: Exchange of water between the cells and ECF",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/23/12662/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12662/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12662/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/23/12662/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12662/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/23/12662/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12662/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/23/12662/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The body water is distributed between three major compartments: the intracellular space; the interstitium, which constitutes the extracellular environment of the cells; and the vascular space. Regulation of the intracellular volume, which is essential for normal cellular function, is achieved in part by regulation of the plasma osmolality through changes in",
"    <strong>",
"     water",
"    </strong>",
"    balance. In comparison, maintenance of the plasma volume, which is essential for adequate tissue perfusion, is closely related to the regulation of",
"    <strong>",
"     sodium",
"    </strong>",
"    balance. Sodium and water homeostasis will be reviewed in detail in the following two chapters. It is useful, however, to first discuss the factors involved in the distribution of water across the cell membrane (between the intracellular and extracellular fluids) and across the capillary wall (between the vascular space and interstitium).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXCHANGE OF WATER BETWEEN CELLULAR AND EXTRACELLULAR FLUIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osmotic forces are the prime determinant of water distribution in the body. Water can freely cross almost all cell membranes; as a result, the body fluids are in osmotic equilibrium as the osmolalities of the intracellular and extracellular fluids are the same [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12662/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concept of osmotic pressure can be easily understood from the simple experiment in this figure (",
"    <a class=\"graphic graphic_figure graphicRef51398 \" href=\"UTD.htm?6/32/6669\">",
"     figure 1",
"    </a>",
"    ). Suppose distilled water in a beaker is separated into two compartments by a membrane that is permeable to water but not to solutes, and that glucose is added to the fluid on one side of the membrane. Water molecules exhibit random motion and can diffuse across a membrane by a mechanism similar to that for diffusion of solutes. When solutes are added to water, however, the intermolecular cohesive forces lead to a reduction in the random movement (or activity) of the water molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12662/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Since water moves from an area of high activity to one of low activity, water will flow into the compartment containing glucose.",
"   </p>",
"   <p>",
"    In theory, this movement of water, called osmosis, should continue indefinitely because the activity of water will always be lower in the glucose compartment. However, since the compartment is rigid, the increase in volume will result in an elevation in hydrostatic pressure, causing the fluid column above the compartment to rise. This hydrostatic pressure tends to push water back into the solute-free compartment. Equilibrium will be reached when the hydrostatic pressure (as measured by the height of the column) is equal to the forces pulling water across the membrane. This hydrostatic pressure which opposes the osmotic movement of water is called the osmotic pressure of the solution.",
"   </p>",
"   <p>",
"    The osmotic pressure that is generated is proportional to the",
"    <strong>",
"     number of particles",
"    </strong>",
"    per unit volume of solvent, not to the type, valence, or weight of the particles. The solute, however, must be unable to cross the cell membrane. Let us now consider what would happen in a beaker, similar to that in this figure (",
"    <a class=\"graphic graphic_figure graphicRef51398 \" href=\"UTD.htm?6/32/6669\">",
"     figure 1",
"    </a>",
"    ), if a lipid-soluble and freely diffusible solute such as urea were added to one compartment (",
"    <a class=\"graphic graphic_figure graphicRef53067 \" href=\"UTD.htm?0/38/621\">",
"     figure 2",
"    </a>",
"    ). The added urea will move down a concentration gradient into the solute-free compartment. The new equilibrium state will be characterized by equal urea concentrations in each compartment and not by water movement into the urea compartment. As a result, no osmotic pressure is generated by urea at equilibrium and urea is considered to be an",
"    <strong>",
"     ineffective osmole",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    Osmotic pressure is important in vivo because it determines the distribution of water between the extracellular and intracellular space. Each of these compartments has one solute that is primarily limited to that compartment and therefore is the major determinant of its osmotic pressure: Na+ salts are the principal extracellular osmoles and act to hold water in the extracellular space; conversely, K+ salts account for almost all the intracellular osmoles (most of the other major cell cation Mg2+ is bound and osmotically inactive) and act to hold water within the cells.",
"   </p>",
"   <p>",
"    Although the cell membrane is permeable to both Na+ and K+, these ions are able to act as effective osmoles because they are restricted to their respective compartments by the Na+-K+-ATPase pump in the cell membrane. The net effect is that the volumes of the extracellular and intracellular fluids are determined by the amount of water present and by the ratio of exchangeable Na+ to exchangeable K+&dagger;.",
"   </p>",
"   <p>",
"    &dagger;The exchangeable portion is used since about 30 percent of the body Na+ and a smaller fraction of the body K+ are bound in areas such as bone where they are \"nonexchangeable\" and therefore osmotically inactive. These ions also may be partially bound in intracellular organelles such as the nucleus and lysosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12662/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Under normal circumstances, the water and electrolyte content in the body is maintained within relatively narrow limits as variations in dietary intake are matched by appropriate changes in urinary excretion. Nevertheless, it is important to understand the potential physiologic effects of alterations in solute or water balance, since these disturbances often occur in the clinical setting.",
"   </p>",
"   <p>",
"    If, for example, the osmolality of one fluid compartment is changed, water will move across the cell membrane to reestablish osmotic equilibrium. How this affects water distribution and solute concentration can be appreciated from the following examples (",
"    <a class=\"graphic graphic_figure graphicRef75959 \" href=\"UTD.htm?2/37/2655\">",
"     figure 3",
"    </a>",
"    ). For the sake of simplicity, let us assume that the osmolality of the body fluids is 280",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    and is due entirely to 140",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of Na+ salts in the extracellular fluid and to 140",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    of K+ salts in the cells, i.e., we are assuming that Na+ and K+ salts dissociate completely into cations and anions. As depicted in part A of the following figure (",
"    <a class=\"graphic graphic_figure graphicRef75959 \" href=\"UTD.htm?2/37/2655\">",
"     figure 3",
"    </a>",
"    ), an average 70-kg man might have a total body water (TBW) of 42 liters (or 42 kg) of which 25 liters (60 percent) is intracellular and 17 liters (40 percent) is extracellular.",
"   </p>",
"   <p>",
"    What will happen if 420 meq of NaCl (420 mosmol) without water is added to the extracellular fluid, as shown in this figure (",
"    <a class=\"graphic graphic_figure graphicRef75959 \" href=\"UTD.htm?2/37/2655\">",
"     figure 3",
"    </a>",
"    )? Since the NaCl remains extracellular, there will be an increase in the extracellular fluid osmolality, resulting in",
"    <strong>",
"     water movement out of the cells",
"    </strong>",
"    down an osmotic gradient. The following calculations can be used to estimate the characteristics of the total body water in the new equilibrium state:",
"   </p>",
"   <p>",
"    &nbsp;1. &nbsp;Initial total body solute &nbsp;= &nbsp;280",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    &nbsp;x &nbsp;42 kg &nbsp;= &nbsp;11,760 mosmol",
"   </p>",
"   <p>",
"    &nbsp;2. &nbsp;Initial extracellular solute &nbsp;= &nbsp;280",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    &nbsp;x &nbsp;17 kg &nbsp;= &nbsp;4760 mosmol",
"   </p>",
"   <p>",
"    &nbsp;3. &nbsp;New total body solute &nbsp;= &nbsp;11,760 &nbsp;+ &nbsp;420 &nbsp;= &nbsp;12,180 mosmol",
"   </p>",
"   <p>",
"    &nbsp;4. &nbsp;New body water osmolality &nbsp;= &nbsp;12,180 mosmol &nbsp;&divide; &nbsp;42 kg &nbsp;= &nbsp;290",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;5. &nbsp;New extracellular solute &nbsp;= &nbsp;4760 &nbsp;+ &nbsp;420 &nbsp;= &nbsp;5180 mosmol",
"   </p>",
"   <p>",
"    &nbsp;6. &nbsp;New extracellular volume &nbsp;= &nbsp;5180 mosmol &nbsp;&divide; &nbsp;290",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    &nbsp;= &nbsp;17.9 kg",
"   </p>",
"   <p>",
"    &nbsp;7. &nbsp;New intracellular volume &nbsp;= &nbsp;42 &nbsp;- &nbsp;17.9 &nbsp;= &nbsp;24.1 kg",
"   </p>",
"   <p>",
"    &nbsp;8. &nbsp;New extracellular or plasma [Na+] &nbsp;= &nbsp;osmolality &nbsp;&divide; &nbsp;2 &nbsp;= &nbsp;145",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    Thus, increasing the quantity of extracellular solute results in the movement of 900 mL of water from the cells into the extracellular fluid. The net effect is an increase in the osmolality of",
"    <strong>",
"     both compartments",
"    </strong>",
"    even though the added solute is restricted to the extracellular space. This illustrates why the total body water (50 to 60 percent of lean body weight) must be used when calculating the volume of distribution of changes in plasma osmolality.",
"   </p>",
"   <p>",
"    A different sequence occurs if 1.5 liters of solute-free water is added to the extracellular fluid, eg, by ingestion. This reduces the extracellular fluid osmolality, creating an osmotic gradient favoring the",
"    <strong>",
"     entry of water into the cells",
"    </strong>",
"    , as in part C of the following figure (",
"    <a class=\"graphic graphic_figure graphicRef75959 \" href=\"UTD.htm?2/37/2655\">",
"     figure 3",
"    </a>",
"    ). To estimate the new steady state, steps 1 and 2 are similar to those above:",
"   </p>",
"   <p>",
"    &nbsp;1. &nbsp;Initial total body solute &nbsp;= &nbsp;11,760 mosmol",
"   </p>",
"   <p>",
"    &nbsp;2. &nbsp;Initial extracellular solute &nbsp;= &nbsp;4760 mosmol",
"   </p>",
"   <p>",
"    &nbsp;3. &nbsp;Initial intracellular solute &nbsp;= &nbsp;11,760 &nbsp;- &nbsp;4760 &nbsp;= &nbsp;7000 mosmol",
"   </p>",
"   <p>",
"    &nbsp;4. &nbsp;New total body water &nbsp;= &nbsp;42 &nbsp;+ &nbsp;1.5 &nbsp;= &nbsp;43.5 kg",
"   </p>",
"   <p>",
"    &nbsp;5. &nbsp;New body water osmolality &nbsp;= &nbsp;11,760 mosmol &nbsp;&divide; &nbsp;43.5 kg &nbsp;= &nbsp;270",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;6. &nbsp;New extracellular volume &nbsp;= &nbsp;4760 mosmol &nbsp;&divide; &nbsp;270",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    &nbsp;= &nbsp;17.6 kg",
"   </p>",
"   <p>",
"    &nbsp;7. &nbsp;New intracellular volume &nbsp;= &nbsp;7000 mosmol &nbsp;&divide; &nbsp;270 &nbsp;",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    &nbsp;= &nbsp;25.9 kg",
"   </p>",
"   <p>",
"    &nbsp;8. &nbsp;Ratio of intracellular volume to TBW &nbsp;= &nbsp;25.9 &nbsp;&divide; &nbsp;43.5 &nbsp;= &nbsp;60 percent",
"   </p>",
"   <p>",
"    &nbsp;9. &nbsp;New extracellular or plasma [Na+] &nbsp;= &nbsp;osmolality &nbsp;&divide; &nbsp;2 &nbsp;= &nbsp;135",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    Since there is no change in the ratio of intracellular to extracellular solute in this example, the fractional composition of the TBW is unchanged (cell water is still 60 percent of TBW). However, the TBW is increased, resulting in",
"    <strong>",
"     expansion and dilution",
"    </strong>",
"    of both compartments&dagger;.",
"   </p>",
"   <p>",
"    &dagger; In this example, it is assumed that the administered water is retained. In normal subjects, however, excess water is excreted so rapidly that there is little change in volume or sodium excretion (see Chap. 11). Increases in extracellular volume and sodium excretion after a water load occur only if there is some defect in water excretion, as with persistent secretion of antidiuretic hormone (see Chap. 23).",
"   </p>",
"   <p>",
"    Finally, if both NaCl and water are given as 1.5 liters of isotonic NaCl, there will be no change in osmolality and consequently no water movement across the cell membrane, as depicted in part D of the following figure (",
"    <a class=\"graphic graphic_figure graphicRef75959 \" href=\"UTD.htm?2/37/2655\">",
"     figure 3",
"    </a>",
"    ). Since the administered NaCl remains in the extracellular space, the only effect is a 1.5-liter increase in the extracellular fluid volume.",
"   </p>",
"   <p>",
"    The results of these experiments are summarized in this table (",
"    <a class=\"graphic graphic_table graphicRef73306 \" href=\"UTD.htm?36/41/37531\">",
"     table 1",
"    </a>",
"    ) and illustrate an important and often misunderstood concept, that the plasma Na+ concentration is a measure of concentration and not of volume. In each instance, the extracellular fluid volume is increased, because of an elevation in either the TBW",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the total exchangeable Na+; despite this uniform change in volume, however, the plasma Na+ concentration is, respectively, increased, decreased, and unchanged. This occurs because the plasma Na+ concentration reflects the",
"    <strong>",
"     ratio",
"    </strong>",
"    of the amounts of solute and water present, not the absolute amount of either solute or water.",
"   </p>",
"   <p>",
"    Thus, there is no necessary correlation between the plasma Na+ concentration and the extracellular fluid volume. These parameters change in a parallel direction when Na+ is administered but in an opposite direction (low plasma Na+ concentration, high extracellular fluid volume) when water retention occurs, as shown in parts b and c of this figure (",
"    <a class=\"graphic graphic_figure graphicRef75959 \" href=\"UTD.htm?2/37/2655\">",
"     figure 3",
"    </a>",
"    ). Furthermore, since the extracellular volume is the primary determinant of urinary sodium excretion (see Chap. 8), there is also",
"    <strong>",
"     no relationship",
"    </strong>",
"    between the plasma Na+ concentration and the rate of sodium excretion (",
"    <a class=\"graphic graphic_table graphicRef73306 \" href=\"UTD.htm?36/41/37531\">",
"     table 1",
"    </a>",
"    ). When water is retained, for example, the plasma Na+ concentration falls by dilution but urinary sodium excretion will rise because of the increase in extracellular volume.",
"   </p>",
"   <p>",
"    One final point deserves emphasis in these experiments. The intracellular volume varies inversely with the plasma Na+ concentration, decreasing with hypernatremia and increasing with hyponatremia. These changes are important clinically because the neurologic symptoms associated with acute changes in the plasma Na+ concentration are primarily related to these alterations in cell volume in the brain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELATION OF PLASMA SODIUM CONCENTRATION TO OSMOLALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The osmolality of the plasma (Posm) is equal to the sum of the osmolalities of the individual solutes in the plasma&dagger;. Most of the plasma osmoles are Na+ salts, with lesser contributions from other ions, glucose, and urea. The osmotic effect of the plasma ions can usually be estimated from 2 x plasma Na+ concentration. The validity of this approximation results from the interplay of several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ionic interactions in plasma reduce the random movement of NaCl so that it acts osmotically as if it were only 75 percent, not 100 percent, dissociated. As a result, 1 mmol of NaCl behaves as if it dissociates into roughly 1.75 particles (0.75 Na+, 0.75 Cl-, and 0.25 NaCl) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12662/abstract/5\">",
"       5",
"      </a>",
"      ]; thus, the plasma Na+ concentration must be multiplied by 1.75 to estimate the osmotic effect of sodium salts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &dagger;A review of the units and the methods used to measure the plasma osmolality can be found elsewhere in the program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30771?source=see_link&amp;anchor=H4#H4\">",
"     \"Chapter 1B: Units of solute measurement\", section on 'Osmotic pressure and osmolality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only 93 percent of the plasma is normally composed of water, with fat and proteins comprising the remaining 7 percent. In most laboratories, the plasma Na+ concentration is measured per liter of plasma. This value must be divided by 0.93 to arrive at the physiologically important Na+ concentration in the plasma water (Na+ being present only in the aqueous phase of plasma). Thus,",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Osmolality of Na+ salts &nbsp; &nbsp;= &nbsp; (1.75 &nbsp;&divide; &nbsp;0.93) &nbsp; x &nbsp; plasma [Na+]",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; = &nbsp; 1.88 &nbsp;x &nbsp;plasma [Na+]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The remaining 0.12 &nbsp;x &nbsp;plasma Na+ concentration is equal to 17",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      (0.12 &nbsp;x &nbsp;140), which fortuitously is the approximate osmotic pressure generated by K+, Ca2+, and Mg2+ salts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp;The osmotic contributions of glucose and urea, both of which are measured in milligrams per deciliter, can be calculated from Eq. (1):",
"   </p>",
"   <p>",
"    (Eq. 1) &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    &nbsp; = &nbsp;",
"    <span class=\"nowrap\">",
"     (mg/dL",
"    </span>",
"    &nbsp;x &nbsp;10) &nbsp;&divide; &nbsp;mol wt",
"   </p>",
"   <p>",
"    The molecular weight of glucose is 180 and that of the two nitrogen atoms in urea (since urea is measured as the blood urea nitrogen or BUN) is 28. &nbsp;Therefore, the Posm can be estimated from:",
"   </p>",
"   <p>",
"    (Eq. 2) &nbsp; &nbsp;Posm &nbsp; &nbsp;&asymp; &nbsp; &nbsp;(2 &nbsp; x &nbsp; plasma [Na+]) &nbsp;+ &nbsp;",
"    <span class=\"nowrap\">",
"     ([glucose]/18)",
"    </span>",
"    &nbsp; + &nbsp;",
"    <span class=\"nowrap\">",
"     (BUN/2.8)",
"    </span>",
"   </p>",
"   <p>",
"    The effective plasma (and extracellular fluid) osmolality is determined by those osmoles that act to hold water within the extracellular space. Since urea is an ineffective osmole:",
"   </p>",
"   <p>",
"    (Eq. 3) &nbsp; &nbsp;Effective Posm &nbsp; &nbsp;&asymp; &nbsp; &nbsp;(2 &nbsp;x &nbsp;plasma [Na+]) &nbsp;+ &nbsp;",
"    <span class=\"nowrap\">",
"     ([glucose]/18)",
"    </span>",
"   </p>",
"   <p>",
"    The normal values for these parameters are:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Plasma [Na+] &nbsp; = &nbsp; &nbsp; 137-145",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp;[Glucose] &nbsp; = &nbsp; &nbsp; 60-100",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    fasting",
"    <br/>",
"    &nbsp; &nbsp;BUN &nbsp; = &nbsp; &nbsp; 10-20",
"    <span class=\"nowrap\">",
"     mg/dL",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp;Posm &nbsp; = &nbsp; &nbsp; 275-290",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp;Effective Posm &nbsp; = &nbsp; &nbsp; 270-285",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"   </p>",
"   <p>",
"    Under normal circumstances, glucose accounts for only 5",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    and Eq. (3) can be simplified to:",
"   </p>",
"   <p>",
"    (Eq. 4) &nbsp; &nbsp;Effective Posm &nbsp; &nbsp;&asymp; &nbsp; 2 &nbsp;x &nbsp;plasma [Na+]",
"   </p>",
"   <p>",
"    Thus, in most conditions, the plasma Na+ concentration is a reflection of the Posm, a finding consistent with the fact that Na+ salts are the principal extracellular osmoles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Determinants of the Plasma Sodium Concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the body fluids are in osmotic equilibrium,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Effective Posm &nbsp; = &nbsp; effective osmolality of total body water",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; = &nbsp; (extracellular solute &nbsp;+ &nbsp;intracellular solute) &nbsp;&divide; &nbsp;total body water",
"   </p>",
"   <p>",
"    As described above, exchangeable Na+ (Nae+) salts are the primary effective extracellular solutes, and exchangeable K+ (Ke+) salts are the primary effective intracellular solutes. Therefore,",
"   </p>",
"   <p>",
"    (Eq. 5) &nbsp; &nbsp;Effective Posm &nbsp; &nbsp;&asymp; &nbsp; (2 &nbsp;x &nbsp;Nae+ &nbsp;+ &nbsp;2 x &nbsp;Ke+) &nbsp; &divide; &nbsp; TBW",
"   </p>",
"   <p>",
"    (The multiple 2 is used to account for the osmotic contribution of the anions accompanying Na+ and K+.) If we now combine Eqs. (4) and (5), both of which are formulas for the effective Posm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12662/abstract/5\">",
"     5",
"    </a>",
"    ] :",
"   </p>",
"   <p>",
"    (Eq. 6) &nbsp; &nbsp;Plasma [Na+] &nbsp; &nbsp;&asymp; &nbsp; (Nae+ &nbsp;+ &nbsp;Ke+) &nbsp; &nbsp;&divide; &nbsp; TBW",
"   </p>",
"   <p>",
"    As illustrated in this figure (",
"    <a class=\"graphic graphic_figure graphicRef71817 \" href=\"UTD.htm?42/31/43518\">",
"     figure 4",
"    </a>",
"    ), this relationship holds over a wide range of plasma Na+ concentrations in humans.",
"   </p>",
"   <p>",
"    The importance of these variables on the plasma Na+ concentration can be appreciated from the examples in Figure 3. Increasing the Nae+ elevates the plasma Na+ concentration; increasing the TBW decreases the plasma Na+ concentration; and increasing the Nae+ and TBW proportionately has no effect on the plasma Na+ concentration (",
"    <a class=\"graphic graphic_figure graphicRef75959 \" href=\"UTD.htm?2/37/2655\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The effect of changes in potassium balance is less apparent but can be important clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12662/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Suppose, for example, that K+ is lost from the extracellular fluid because of diarrhea, leading to a fall in the plasma K+ concentration. This will create a concentration gradient favoring the movement of K+ from the cells into the extracellular fluid. Since large proteins and organic phosphates are the major intracellular anions and cannot easily leave the cells, electroneutrality is preserved by Na+ (and H+) entry into the cells, thereby lowering the plasma Na+ concentration.",
"   </p>",
"   <p>",
"    The major clinical application of these concepts occurs in patients with hyponatremia (low plasma Na+ concentration) or hypernatremia (high plasma Na+ concentration). From the relationships in Eq. 4 and 6, we can see that hyponatremia usually represents hypoosmolality and can be produced by Na+ and K+ loss or, most commonly, by water retention. Excretion of the excess water in the urine is normally a very effective defense against the development of hyponatremia. Thus, a fall in the plasma Na+ concentration is almost always associated with a defect in urinary water excretion, due most often to the presence of antidiuretic hormone.",
"   </p>",
"   <p>",
"    On the other hand, hypernatremia represents hyperosmolality and can be produced by Na+ gain or water loss. The toxicity of hyperkalemia (high plasma K+ concentration) prevents the retention of enough K+ to cause an important elevation in the plasma Na+ concentration. The primary protective mechanism against hypernatremia is the stimulation of thirst, thereby increasing water intake and lowering the plasma Na+ concentration to normal. Thus, hypernatremia generally occurs in infants or comatose adults who cannot express a normal thirst response.",
"   </p>",
"   <p>",
"    Notice that the regulation of the plasma Na+ concentration and therefore the plasma osmolality occurs by changes in",
"    <strong>",
"     water balance",
"    </strong>",
"    . Although it is tempting to assume that maintenance of the plasma Na+ concentration must be related to Na+ balance, this is not the case. Alterations in sodium balance are used to maintain the plasma volume and tissue perfusion, not the plasma Na+ concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=see_link\">",
"     \"Chapter 8C: Regulation of renal Na+ excretion\"",
"    </a>",
"    .) Too much sodium is manifested as edema and too little sodium results in hypovolemia.",
"   </p>",
"   <p>",
"    This discussion is continued elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40133?source=see_link\">",
"     \"Chapter 7B: Exchange of water between plasma and interstitial fluid\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12662/abstract/1\">",
"      MAFFLY RH, LEAF A. The potential of water in mammalian tissues. J Gen Physiol 1959; 42:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12662/abstract/2\">",
"      Kiil F. Molecular mechanisms of osmosis. Am J Physiol 1989; 256:R801.",
"     </a>",
"    </li>",
"    <li>",
"     Wright, E, Schulman, G. Principles of epithelial transport. In: Clinical Disorders of Fluid and Electrolyte Metabolism, 4th, Maxwell MH, Kleeman CR, Narins RG (Ed), McGraw-Hill, New York, 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12662/abstract/4\">",
"      LeFurgey A, Spencer AJ, Jacobs WR, et al. Elemental microanalysis of organelles in proximal tubules. I. Alterations in transport and metabolism. J Am Soc Nephrol 1991; 1:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12662/abstract/5\">",
"      EDELMAN IS, LEIBMAN J, O'MEARA MP, BIRKENFELD LW. Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water. J Clin Invest 1958; 37:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12662/abstract/6\">",
"      LARAGH JH. The effect of potassium chloride on hyponatremia. J Clin Invest 1954; 33:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12662/abstract/7\">",
"      Fichman MP, Vorherr H, Kleeman CR, Telfer N. Diuretic-induced hyponatremia. Ann Intern Med 1971; 75:853.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7253 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12662=[""].join("\n");
var outline_f12_23_12662=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXCHANGE OF WATER BETWEEN CELLULAR AND EXTRACELLULAR FLUIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELATION OF PLASMA SODIUM CONCENTRATION TO OSMOLALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Determinants of the Plasma Sodium Concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7253\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7253|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/32/6669\" title=\"figure 1\">",
"      Generation of osmotic pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/38/621\" title=\"figure 2\">",
"      Urea as an ineffective osmole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/37/2655\" title=\"figure 3\">",
"      Osmotic pressure and body water",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/31/43518\" title=\"figure 4\">",
"      Determinants of plasma sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7253|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/41/37531\" title=\"table 1\">",
"      Plasma sodium and volume",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30771?source=related_link\">",
"      Chapter 1B: Units of solute measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40133?source=related_link\">",
"      Chapter 7B: Exchange of water between plasma and interstitial fluid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=related_link\">",
"      Chapter 8C: Regulation of renal Na+ excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_23_12663="Diagnostic thoracentesis";
var content_f12_23_12663=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic thoracentesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/23/12663/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12663/contributors\">",
"     John E Heffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/23/12663/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12663/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/23/12663/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12663/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/23/12663/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracentesis is a percutaneous procedure during which a needle is inserted into the pleural space and pleural fluid is removed. \"Diagnostic thoracentesis\" refers to removal of a small volume of pleural fluid for analysis, while \"therapeutic thoracentesis\" refers to removal of a large volume of pleural fluid for relief of symptoms.",
"   </p>",
"   <p>",
"    The indications, contraindications, technique, and complications of diagnostic thoracentesis will be reviewed here. Pleural fluid analysis, pleural manometry, and large volume thoracentesis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=see_link\">",
"     \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=see_link\">",
"     \"Measurement of pleural pressure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32582?source=see_link\">",
"     \"Large volume thoracentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusions are usually detected by physical examination and then confirmed radiographically. Most patients who have a pleural effusion should undergo diagnostic thoracentesis to determine the nature of the effusion (ie, transudate, exudate) and to identify potential causes (eg, malignancy, infection).",
"   </p>",
"   <p>",
"    There are two circumstances in which diagnostic thoracentesis is usually not required: when there is a small amount of pleural fluid and a secure clinical diagnosis (eg, viral pleurisy), or when there is clinically obvious heart failure (HF) without atypical features [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/1\">",
"     1",
"    </a>",
"    ]. Atypical features that should prompt consideration of diagnostic thoracentesis in a patient with HF include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A unilateral effusion, especially if it is left-sided",
"     </li>",
"     <li>",
"      Bilateral effusions that are of disparate sizes",
"     </li>",
"     <li>",
"      Pleurisy",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Normal cardiac silhouette on chest radiograph",
"     </li>",
"     <li>",
"      An echocardiogram that is inconsistent with heart failure",
"     </li>",
"     <li>",
"      B-type brain natriuretic peptide (BNP) levels that are inconsistent with heart failure",
"     </li>",
"     <li>",
"      An alveolar-arterial oxygen gradient that is larger than expected",
"     </li>",
"     <li>",
"      The effusion does not resolve with heart failure therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no absolute contraindications to thoracentesis. The procedure should be performed if clinical judgment indicates that the information gained from pleural fluid analysis is sufficiently important for diagnosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    therapy that it outweighs the risks of the procedure. Increased caution is warranted in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticoagulation or a bleeding diathesis, with a PT or PTT greater than twice the midpoint of the normal range, a platelet count less than 25,000",
"      <span class=\"nowrap\">",
"       platelets/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      or a serum creatinine concentration greater than 6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/2\">",
"       2",
"      </a>",
"      ]. Decisions to reverse the coagulopathy or correct the thrombocytopenia should be individualized.",
"     </li>",
"     <li>",
"      A very small volume of pleural fluid, with less than 1 cm distance from the pleural fluid line to the chest wall on a decubitus chest radiograph. In this situation, the risk of thoracentesis generally outweighs the usefulness of pleural fluid analysis. If the underlying disease or pleural effusion is clinically important, the effusion will increase in size and become amenable to thoracentesis.",
"     </li>",
"     <li>",
"      Mechanical ventilation. Patients receiving mechanical ventilation with positive end-expiratory pressure (PEEP) are not at increased risk for developing a pneumothorax compared with non-mechanically ventilated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]. However, mechanically ventilated patients are at increased risk of developing tension physiology or persistent air leak (ie, bronchopleural fistula) if a pneumothorax does occur [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/6-9\">",
"       6-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Active skin infection at the point of needle insertion, because insertion of a thoracentesis needle through infected tissue could result in pleural space infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians who perform thoracentesis should have extensive experience and demonstrated competency with the procedure. Resident trainees at teaching hospitals self-report comfort in performing thoracentesis after 5 to 6 procedures, yet 18 percent state they have supervised trainees more junior to themselves before they had gained comfort with the technique themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/10\">",
"     10",
"    </a>",
"    ]. Standardized curricula and training programs for teaching thoracentesis with structured proficiency and competency standards have been shown to improve thoracentesis knowledge and skills [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic thoracentesis should be explained in detail to the patient and informed consent obtained. Patient anxiety can often be allayed by assuring the patient that the procedure causes minimal discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/13\">",
"     13",
"    </a>",
"    ]. Opiates, anxiolytics, or sedatives are rarely necessary, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    is not routinely given.",
"   </p>",
"   <p>",
"    Once the procedure has been explained to the patient and informed consent obtained, the patient is positioned for the procedure. Thoracentesis is usually performed with the patient in a sitting position, sitting upright with his or her arms resting on a surface, such as a bedside table. The lateral recumbent position can be used if the patient is unable to sit upright.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Site selection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1913753\">",
"    <span class=\"h3\">",
"     Location of fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of the puncture site is guided by ultrasound or physical examination. Ultrasound-assisted thoracentesis is becoming the standard of practice for the procedure, because of the considerable inaccuracy of the physical examination in selecting an appropriate and safe thoracentesis site [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/14-22\">",
"     14-22",
"    </a>",
"    ]. Routine use of ultrasound for all diagnostic thoracenteses to mark the site",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    guide thoracentesis has been shown to decrease the rate of pneumothorax from 8.6 percent to 1.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/11\">",
"     11",
"    </a>",
"    ]. Ultrasound guidance is definitely indicated for patients with loculated effusions, but may need to be supplemented by chest-computed tomography in the setting of complex pleural and lung parenchymal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26408?source=see_link\">",
"     \"Thoracic ultrasound: Indications, advantages, and technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasound localization is performed with the patient in the same position that he or she will be in during the thoracentesis, especially if it is being used for a loculated effusion. The advantages of ultrasound guidance diminish if ultrasound is used to mark the puncture site and then the patient is moved to a different location or into a different position for the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/25\">",
"     25",
"    </a>",
"    ]. A thoracentesis puncture site can usually be identified within two minutes using a portable ultrasound machine.",
"   </p>",
"   <p>",
"    For patients with a nonloculated, free-flowing effusion, when ultrasound is not available and the physical examination is being used to guide selection of the puncture site, the following landmarks are employed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One to two interspaces below the level at which breath sounds decrease or disappear on auscultation, percussion becomes dull, and fremitus disappears",
"     </li>",
"     <li>",
"      Above the ninth rib, to avoid subdiaphragmatic puncture",
"     </li>",
"     <li>",
"      Midway between the spine and the posterior axillary line, because the ribs are easily palpated in this location.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1913760\">",
"    <span class=\"h3\">",
"     Avoidance of intercostal arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to choosing a puncture site that correctly guides the needle to the effusion, it is also important to choose a site that avoids laceration of tortuous intercostal arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. Among elderly patients, the intercostal arteries can follow a particularly tortuous course that places them in danger of puncture even when the operator is careful to pass the thoracentesis needle over the upper edge of the rib [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/26\">",
"     26",
"    </a>",
"    ]. The typical location of intercostal tortuosities was examined using 3D-computed tomography (3D-CT) studies from 33 patients with a mean age of 74 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/27\">",
"     27",
"    </a>",
"    ]. The predicted safety of potential puncture sites in the area 5 to 6 cm lateral to the spine was compared with that for an area 9 to 10 cm lateral at the level of the eighth and ninth ribs. The &ldquo;safe&rdquo; area that would most likely avoid puncture of a tortuous vessel was larger in the more lateral location. Thus, when performing a thoracentesis on an elderly patient, it is prudent to choose a puncture site 9 to 10 cm lateral to the spine, assuming that the fluid collection will be equally accessible. This site is approximately at the posterior axillary line. However, choosing this area for a puncture site does not entirely avoid tortuous blood vessels, so patients still need careful follow-up after thoracentesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Site preparation and local anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracentesis is a sterile procedure. A wide area surrounding the puncture site should be sterilized with 0.05 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    or 10 percent povidone-iodine solution, prior to placement of sterile drapes around the puncture site. Although the normal pleural space is efficient in clearing bacteria, patients who are immunocompromised or have severe preexisting pleural injury are probably at increased risk for iatrogenic empyema if adherence to aseptic technique is not maintained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9735?source=see_link\">",
"     \"Mechanisms of pleural liquid turnover in the normal state\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36695?source=see_link\">",
"     \"Mechanisms of pleural liquid accumulation in disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the puncture site and surrounding skin is sterilized, local anesthetic (eg, 1 or 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) should be administered. The epidermis is initially infiltrated with anesthetic using a syringe and 25-gauge needle. Next, a syringe with a 22-gauge needle is inserted, advanced toward the rib, and then \"walked\" over the superior edge of the rib. Passing the needle over the superior aspect of the rib decreases the risk of injury to the neurovascular bundle, which traverses the inferior rib margin. However, passing the needle over the rib does not entirely protect against laceration of tortuous intercostal vessels. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Site selection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As the needle is advanced, aspiration should be attempted by intermittently pulling back on the plunger of the syringe. Anesthetic is injected if there is no return of blood or pleural fluid into the syringe. Intermittent aspiration serves two purposes. First, blood return indicates that the needle is intravascular and prevents the operator from injecting anesthetic intravascularly. Second, pleural fluid return indicates that the needle has entered the pleural space. Additional anesthetic should be injected to anesthetize pleural nerve endings and then the needle should be withdrawn. This technique infiltrates the skin, rib periosteum, and parietal pleura with local anesthetic, thereby minimizing pain and rendering the discomfort of the procedure similar to that of venipuncture [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fluid removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 50 mL syringe is attached to a 22-gauge needle that is 1.5 inches in length. A longer needle is selected for markedly obese patients. Adding 1 mL of 1:1000",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    to the 50 mL syringe prevents clotting of hemorrhagic or highly proteinaceous fluid and improves the quality of the cytologic examination of the pleural fluid. With continuous negative pressure applied to the syringe by gently pulling back on the plunger, the needle is advanced through the anesthetized tract until pleural fluid returns. Approximately 30 to 75 mL of pleural fluid should be withdrawn for analysis, and then the needle removed.",
"   </p>",
"   <p>",
"    When evaluating for possible malignancy, increasing the volume of fluid analyzed above 50 mL does not significantly increase the yield of pleural fluid cytology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. This was illustrated in a prospective study of 44 patients, 31 of whom had a known extrapleural malignancy; both 50 mL and large volume (approximately 890 mL) samples of pleural fluid were analyzed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/31\">",
"     31",
"    </a>",
"    ]. In 23 patients with positive and 21 with negative cytology, the large and 50 mL samples yielded identical results.",
"   </p>",
"   <p>",
"    On the other hand, analyzing less than 60 mL of pleural fluid appears to reduce the diagnostic yield for pleural malignancy. In a study of 102 patients, the sensitivity and negative predictive value were lower for direct",
"    <span class=\"nowrap\">",
"     smear/cytospin",
"    </span>",
"    techniques when 10 mL of pleural fluid was analyzed compared with 60 mL or 150 mL samples [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/32\">",
"     32",
"    </a>",
"    ]. When both direct",
"    <span class=\"nowrap\">",
"     smear/cytospin",
"    </span>",
"    and cell block preparations were used, a volume of 150 mL provided greater sensitivity and negative predictive value than the 10 mL volume, but not the 60 mL volume. Based on these data, we recommend a sample of 50 to 60 mL for cytologic examination.",
"   </p>",
"   <p>",
"    A \"dry\" thoracentesis may result from absence of pleural fluid, incorrect needle placement, thick pleural fluid, or use of an inappropriately short needle. The needle can be withdrawn and reinserted in a slightly different angle if the patient tolerated the initial dry tap. A second dry tap warrants reevaluation of the patient and ultrasound guidance if not initially employed.",
"   </p>",
"   <p>",
"    Certain findings may provide clues to the cause of a dry tap. Aspiration of air implies that the lung has been punctured because the needle was inserted superior to the effusion or too deeply. Aspiration of a small amount of blood suggests that the needle may have been inserted inferior to the effusion (ie, subdiaphragmatically). Failure to aspirate anything implies that the needle may have been too short to penetrate the pleura, especially in an obese patient.",
"   </p>",
"   <p>",
"    Patients with large pleural effusions may require thoracentesis for both diagnosis and therapeutic removal of fluid. Large volume thoracentesis and the technique for measuring pleural pressure to guide fluid removal are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32582?source=see_link\">",
"     \"Large volume thoracentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=see_link\">",
"     \"Measurement of pleural pressure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Specimen preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common tests performed on pleural fluid include cell count, pH, protein, lactate dehydrogenase, glucose, amylase, gram stain, culture, and cytology. The pleural fluid should be immediately placed in the appropriate specimen tubes and bottles, and then sent to the laboratory for analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Collection of pleural fluid for measurement of pH requires careful technique because the admixture of air,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    with pleural fluid alters the measured pH. The syringe used to anesthetize the thoracentesis site should not be used to collect pleural fluid because even a small volume of residual lidocaine will affect pH. A standard 3 mL syringe pre-coated with heparin (&lt;0.4 mL or &lt;~8 units) or a 3 mL arterial blood gas syringe that comes pre-coated with heparin is attached to the thoracentesis catheter to draw pleural fluid directly from the patient. Any air bubbles in the syringe should be immediately expelled from the syringe and the syringe placed on ice. Fluid should be analyzed by a blood gas analyzer within one hour of collection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link&amp;anchor=H9#H9\">",
"     \"Arterial blood gases\", section on 'Specimen care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;A routine chest radiograph after thoracentesis is not indicated for most asymptomatic, non-ventilated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. This was best illustrated by a prospective cohort study in which only 1 percent of 488 asymptomatic patients were found to have a pneumothorax on a post-thoracentesis chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A chest radiograph is indicated if air was aspirated during the procedure, symptoms or signs of pneumothorax develop, or multiple needle passes were required [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/37\">",
"     37",
"    </a>",
"    ]. Whether a post-thoracentesis chest radiograph is needed for mechanically ventilated patients is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/38\">",
"     38",
"    </a>",
"    ]. Only 2 to 7 percent of thoracenteses performed in mechanically ventilated patients develop pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]; however, these pneumothoraces are at increased risk of developing tension physiology or persistent air leak (ie, bronchopleural fistula) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential complications of thoracentesis include pain at the puncture site, bleeding (eg, hematoma, hemothorax, or hemoperitoneum), pneumothorax, empyema, soft tissue infection, spleen or liver puncture, vasovagal events, seeding the needle tract with tumor, and adverse reactions to the anesthetic or topical antiseptic solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/13,42,43\">",
"     13,42,43",
"    </a>",
"    ]. Cases of retained intrapleural catheter fragments have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pneumothorax is the most common complication that is clinically important. Prospective observational studies indicate that pneumothorax occurs in up to 30 percent of thoracenteses, although most studies found rates less than 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/13,20,45,46\">",
"     13,20,45,46",
"    </a>",
"    ]. When a pneumothorax occurs, it is usually small and can be observed. Tube thoracostomy should be considered if the pneumothorax is large, progressive, the patient is symptomatic, or the patient is mechanically ventilated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infectious complications are exceptionally rare (no occurrences in 2486 procedures) when thoracentesis is performed by experienced operators under ultrasound guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12663/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver or spleen puncture tends to occur when the patient is not sitting absolutely upright because movement toward recumbency causes cephalad migration of the abdominal viscera. The outcome is generally favorable if a small bore needle was used, the patient is not receiving anticoagulants, and the patient does not have a bleeding diathesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/3/24624?source=see_link\">",
"       \"Patient information: Thoracentesis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thoracentesis is a percutaneous procedure during which a needle is inserted into the pleural space and pleural fluid is removed. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients who have a pleural effusion should undergo thoracentesis. However, there are two circumstances in which thoracentesis is usually not required: when there is a small amount of pleural fluid and a secure clinical diagnosis (eg, viral pleurisy), or when there is clinically obvious heart failure (HF) without atypical features. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no absolute contraindications to thoracentesis. However, elevated caution is warranted in patients who are receiving anticoagulant therapy, have a bleeding diathesis, are receiving mechanical ventilation, have a small effusion, or have a skin infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thoracentesis involves a series of steps including informed consent, site selection, site sterilization, local anesthesia, fluid removal, specimen preparation, and post-thoracentesis evaluation. Using ultrasound to identify the site for thoracentesis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      for guiding the procedure decreases complication rates. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Technique'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26408?source=see_link\">",
"       \"Thoracic ultrasound: Indications, advantages, and technique\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The sensitivity of thoracentesis for the diagnosis of a malignant pleural effusion depends on the volume of pleural fluid analyzed. Cytologic analysis of 50 to 60 mL of pleural fluid improves the sensitivity compared with 10 mL. Analysis of volumes of fluid greater than 50 to 60 mL does not further increase diagnostic yield. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Fluid removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential complications of thoracentesis include pain at the puncture site, bleeding, pneumothorax, empyema, soft tissue infection, spleen or liver puncture, vasovagal events, seeding the needle tract with tumor, and adverse reactions to the anesthetic or topical antiseptic solutions. Pneumothorax is the most common complication that is clinically important. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/1\">",
"      Sahn SA. State of the art. The pleura. Am Rev Respir Dis 1988; 138:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/2\">",
"      McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/3\">",
"      Godwin JE, Sahn SA. Thoracentesis: a safe procedure in mechanically ventilated patients. Ann Intern Med 1990; 113:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/4\">",
"      McCartney, JP, Adams, JW II, Hazard, PP. Safety of thoracentesis in mechanically ventilated patients. Chest 1993; 103:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/5\">",
"      LeMense, GP, Sahn, SA. Safety and value of thoracentesis in medical ICU patients. J Intensive Care Med 1998; 13:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/6\">",
"      Rohlfing BM, Webb WR, Schlobohm RM. Ventilator-related extra-alveolar air in adults. Radiology 1976; 121:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/7\">",
"      Zimmerman JE, Dunbar BS, Klingenmaier CH. Management of subcutaneous emphysema, pneumomediastinum, and pneumothorax during respirator therapy. Crit Care Med 1975; 3:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/8\">",
"      Petersen GW, Baier H. Incidence of pulmonary barotrauma in a medical ICU. Crit Care Med 1983; 11:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/9\">",
"      Leigh-Smith S, Harris T. Tension pneumothorax--time for a re-think? Emerg Med J 2005; 22:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/10\">",
"      Mourad M, Kohlwes J, Maselli J, et al. Supervising the supervisors--procedural training and supervision in internal medicine residency. J Gen Intern Med 2010; 25:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/11\">",
"      Duncan DR, Morgenthaler TI, Ryu JH, Daniels CE. Reducing iatrogenic risk in thoracentesis: establishing best practice via experiential training in a zero-risk environment. Chest 2009; 135:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/12\">",
"      Lenchus J, Issenberg SB, Murphy D, et al. A blended approach to invasive bedside procedural instruction. Med Teach 2011; 33:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/13\">",
"      Collins TR, Sahn SA. Thoracocentesis. Clinical value, complications, technical problems, and patient experience. Chest 1987; 91:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/14\">",
"      Feller-Kopman D. Therapeutic thoracentesis: the role of ultrasound and pleural manometry. Curr Opin Pulm Med 2007; 13:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/15\">",
"      Hirsch JH, Rogers JV, Mack LA. Real-time sonography of pleural opacities. AJR Am J Roentgenol 1981; 136:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/16\">",
"      Kohan JM, Poe RH, Israel RH, et al. Value of chest ultrasonography versus decubitus roentgenography for thoracentesis. Am Rev Respir Dis 1986; 133:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/17\">",
"      Weingardt JP, Guico RR, Nemcek AA Jr, et al. Ultrasound findings following failed, clinically directed thoracenteses. J Clin Ultrasound 1994; 22:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/18\">",
"      Diacon AH, Brutsche MH, Sol&egrave;r M. Accuracy of pleural puncture sites: a prospective comparison of clinical examination with ultrasound. Chest 2003; 123:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/19\">",
"      Lipscomb DJ, Flower CD, Hadfield JW. Ultrasound of the pleura: an assessment of its clinical value. Clin Radiol 1981; 32:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/20\">",
"      Grogan DR, Irwin RS, Channick R, et al. Complications associated with thoracentesis. A prospective, randomized study comparing three different methods. Arch Intern Med 1990; 150:873.",
"     </a>",
"    </li>",
"    <li>",
"     Doelken P, Sahn SA. Thoracentesis. In: Testbook of Critical Care, 5th Ed, Fink MP, Abraham E, Kochanek PM, Vincent JL (Eds), Elsevier, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/22\">",
"      Gordon CE, Feller-Kopman D, Balk EM, Smetana GW. Pneumothorax following thoracentesis: a systematic review and meta-analysis. Arch Intern Med 2010; 170:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/23\">",
"      Akhan O, Ozkan O, Akinci D, et al. Image-guided catheter drainage of infected pleural effusions. Diagn Interv Radiol 2007; 13:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/24\">",
"      Heffner JE, Klein JS, Hampson C. Diagnostic utility and clinical application of imaging for pleural space infections. Chest 2010; 137:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/25\">",
"      Raptopoulos V, Davis LM, Lee G, et al. Factors affecting the development of pneumothorax associated with thoracentesis. AJR Am J Roentgenol 1991; 156:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/26\">",
"      Carney M, Ravin CE. Intercostal artery laceration during thoracocentesis: increased risk in elderly patients. Chest 1979; 75:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/27\">",
"      Yoneyama H, Arahata M, Temaru R, et al. Evaluation of the risk of intercostal artery laceration during thoracentesis in elderly patients by using 3D-CT angiography. Intern Med 2010; 49:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/28\">",
"      Salamonsen M, Ellis S, Paul E, et al. Thoracic ultrasound demonstrates variable location of the intercostal artery. Respiration 2012; 83:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/29\">",
"      Helm EJ, Rahman NM, Talakoub O, et al. Course and Variation of the Intercostal Artery by Computed Tomography. Chest 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/30\">",
"      Sallach SM, Sallach JA, Vasquez E, et al. Volume of pleural fluid required for diagnosis of pleural malignancy. Chest 2002; 122:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/31\">",
"      Abouzgheib W, Bartter T, Dagher H, et al. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. Chest 2009; 135:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/32\">",
"      Swiderek J, Morcos S, Donthireddy V, et al. Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest 2010; 137:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/33\">",
"      Rahman NM, Mishra EK, Davies HE, et al. Clinically important factors influencing the diagnostic measurement of pleural fluid pH and glucose. Am J Respir Crit Care Med 2008; 178:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/34\">",
"      Alem&aacute;n C, Alegre J, Armadans L, et al. The value of chest roentgenography in the diagnosis of pneumothorax after thoracentesis. Am J Med 1999; 107:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/35\">",
"      Capizzi SA, Prakash UB. Chest roentgenography after outpatient thoracentesis. Mayo Clin Proc 1998; 73:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/36\">",
"      Doyle JJ, Hnatiuk OW, Torrington KG, et al. Necessity of routine chest roentgenography after thoracentesis. Ann Intern Med 1996; 124:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/37\">",
"      Thomsen TW, DeLaPena J, Setnik GS. Videos in clinical medicine. Thoracentesis. N Engl J Med 2006; 355:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/38\">",
"      Temes RT. Thoracentesis. N Engl J Med 2007; 356:641; author reply 641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/39\">",
"      Mayo PH, Goltz HR, Tafreshi M, Doelken P. Safety of ultrasound-guided thoracentesis in patients receiving mechanical ventilation. Chest 2004; 125:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/40\">",
"      Barnes TW, Morgenthaler TI, Olson EJ, et al. Sonographically guided thoracentesis and rate of pneumothorax. J Clin Ultrasound 2005; 33:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/41\">",
"      Gervais DA, Petersein A, Lee MJ, et al. US-guided thoracentesis: requirement for postprocedure chest radiography in patients who receive mechanical ventilation versus patients who breathe spontaneously. Radiology 1997; 204:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/42\">",
"      Heffner JE, Sahn SA. Abdominal hemorrhage after perforation of a diaphragmatic artery during thoracentesis. Arch Intern Med 1981; 141:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/43\">",
"      Stewart, BN, Block, AJ. Subcutaneous implantation of cancer following thoracentesis. Chest 1974; 66:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/44\">",
"      Sue DY, Lam K. Retention of catheter fragment after thoracentesis: report of two cases. Postgrad Med 1982; 72:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/45\">",
"      Bartter T, Mayo PD, Pratter MR, et al. Lower risk and higher yield for thoracentesis when performed by experienced operators. Chest 1993; 103:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/46\">",
"      Seneff MG, Corwin RW, Gold LH, Irwin RS. Complications associated with thoracocentesis. Chest 1986; 90:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12663/abstract/47\">",
"      Cervini P, Hesley GK, Thompson RL, et al. Incidence of infectious complications after an ultrasound-guided intervention. AJR Am J Roentgenol 2010; 195:846.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6686 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12663=[""].join("\n");
var outline_f12_23_12663=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Site selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1913753\">",
"      - Location of fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1913760\">",
"      - Avoidance of intercostal arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Site preparation and local anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fluid removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Specimen preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=related_link\">",
"      Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32582?source=related_link\">",
"      Large volume thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/27/4534?source=related_link\">",
"      Measurement of pleural pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36695?source=related_link\">",
"      Mechanisms of pleural liquid accumulation in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9735?source=related_link\">",
"      Mechanisms of pleural liquid turnover in the normal state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/3/24624?source=related_link\">",
"      Patient information: Thoracentesis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26408?source=related_link\">",
"      Thoracic ultrasound: Indications, advantages, and technique",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_23_12664="Major causes of upper gastrointestinal bleeding in adults";
var content_f12_23_12664=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Major causes of upper gastrointestinal bleeding in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/23/12664/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12664/contributors\">",
"     Don C Rockey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/23/12664/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12664/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/23/12664/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12664/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/23/12664/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper gastrointestinal bleeding is a common medical condition that results in high patient morbidity and medical care costs. In a study from one large health maintenance organization in the United States, the annual incidence of hospitalization for acute upper gastrointestinal bleeding was approximately 100 per 100,000 adults; the incidence was twice as common in males as in females and increased with age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/1\">",
"     1",
"    </a>",
"    ]. Interestingly, the prognosis of patients with upper gastrointestinal bleeding appears to be improving, whether due to nonvariceal or variceal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upper gastrointestinal bleeding commonly presents with hematemesis (vomiting of blood or coffee-ground like material)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    melena (black, tarry stools). In a small proportion of cases, upper gastrointestinal bleeding presents as hematochezia. In this situation, bleeding is typically brisk, and if accompanied by hemodynamic instability, represents a medical emergency. Nasogastric tube lavage may be used to confirm this clinical diagnosis, but it is often not necessary and may not be positive, even in the presence of an upper gastrointestinal tract lesion, if bleeding has ceased or arises beyond a closed pylorus. It is important to take a careful history and perform a careful physical examination since this will help localize the source of bleeding and, in turn, shed light on the possible etiology of bleeding. Although helpful, localization of the source of bleeding based upon stool color is not absolute since melena can be seen with proximal lower GI bleeding (especially slow bleeding in some patients), and hematochezia can be seen with massive upper GI bleeding as highlighted above [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=see_link\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the major causes of bleeding from the upper gastrointestinal tract. The most common causes of upper gastrointestinal bleeding are ulcerative disease of the stomach",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    duodenum (often referred to as \"peptic ulcer disease\") and gastroesophageal varices. The approach to the diagnosis and management of patients with upper gastrointestinal bleeding, as well as other causes of upper gastrointestinal bleeding, such as angiodysplasia, neoplasms, and hemobilia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=see_link\">",
"     \"Uncommon causes of upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43317?source=see_link\">",
"     \"Mallory-Weiss syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMMON CAUSES OF UPPER GASTROINTESTINAL BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper gastrointestinal bleeding can be classified into several broad categories based upon anatomic and pathophysiologic factors (",
"    <a class=\"graphic graphic_table graphicRef71768 \" href=\"UTD.htm?38/23/39293\">",
"     table 1",
"    </a>",
"    ). Several endoscopic studies have described the most common causes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. The reported frequencies of the causes vary, possibly reflecting trends over time or differences in study design, populations, and definitions.",
"   </p>",
"   <p>",
"    The most common causes of upper gastrointestinal bleeding include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gastric",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      duodenal ulcers",
"     </li>",
"     <li>",
"      Esophagogastric varices with or without portal hypertensive gastropathy",
"     </li>",
"     <li>",
"      Esophagitis",
"     </li>",
"     <li>",
"      Erosive",
"      <span class=\"nowrap\">",
"       gastritis/duodenitis",
"      </span>",
"     </li>",
"     <li>",
"      Mallory-Weiss syndrome",
"     </li>",
"     <li>",
"      Angiodysplasia",
"     </li>",
"     <li>",
"      Mass lesions",
"      <span class=\"nowrap\">",
"       (polyps/cancers)",
"      </span>",
"     </li>",
"     <li>",
"      Dieulafoy's lesion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Uncommon causes of upper gastrointestinal bleeding include hemobilia, hemosuccus pancreaticus, and aortoenteric fistula. In 11 percent of cases, no upper GI lesion can be identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=see_link\">",
"     \"Uncommon causes of upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whereas older studies suggested that peptic ulcer disease was responsible for approximately half of upper gastrointestinal bleeds [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/6\">",
"     6",
"    </a>",
"    ], more recent studies suggest it is now a less common cause [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/7,8,10\">",
"     7,8,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peptic ulcers were responsible for 21 percent of episodes of upper gastrointestinal bleeding among 7822 patients included in a national, United States database between 1999 and 2001 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/7\">",
"       7",
"      </a>",
"      ]. The most common cause was nonspecific mucosal abnormalities (42 percent), while esophageal inflammation and varices accounted for approximately 15 and 12 percent, respectively. Other causes (angiodysplasia, Mallory-Weiss tears, and tumors) each accounted for less than 5 percent of cases. Among ulcer cases, gastric ulcers were more common than duodenal ulcers, representing about 55 percent of all ulcers.",
"     </li>",
"     <li>",
"      A large database study focused on 243,428 upper endoscopies performed between 2000 and 2004 in a practice setting (rather than in tertiary care) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/8\">",
"       8",
"      </a>",
"      ]. The most common endoscopic findings in patients with upper gastrointestinal bleeding were an ulcer (33 percent) followed by an erosion (19 percent). Gastric ulcers were more common than duodenal ulcers (55 versus 37 percent). Patients with variceal bleeding were excluded from the analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PEPTIC ULCER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroduodenal ulcer disease remains a common cause of upper gastrointestinal bleeding (",
"    <a class=\"graphic graphic_picture graphicRef86668 graphicRef87064 \" href=\"UTD.htm?17/56/18311\">",
"     picture 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef56986 \" href=\"UTD.htm?13/4/13383\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef87065 \" href=\"UTD.htm?22/47/23285\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef50116 \" href=\"UTD.htm?39/39/40574\">",
"     movie 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/6\">",
"     6",
"    </a>",
"    ]. There are four major risk factors for bleeding peptic ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/11,12\">",
"     11,12",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19113?source=see_link\">",
"     \"Epidemiology and etiology of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"     \"Unusual causes of peptic ulcer disease\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Helicobacter pylori infection",
"     </li>",
"     <li>",
"      Nonsteroidal anti-inflammatory drugs (NSAIDs)",
"     </li>",
"     <li>",
"      Physiologic stress",
"     </li>",
"     <li>",
"      Excess gastric acid",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reduction or elimination of these risk factors reduces ulcer recurrence and rebleeding rates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Helicobacter pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helicobacter pylori is a spiral bacterium that infects the superficial gastric mucosa and appears to be transmitted by the fecal-oral route. The bacterium generally does not invade gastroduodenal tissue. Instead, it renders the underlying mucosa more vulnerable to acid peptic damage by disrupting the mucous layer, liberating enzymes and toxins, and adhering to the gastric epithelium. In addition, the host immune response to H. pylori incites an inflammatory reaction which further perpetuates tissue injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4809?source=see_link\">",
"     \"Pathophysiology of and immune response to Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The chronic inflammation induced by H. pylori upsets gastric secretory physiology to varying degrees and leads to chronic gastritis that, in most individuals, is asymptomatic and does not progress. In some cases, however, altered gastric secretion coupled with tissue injury leads to peptic ulcer disease, while in other cases, gastritis progresses to atrophy, intestinal metaplasia, and eventually to gastric carcinoma or rarely, due to persistent immune stimulation of gastric lymphoid tissue, gastric lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    H. pylori eradication should be attempted for all patients who are diagnosed with the infection and who have peptic ulcer disease to prevent ulcer recurrence and rebleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In one report of 19 published studies, for example, the recurrence rates in cured versus noncured H. pylori infection were 6 versus 67 percent for duodenal ulcers, and 4 versus 59 percent for gastric ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/22\">",
"     22",
"    </a>",
"    ]. Various multidrug regimens (usually a combination of antibiotics and an antisecretory agent) have eradication rates in the range of 80 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nonsteroidal anti-inflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs, including low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , are a common cause of gastrointestinal ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/24-29\">",
"     24-29",
"    </a>",
"    ]. NSAID-induced injury results from both local effects and systemic prostaglandin inhibition. The majority of these ulcers are asymptomatic and uncomplicated. However, elderly patients with a prior history of bleeding ulcer disease are at increased risk for recurrent ulcer and complications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. NSAIDs also have been implicated as an important factor for non-healing ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress related ulcers are a common cause of acute upper gastrointestinal bleeding in patients who are hospitalized for life-threatening non-bleeding illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients with these secondary episodes of bleeding have a higher mortality than those admitted to the hospital with primary upper gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/35\">",
"     35",
"    </a>",
"    ]. The risk of stress ulcer-related bleeding is increased in patients with respiratory failure and those with a coagulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/36\">",
"     36",
"    </a>",
"    ]. Primary ulcer prophylaxis with antisecretory agents such as H2 receptor antagonists or proton pump inhibitors decreases the risk of stress related mucosal damage and upper gastrointestinal bleeding in high-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gastric acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric acid and pepsin are essential cofactors in the pathogenesis of peptic ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/40\">",
"     40",
"    </a>",
"    ]. Impairment of mucosal integrity by factors such as H. pylori, NSAIDs, or physiologic stress leads to increased cell membrane permeability to back diffusion of hydrogen ions, resulting in intramural acidosis, cell death, and ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/40\">",
"     40",
"    </a>",
"    ]. Rarely, hyperacidity is the sole cause of peptic ulceration, as in patients with the Zollinger-Ellison syndrome. Control of gastric acidity is considered an essential therapeutic maneuver in patients with active upper gastrointestinal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of bleeding peptic ulcers typically involves acid suppression, endoscopic therapy, and",
"    <span class=\"nowrap\">",
"     treatment/removal",
"    </span>",
"    of risk factors for peptic ulcer disease. The approach to the treatment of bleeding peptic ulcers is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ESOPHAGOGASTRIC VARICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophagogastric varices develop as a consequence of portal hypertension (",
"    <a class=\"graphic graphic_picture graphicRef87066 graphicRef87067 \" href=\"UTD.htm?9/58/10148\">",
"     picture 4A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef87068 \" href=\"UTD.htm?25/10/25766\">",
"     picture 5",
"    </a>",
"    ). The most common causes of portal hypertension in the United States are viral hepatitis, alcoholic liver disease, and nonalcoholic steatohepatitis (NASH). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link\">",
"     \"Prediction of variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link\">",
"     \"Diagnostic approach to the patient with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isolated gastric varices can result from segmental portal hypertension due to obstruction of the splenic vein from pancreatitis, pancreatic carcinoma, or trauma in the left upper quadrant (",
"    <a class=\"graphic graphic_picture graphicRef87068 \" href=\"UTD.htm?25/10/25766\">",
"     picture 5",
"    </a>",
"    ). The risk factors for bleeding from gastric varices are similar to the risk factors for bleeding from esophageal varices [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link\">",
"     \"Prediction of variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy is the diagnostic modality of choice for esophagogastric varices [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/6\">",
"     6",
"    </a>",
"    ]. If endoscopy is inconclusive and gastric variceal bleeding is suspected, one of the following tests should be considered to confirm the clinical suspicion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic ultrasound may be useful for differentiating gastric varices from gastric folds. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1242?source=see_link&amp;anchor=H38#H38\">",
"       \"Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract\", section on 'Varices'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Portal vein angiography or an abdominal computed tomography scan may show venous collaterals and recanalization of the umbilical vein.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       Barium",
"      </a>",
"      x-rays may image large esophageal varices or large gastric folds suggestive of gastric varices.",
"     </li>",
"     <li>",
"      Capsule endoscopy of the esophagus may represent a minimally invasive alternative to endoscopy for the detection of esophageal varices and portal hypertensive gastropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link&amp;anchor=H19#H19\">",
"       \"Wireless video capsule endoscopy\", section on 'Esophageal capsule endoscopy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variceal bleeding stops spontaneously in over 50 percent of patients, but the mortality rate approaches 70 to 80 percent in those with continued bleeding. Each episode of variceal hemorrhage is associated with a 30 percent risk of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/42\">",
"     42",
"    </a>",
"    ]. The risk of rebleeding is high (60 to 70 percent) until gastroesophageal varices are obliterated.",
"   </p>",
"   <p>",
"    The risk of rebleeding can be substantially reduced by follow-up endoscopic therapy to obliterate residual varices. However, long-term survival depends upon the severity of liver disease and may not be improved following successful variceal obliteration. The administration of a nonselective beta blocker such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    can also decrease the risk of rebleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=see_link\">",
"     \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The onset of massive upper gastrointestinal bleeding from gastroesophageal varices usually signifies advanced liver disease (Child class B or C), and patients who develop bleeding while being treated with a beta-blocker have a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/43\">",
"     43",
"    </a>",
"    ]. Liver transplantation is the only treatment that significantly improves the long-term prognosis in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prophylaxis against variceal hemorrhage is desirable in view of the relatively high rate of bleeding from esophageal varices and the high mortality associated with this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/44\">",
"     44",
"    </a>",
"    ]. \"Pre-primary\" prophylaxis, in an attempt to prevent development of varices, is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Various treatments are available for acute hemostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/44\">",
"     44",
"    </a>",
"    ]. Endoscopic band ligation is the standard treatment, with sclerotherapy used in situations where band ligation is not technically feasible. Early transjugular intrahepatic portosystemic shunt (TIPS) placement may be appropriate early in the course for some patients with gastroesophageal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12664/abstract/46\">",
"     46",
"    </a>",
"    ]. If this treatment is considered, it is critical that it be undertaken in collaboration with an experienced hepatologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=see_link\">",
"       \"Patient information: Peptic ulcers (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"       \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22727270\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper gastrointestinal bleeding is a common medical condition that results in high patient morbidity and medical care costs, with an annual incidence in the Unites States of approximately 100 per 100,000 adults.",
"     </li>",
"     <li>",
"      The most common causes of upper gastrointestinal bleeding include gastric",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      duodenal ulcers (",
"      <a class=\"graphic graphic_picture graphicRef61604 \" href=\"UTD.htm?0/26/416\">",
"       picture 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef56986 \" href=\"UTD.htm?13/4/13383\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef50116 \" href=\"UTD.htm?39/39/40574\">",
"       movie 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57603 \" href=\"UTD.htm?21/30/21999\">",
"       image 1",
"      </a>",
"      ) and esophagogastric varices (",
"      <a class=\"graphic graphic_picture graphicRef63682 graphicRef64026 \" href=\"UTD.htm?11/32/11780\">",
"       picture 7A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef71768 \" href=\"UTD.htm?38/23/39293\">",
"       table 1",
"      </a>",
"      ), with or without portal hypertensive gastropathy. Other common causes include. Other common causes include (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Common causes of upper gastrointestinal bleeding'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Esophagitis",
"     </li>",
"     <li>",
"      Severe or erosive",
"      <span class=\"nowrap\">",
"       gastritis/duodenitis",
"      </span>",
"     </li>",
"     <li>",
"      Mallory-Weiss syndrome",
"     </li>",
"     <li>",
"      Angiodysplasia",
"     </li>",
"     <li>",
"      Mass lesions",
"      <span class=\"nowrap\">",
"       (polyps/cancers)",
"      </span>",
"     </li>",
"     <li>",
"      Dieulafoy's lesion",
"     </li>",
"     <li>",
"      No lesion identified",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uncommon causes of upper gastrointestinal bleeding include hemobilia, hemosuccus pancreaticus, and aortoenteric fistula. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=see_link\">",
"       \"Uncommon causes of upper gastrointestinal bleeding in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs, physiologic stress, and excess gastric acid are major risk factors for bleeding peptic ulcers. Reduction or elimination of these risk factors reduces ulcer recurrence and rebleeding rates. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Peptic ulcer disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Esophagogastric varices develop as a consequence of portal hypertension. The most common causes of portal hypertension in the United States are viral hepatitis, alcoholic liver disease, and nonalcoholic steatohepatitis (NASH). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Esophagogastric varices'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7345438\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Drs. Rome Jutabha and Dennis Jensen, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/1\">",
"      Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995; 90:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/2\">",
"      Crooks C, Card T, West J. Reductions in 28-day mortality following hospital admission for upper gastrointestinal hemorrhage. Gastroenterology 2011; 141:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/3\">",
"      Jensen DM, Machicado GA. Diagnosis and treatment of severe hematochezia. The role of urgent colonoscopy after purge. Gastroenterology 1988; 95:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/4\">",
"      Zuckerman GR, Trellis DR, Sherman TM, Clouse RE. An objective measure of stool color for differentiating upper from lower gastrointestinal bleeding. Dig Dis Sci 1995; 40:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/5\">",
"      Wilcox CM, Alexander LN, Cotsonis G. A prospective characterization of upper gastrointestinal hemorrhage presenting with hematochezia. Am J Gastroenterol 1997; 92:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/6\">",
"      Jutabha R, Jensen DM. Management of upper gastrointestinal bleeding in the patient with chronic liver disease. Med Clin North Am 1996; 80:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/7\">",
"      Boonpongmanee S, Fleischer DE, Pezzullo JC, et al. The frequency of peptic ulcer as a cause of upper-GI bleeding is exaggerated. Gastrointest Endosc 2004; 59:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/8\">",
"      Enestvedt BK, Gralnek IM, Mattek N, et al. An evaluation of endoscopic indications and findings related to nonvariceal upper-GI hemorrhage in a large multicenter consortium. Gastrointest Endosc 2008; 67:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/9\">",
"      Balderas V, Bhore R, Lara LF, et al. The hematocrit level in upper gastrointestinal hemorrhage: safety of endoscopy and outcomes. Am J Med 2011; 124:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/10\">",
"      Loperfido S, Baldo V, Piovesana E, et al. Changing trends in acute upper-GI bleeding: a population-based study. Gastrointest Endosc 2009; 70:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/11\">",
"      Hunt RH, Malfertheiner P, Yeomans ND, et al. Critical issues in the pathophysiology and management of peptic ulcer disease. Eur J Gastroenterol Hepatol 1995; 7:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/12\">",
"      Hallas J, Lauritsen J, Villadsen HD, Gram LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995; 30:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/13\">",
"      Graham DY, Hepps KS, Ramirez FC, et al. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993; 28:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/14\">",
"      Tytgat GN. Peptic ulcer and Helicobacter pylori: eradication and relapse. Scand J Gastroenterol Suppl 1995; 210:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/15\">",
"      Rokkas T, Karameris A, Mavrogeorgis A, et al. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 1995; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/16\">",
"      Bayerd&ouml;rffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995; 345:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/17\">",
"      Nakamura S, Yao T, Aoyagi K, et al. Helicobacter pylori and primary gastric lymphoma. A histopathologic and immunohistochemical analysis of 237 patients. Cancer 1997; 79:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/18\">",
"      Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/19\">",
"      Pajares JM. H. pylori infection: its role in chronic gastritis, carcinoma and peptic ulcer. Hepatogastroenterology 1995; 42:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/20\">",
"      Shibata T, Imoto I, Ohuchi Y, et al. Helicobacter pylori infection in patients with gastric carcinoma in biopsy and surgical resection specimens. Cancer 1996; 77:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/21\">",
"      Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 1996; 275:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/22\">",
"      Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/23\">",
"      Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/24\">",
"      Scheiman JM. NSAID-induced peptic ulcer disease: a critical review of pathogenesis and management. Dig Dis 1994; 12:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/25\">",
"      Bretagne JF, Raoul JL. Management of nonsteroidal anti-inflammatory drug-induced upper gastrointestinal bleeding and perforation. Dig Dis 1995; 13 Suppl 1:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/26\">",
"      Bjorkman DJ, Kimmey MB. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease: pathophysiology, treatment and prevention. Dig Dis 1995; 13:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/27\">",
"      Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/28\">",
"      Lanas A, Wu P, Medin J, Mills EJ. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol 2011; 9:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/29\">",
"      De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012; 307:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/30\">",
"      Hansen JM, Hallas J, Lauritsen JM, Bytzer P. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 1996; 31:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/31\">",
"      Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 1996; 156:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/32\">",
"      Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995; 141:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/33\">",
"      Lanas AI, Remacha B, Esteva F, S&aacute;inz R. Risk factors associated with refractory peptic ulcers. Gastroenterology 1995; 109:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/34\">",
"      Navab F, Steingrub J. Stress ulcer: is routine prophylaxis necessary? Am J Gastroenterol 1995; 90:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/35\">",
"      Zimmerman J, Meroz Y, Siguencia J, et al. Upper gastrointestinal hemorrhage. Comparison of the causes and prognosis in primary and secondary bleeders. Scand J Gastroenterol 1994; 29:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/36\">",
"      Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994; 330:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/37\">",
"      Kuusela AL, Ruuska T, Karikoski R, et al. A randomized, controlled study of prophylactic ranitidine in preventing stress-induced gastric mucosal lesions in neonatal intensive care unit patients. Crit Care Med 1997; 25:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/38\">",
"      Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996; 275:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/39\">",
"      Balaban DH, Duckworth CW, Peura DA. Nasogastric omeprazole: effects on gastric pH in critically Ill patients. Am J Gastroenterol 1997; 92:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/40\">",
"      Peterson WL. The role of acid in upper gastrointestinal haemorrhage due to ulcer and stress-related mucosal damage. Aliment Pharmacol Ther 1995; 9 Suppl 1:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/41\">",
"      Kim T, Shijo H, Kokawa H, et al. Risk factors for hemorrhage from gastric fundal varices. Hepatology 1997; 25:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/42\">",
"      Smith JL, Graham DY. Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology 1982; 82:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/43\">",
"      de Souza AR, La Mura V, Reverter E, et al. Patients whose first episode of bleeding occurs while taking a &beta;-blocker have high long-term risks of rebleeding and death. Clin Gastroenterol Hepatol 2012; 10:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/44\">",
"      Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/45\">",
"      Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12664/abstract/46\">",
"      Garc&iacute;a-Pag&aacute;n JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362:2370.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2644 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-5682FA82D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12664=[""].join("\n");
var outline_f12_23_12664=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22727270\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMMON CAUSES OF UPPER GASTROINTESTINAL BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PEPTIC ULCER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nonsteroidal anti-inflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gastric acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ESOPHAGOGASTRIC VARICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22727270\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7345438\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2644\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2644|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/30/21999\" title=\"diagnostic image 1\">",
"      Duodenal ulcer on fluoroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2644|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/30/3554\" title=\"picture 1A\">",
"      Large duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/42/7842\" title=\"picture 1B\">",
"      Duodenal ulcer with a visible vessel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/4/13383\" title=\"picture 2\">",
"      Epi MPEC hemostasis NBVV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/47/23285\" title=\"picture 3\">",
"      Severe esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/20/15680\" title=\"picture 4A\">",
"      Nonbleeding esophageal varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/57/25503\" title=\"picture 4B\">",
"      Bleeding esophageal varix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/10/25766\" title=\"picture 5\">",
"      Gastric varix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/26/416\" title=\"picture 6\">",
"      Visible vessel GU Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/27/42416\" title=\"picture 7A\">",
"      Esophageal varices Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/1/4127\" title=\"picture 7B\">",
"      Bleeding esoph varix Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2644|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?39/39/40574\" title=\"movie 1\">",
"      Bleeding duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2644|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/23/39293\" title=\"table 1\">",
"      Etiology acute UGI bleeding in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=related_link\">",
"      Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1242?source=related_link\">",
"      Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19113?source=related_link\">",
"      Epidemiology and etiology of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43317?source=related_link\">",
"      Mallory-Weiss syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4809?source=related_link\">",
"      Pathophysiology of and immune response to Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=related_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=related_link\">",
"      Patient information: Peptic ulcers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=related_link\">",
"      Prediction of variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=related_link\">",
"      Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=related_link\">",
"      Treatment of active variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=related_link\">",
"      Uncommon causes of upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=related_link\">",
"      Unusual causes of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_23_12665="Hysteroscopic sterilization";
var content_f12_23_12665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hysteroscopic sterilization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/23/12665/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12665/contributors\">",
"     James Greenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/23/12665/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12665/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12665/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/23/12665/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/23/12665/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/23/12665/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female surgical sterilization is the second most commonly used method of contraception among women in the United States. In 2006 to 2008, 16.7 percent of women 15 to 44 years old used female sterilization as their method of contraception, compared with 17.3 percent who used oral contraceptive pills and 10.0 percent who used condoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For women who no longer desire fertility, sterilization is a safe and highly effective option. With today's technology, hysteroscopic sterilization can easily be performed in an outpatient setting and is the least invasive approach to nonreversible contraception.",
"   </p>",
"   <p>",
"    Hysteroscopic sterilization will be reviewed here. Other methods of female sterilization and general issues related to hysteroscopy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15018?source=see_link\">",
"     \"Surgical sterilization of women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link\">",
"     \"Overview of hysteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACHES TO TRANSCERVICAL STERILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous techniques and technologies have been applied to transcervical sterilization, with varying degrees of success. However, until recently, no method had become established due to high failure and complication rates. Some methods require visualization of the tubal ostia with hysteroscopy, while others do not. Methods that have been attempted include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Corrosive agents &mdash; nitric acid, phenol&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/2\">",
"       2",
"      </a>",
"      ], quinacrine [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/3\">",
"       3",
"      </a>",
"      ], methylcyanoacrylate [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mechanical obstruction devices &mdash; silicone [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/5\">",
"       5",
"      </a>",
"      ], polyethylene, nylon, ceramic [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Destruction using thermal energy &mdash; electrosurgery [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/7\">",
"       7",
"      </a>",
"      ], YAG laser [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of these methods are not in use. Quinacrine is used for transcervical sterilization in some settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link&amp;anchor=H45#H45\">",
"     \"Overview of contraception\", section on 'Quinacrine sterilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HYSTEROSCOPIC STERILIZATION DEVICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;One hysteroscopic sterilization device is available in the United States: the micro-insert system (Essure), approved by the United States Food and Drug Association (FDA) in 2002. Adiana, another device, was introduced in 2009 and removed from the market in 2012 by the manufacturer for business reasons. Information about Adiana that is relevant to the care of women who had the device placed is discussed where appropriate below. (See",
"    <a class=\"local\" href=\"#H24219815\">",
"     'Polymer matrix (no longer available)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For this topic review, use of the terms \"micro-insert\" or \"Essure\" will refer specifically to the currently available version of the device.",
"   </p>",
"   <p>",
"    The device is a metal and polymer micro-insert 4 cm long and 1 to 2 mm wide when deployed. It consists of an inner coil of stainless steel and polyethylene terephthalate (PET) fibers and an outer coil of nickel-titanium (nitinol). It comes loaded in a single-use delivery system.",
"   </p>",
"   <p>",
"    The device is placed under hysteroscopic guidance in the proximal fallopian tube (",
"    <a class=\"graphic graphic_figure graphicRef73083 \" href=\"UTD.htm?2/60/3010\">",
"     figure 1",
"    </a>",
"    ). The coil initially is in a tightly wound state and then is deployed to an expanded state that anchors the insert in the tube. After placement, the PET fibers stimulate benign tissue growth that surrounds and infiltrates the device over the course of several weeks, resulting in tubal occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Twelve weeks after placement, a hysterosalpingogram is performed to confirm tubal occlusion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60277 \" href=\"UTD.htm?3/51/3888\">",
"     image 1",
"    </a>",
"    ). Contraception must be used until satisfactory micro-insert location and bilateral tubal occlusion are confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COMPARISON WITH OTHER STERILIZATION APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sterilization can be performed using hysteroscopy, laparoscopy, or laparotomy.",
"   </p>",
"   <p>",
"    Advantages of hysteroscopic sterilization over sterilization via laparoscopy or laparotomy are [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No incision",
"     </li>",
"     <li>",
"      Less postoperative pain [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Can be performed in women with extensive pelvic adhesions",
"     </li>",
"     <li>",
"      Can be performed in women with comorbidities that preclude laparoscopy or laparotomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The micro-insert (Essure) can be placed under minimal or no anesthesia in an office setting, and is therefore cost-effective and time-efficient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disadvantages are [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Need for contraception for three months post-procedure (until tubal occlusion is confirmed)",
"     </li>",
"     <li>",
"      Need for imaging study to confirm tubal occlusion",
"     </li>",
"     <li>",
"      Higher risk of unilateral tubal occlusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After placement of the micro-insert, electrical conductivity of the insert limits the use of electrosurgery for subsequent pelvic procedures (eg, endometrial ablation) (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Post-procedure restrictions'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Cost-effectiveness studies have reported that office-based hysteroscopic sterilization with micro-inserts is less expensive compared with laparoscopic bilateral tubal ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/11,15,17\">",
"     11,15,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to hysteroscopic sterilization include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uncertainty about non-reversible sterilization",
"     </li>",
"     <li>",
"      Pregnancy or suspected pregnancy",
"     </li>",
"     <li>",
"      Less than six weeks from a delivery or abortion (spontaneous or induced)",
"     </li>",
"     <li>",
"      Active or recent pelvic infection",
"     </li>",
"     <li>",
"      Uterine or tubal pathology that impedes access to one or both tubal ostia",
"     </li>",
"     <li>",
"      Known allergy to contrast media (not able to undergo hysterosalpingogram [HSG] to confirm tubal occlusion)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypersensitivity reaction to nickel is a potential complication of the Essure procedure. However, in 2011, the United States Food and Drug Association (FDA) removed known hypersensitivity to nickel as a contraindication for the procedure, since the number of adverse events reported had been extremely low (less than 1 in 5000) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative examination, cervical preparation and dilation, and surgical site infection prevention for hysteroscopic sterilization are the same as for other hysteroscopic procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of hysteroscopy\", section on 'Preoperative evaluation and preparation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\"",
"    </a>",
"    .) As with other hysteroscopic procedures, a pregnancy test should be performed prior to the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patient counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients considering hysteroscopic sterilization should be counseled regarding other methods of contraception (particularly long acting methods such as the intrauterine device) and other approaches to female and male sterilization. In addition, it is important for a patient to understand that sterilization is not reversible and to discuss the possibility of future regret. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15018?source=see_link\">",
"     \"Surgical sterilization of women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women should also be counseled that the procedure may not be possible if intrauterine pathology is occluding visualization of the tubal ostia. Other consent issues are the same as for other hysteroscopic procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link\">",
"     \"Overview of hysteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Women using intrauterine contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with an intrauterine device (IUD) in place may desire to continue this method for the post-procedure follow-up period prior to confirmation of tubal occlusion. Successful placement of hysteroscopic sterilization micro-inserts with an IUD in place has been reported with success rates up to 100 percent in small case series of 6, 12 and 20 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. In these small case series, three-month hysterosalpingograms (HSG) showed bilateral tubal occlusion. Patients should be counseled that in approximately 8 to 10 percent of women, the tubal ostia will not be visible and the IUD will need to be removed intraoperatively. Data on safety of this technique are limited. The three-month HSG can be performed with the IUD in place, followed by removal if correct micro-insert placement and bilateral tubal occlusion are confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Timing and endometrial preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clear view of the tubal ostia is the key element in success of the procedure. To optimize visualization, the procedure should be performed while the endometrium is thin. A thin endometrium is best achieved by pre-treating with a progestin; options include: estrogen-progestin contraceptives (pill, ring, or patch), progestin-only contraceptive pills, or depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    . While there are no data regarding the best method of endometrial preparation, we have found that progestin-only agents are more effective at endometrial thinning than combined estrogen-progestin formulations.",
"   </p>",
"   <p>",
"    In women who are using a progestin-containing contraceptive, the procedure can be scheduled at any time other than during menses.",
"   </p>",
"   <p>",
"    In women who are not using a progestin-containing contraceptive, pre-treatment should be initiated with the start of menses and continued for at least two weeks prior to the procedure. These agents provide the dual effect of endometrial lining suppression and birth control, which can be continued for the three-month follow-up period.",
"   </p>",
"   <p>",
"    For women in whom a progestin is contraindicated or who do not wish to use hormonal contraception, the best time to view the ostia is shortly after menses during the follicular phase of the menstrual cycle. Also, pregnancy is improbable during this part of the cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PREOPERATIVE SET-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necessary equipment includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hysteroscopic sterilization device &ndash; Two individually wrapped micr0-insert devices; since difficulty with bilateral placement is encountered in at least 5 percent of procedures, extra devices should be available in case a device is damaged or does not deploy properly [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/16,23\">",
"       16,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rigid hysteroscope &ndash; Minimum requirements are either a 12&ordm; lens or a 30&ordm; lens (depending upon the surgeon's preference), an inflow channel, and a working channel.",
"     </li>",
"     <li>",
"      Hysteroscopic grasper &ndash; For use if an errantly deployed device needs to be retrieved from the uterine cavity.",
"     </li>",
"     <li>",
"      Distension media &ndash; Electrolyte solution (eg, normal saline or lactated Ringer's) can be used for uterine distention since no energy source is used. In our experience, it is preferable to use warm solution to minimize tubal spasm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22951?source=see_link\">",
"       \"Hysteroscopy: Managing fluid and gas distending media\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Personnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure is most efficiently performed with a three-person team that includes the operating surgeon, an assistant wearing sterile gloves to insert the device into the introducer and working channel, and a circulating assistant to tend to the patient and provide supplies as needed. Many surgeons perform the procedure with one assistant. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premedication with nonsteroidal antiinflammatory drugs (NSAIDs) has been recommended to minimize spasm of the fallopian tubes, although there is no evidence to support this practice [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/24\">",
"     24",
"    </a>",
"    ]. This can be administered as oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (eg, 600 mg every six hours) for one to two days or intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    (eg, 30 mg 15 minutes before the procedure); use of both simultaneously is contraindicated. These drugs should not be given to patients in whom they are contraindicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The micro-insert can be placed comfortably in an office setting, under no or local anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/10,25,26\">",
"     10,25,26",
"    </a>",
"    ]; we use a paracervical block. The addition of an oral benzodiazepine or intravenous (IV) conscious sedation is a reasonable option for patients who otherwise cannot tolerate the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perform routine hysteroscopic cervical preparation, insert the hysteroscope, and briefly inspect the uterine cavity (",
"    <a class=\"graphic graphic_table graphicRef70591 \" href=\"UTD.htm?21/31/22013\">",
"     table 1",
"    </a>",
"    ). Note whether both tubal ostia can be visualized and are accessible; also note any pathology. The devices are single-use and should not be opened until visualization of both ostia is confirmed. Hysteroscopic entry is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of hysteroscopy\", section on 'Procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Throughout the procedure, use the distension medium as sparingly as possible. This will both reduce the risk of excessive fluid absorption and minimize endometrial tissue edema (which can obscure the view of the ostia). Prevention of tissue edema, which can develop within several minutes, is an important way of ensuring success of the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22951?source=see_link\">",
"     \"Hysteroscopy: Managing fluid and gas distending media\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insert (or have an assistant insert) the Essure device introducer sheath into the working channel of the hysteroscope. Position the hysteroscope in front of one of the tubal ostia while the assistant threads the first device delivery system into the introducer sheath. With the delivery system threaded, take hold of the device handle and guide the tip of the micro-insert through the tubal ostium into the fallopian tube (",
"    <a class=\"graphic graphic_figure graphicRef73083 \" href=\"UTD.htm?2/60/3010\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The maneuvers to correctly position and deploy the device must be performed precisely. While learning the procedure, it may be helpful to review the following steps before each procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thread the device into the tube with gentle, constant forward movement until the black positioning marker is at the tubal ostium",
"     </li>",
"     <li>",
"      Rotate the thumbwheel towards yourself until it can no longer rotate (this will retract the delivery catheter and expose the wound down micro-insert)",
"     </li>",
"     <li>",
"      Align the gold marker band just outside the tubal ostium",
"     </li>",
"     <li>",
"      Press the deployment button",
"     </li>",
"     <li>",
"      Rotate the thumbwheel towards yourself again until it can no longer rotate (the micro-insert will unwind and detach from the delivery system)",
"     </li>",
"     <li>",
"      Remove the device delivery system",
"     </li>",
"     <li>",
"      Count and record the number of expanded coils extruding from the tubal ostium. Ideally, according to the manufacturer, there should be three to eight expanded coils trailing into the uterus; if there are 18 or more expanded coils, remove the micro-insert and re-attempt insertion with a new device.",
"     </li>",
"     <li>",
"      Repeat the procedure at the contralateral tubal ostium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After placement of the second micro-insert, the procedure is complete and the patient may be discharged home or to the post-anesthesia care unit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CONCOMITANT OR SUBSEQUENT PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few other transcervical procedures can be performed concomitant with hysteroscopic sterilization due to concerns regarding visualization of the uterine cavity and the fallopian tubes postoperatively.",
"   </p>",
"   <p>",
"    The decision of whether to perform a procedure immediately prior to hysteroscopic sterilization depends on the likelihood that bleeding or debris caused by a procedure will occlude visualization of the tubal ostia; examples of procedures that are likely to interfere with visualization are hysteroscopic myomectomy or uterine curettage. On the other hand, it is likely that endometrial polypectomy or intrauterine contraceptive (IUC) removal can be performed without interfering with hysteroscopic sterilization (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Women using intrauterine contraception'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9272913\">",
"    <span class=\"h2\">",
"     Endometrial ablation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4673280\">",
"    <span class=\"h3\">",
"     Prior to confirmation of tubal occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant endometrial ablation and hysteroscopic sterilization are advised against by the United States Food and Drug Administration (FDA), the manufacturers of devices, and the American College of Obstetricians and Gynecologists (ACOG) due to concerns that uterine synechiae formed following endometrial ablation will interfere with the ability to perform a hysterosalpingogram (HSG) to confirm tubal occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. These concerns are based on two small studies in which 2 of 21 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/31\">",
"     31",
"    </a>",
"    ] and 5 of 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/28\">",
"     28",
"    </a>",
"    ] women who underwent the Essure placement and ablation concurrently had severe intrauterine synechiae that precluded assessment of tubal patency. On the other hand, prospective and retrospective case series regarding women who have had both procedures include only rare reports of failure of HSG due to intrauterine adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/30,32-34\">",
"     30,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4673272\">",
"    <span class=\"h3\">",
"     Subsequent to confirmation of tubal occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once tubal occlusion has been confirmed (typically at three months after sterilization), the FDA has approved endometrial ablation using bipolar radiofrequency, a hot liquid filled balloon, or circulating hot water (hydrothermal), as long as there is no reasonable concern that uterine perforation occurred during the sterilization procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/35\">",
"     35",
"    </a>",
"    ]. The use of monopolar electrosurgical instruments for endometrial ablation following hysteroscopic sterilization with micro-inserts may lead to damage of surrounding tissues from inadvertent conduction of current and should be avoided.",
"   </p>",
"   <p>",
"    The safety of use of some endometrial ablation techniques following hysteroscopic sterilization is supported by few data. In several small observational studies, women who were scheduled for hysterectomy underwent hysteroscopic sterilization followed immediately by endometrial ablation (one with Essure and Thermachoice hot liquid-filled balloon ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/29\">",
"     29",
"    </a>",
"    ], one with Essure and NovaSure bipolar radiofrequency ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/36\">",
"     36",
"    </a>",
"    ], and one with Adiana and Novasure bipolar radiofrequency ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/37\">",
"     37",
"    </a>",
"    ]), followed by pathologic analysis of the uterus and fallopian tubes. These studies found no significant thermal injury to the tubes; one study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/29\">",
"     29",
"    </a>",
"    ] also reported no disruption of the position of the sterilization device and complete ablation results, with the exception of some sparing of the area near the tubal ostia. There are no long-term studies regarding the safety of this sequence of procedures or whether subsequent endometrial ablation affects the contraceptive efficacy of the sterilization procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Routine postprocedure care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women can return to their daily activities on the day of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/38\">",
"     38",
"    </a>",
"    ]. We give patients routine post-hysteroscopy instructions. Particular concerns for hysteroscopic sterilization include tubal perforation or expulsion of a micro-insert. We counsel patients to call if they have severe or persistent pelvic pain or if they pass a sterilization device. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=see_link\">",
"     \"Patient information: Care after gynecologic surgery (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, women who have undergone hysteroscopic sterilization must use another method of contraception until bilateral tubal occlusion is confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Confirming occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, hysterosalpingogram (HSG) is the United States Food and Drug Administration (FDA)-approved standard for confirming bilateral tubal occlusion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60277 \" href=\"UTD.htm?3/51/3888\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58984 \" href=\"UTD.htm?36/35/37425\">",
"     image 2",
"    </a>",
"    ). A potential pitfall of hysteroscopic sterilization is the apparently low rate of compliance with post-operative HSG (12 to 71 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to note that tubal spasm may be misread as tubal occlusion on a HSG. Thus, for women in whom a device appears to be misplaced, but the tube appears occluded, the HSG should be repeated.",
"   </p>",
"   <p>",
"    History of tubal blockage even when confirmed by HSG is not sufficient to ensure contraceptive efficacy unless a device has been placed in the tube [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since HSGs are costly, time-consuming, and uncomfortable, some experts use pelvic radiography or transvaginal ultrasound as an initial test for appropriate placement following the Essure procedure, with HSG reserved for patients in whom unsatisfactory placement is suspected. However, these imaging modalities cannot confirm tubal occlusion; they can evaluate location of the micro-inserts.",
"   </p>",
"   <p>",
"    However, use of pelvic radiograph or sonography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73850 \" href=\"UTD.htm?28/13/28885\">",
"     image 3",
"    </a>",
"    ) following Essure is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Representative reports regarding using pelvic radiograph or ultrasound to confirm tubal occlusion are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case series, 150 women underwent Essure procedures followed at 12 weeks by pelvic ultrasound, pelvic radiograph, and HSG [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/42\">",
"       42",
"      </a>",
"      ]. A \"satisfactory\" pelvic radiograph or ultrasound had high predictive values for HSG-confirmed tubal occlusion (100 and 99 percent, respectively).",
"     </li>",
"     <li>",
"      However, in a case series of approximately 6000 Essure procedures, 4 of 10 women who became pregnant after the procedure had post-procedure confirmation of placement with ultrasound alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The three-month follow-up period is based on early efficacy trials when the micro-insert device was tested in a small cohort of subjects undergoing subsequent hysterectomy. There are few data regarding a shorter interval to tubal occlusion for either device [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Post-procedure restrictions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essure micro-inserts are metallic, and thus, patients should be counseled about the following post-procedure issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Magnetic resonance imaging is safe using a 1.5 tesla magnet (according to the manufacturer) and the 3-T field is under investigation; however, the micro-inserts produce an artifact, which will obscure imaging of local tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Procedures involving pelvic use of unipolar electrosurgery are contraindicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because micro-insert coils conduct electricity, electrosurgical procedures (eg, some types of endometrial ablation) in the vicinity of the device can cause thermal injury. According to the manufacturer, with the Essure micro-inserts in place, electrosurgery should be avoided in procedures undertaken on the uterine cornua and proximal fallopian tubes without either hysteroscopic visualization of the micro-inserts, or visualization of the proximal portion of the fallopian tube via open surgical procedures or laparoscopy. During salpingectomy or other procedures in which electrosurgical instruments could contact the serosa of the fallopian tube, instruments should not be placed more proximal to location of the micro-inserts than the ampullary portion of the tube [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/48\">",
"     48",
"    </a>",
"    ]. There have been no reports of complications due to electrical conduction. Similarly, there are no data to suggest there could be complications from electrical conduction injuries related to loop electrosurgical excision procedures of the cervix.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few long-term follow-up data regarding hysteroscopic sterilization. The longest follow-up study is a case series in which 163 women completed five years of follow-up; no adverse device-related events were reported and 99 percent were tolerating the device well [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Tubal or uterine perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubal and uterine perforation has been reported in 1 to 3 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/47\">",
"     47",
"    </a>",
"    ] with micro-inserts.",
"   </p>",
"   <p>",
"    Perforation during or following micro-insert placement may be asymptomatic or present as pelvic pain; some perforations were noted when a patient has a post-procedure pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/43,48,50\">",
"     43,48,50",
"    </a>",
"    ]. A tubal perforation may be suspected intraoperatively if a micro-insert is noted to move distally in a tube in an unusual manner.",
"   </p>",
"   <p>",
"    Also, some cases were suspected postoperatively when a micro-insert was seen in an abnormal configuration on hysterosalpingogram (HSG), and subsequently confirmed using laparoscopy. Pelvic ultrasonography does not appear to be able to accurately diagnose tubal perforation with the hysteroscopic sterilization micro-inserts.",
"   </p>",
"   <p>",
"    Alternatively, if a micro-insert is found in the peritoneal cavity and there is no evidence of tubal or uterine perforation, migration through the distal end of the tube is a possible explanation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A perforated or expulsed micro-insert that is protruding into or is free within the peritoneal cavity may need to be removed, since it may be a nidus for intraabdominal adhesions. At this time, there are not enough data to state definitively that the device must be removed or is safe to stay in asymptomatic patients. If the decision is made to remove the device, this can be accomplished using either hysteroscopy or laparoscopy, depending on the location of the device [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/51\">",
"     51",
"    </a>",
"    ]. A patient planned for laparoscopy should be offered laparoscopic tubal ligation (using a non-electrosurgery method).",
"   </p>",
"   <p>",
"    Uterine perforation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=see_link\">",
"     \"Uterine perforation during gynecologic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Device expulsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expulsion of one or both micro-inserts has been reported. As an example, in one large series (n = 1630), at up to 42 months of follow-up, the rate of expulsion of one micro-insert was less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/38\">",
"     38",
"    </a>",
"    ]. There have been no reports of expulsion of a polymer matrix (Adiana).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Pelvic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are reports of persistent pain in women with correctly placed micro-inserts. The reasons for this pain are unknown. Surgery to remove the devices should be performed only after other etiologies of the pain have been excluded only as a last resort. As an example, in one case report, a woman's pain resolved after laparoscopic removal of the micro-inserts [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the study regarding the polymer matrices, dysmenorrhea was the most commonly reported adverse event reported in the 12 months after placement; pelvic pain was also reported by some women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of infectious complications is likely to be similar to that with other hysteroscopic procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link&amp;anchor=H45#H45\">",
"     \"Overview of hysteroscopy\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cornual abscesses have been described in a woman who underwent hysteroscopic sterilization combined with endometrial ablation, although this is likely a very rare complication [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/53\">",
"     53",
"    </a>",
"    ]. No infectious complications have been reported following placement of the polymer matrices [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no reports of allergic reactions to nickel in women with Essure implants. However, experience from coronary artery nickel stents suggests that nickel allergy would present as local inflammation at the site of the implant (leading to re-stenosis in the case of coronary stents) and not with systemic symptoms. If a nickel allergy is suspected, a patch test can be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link&amp;anchor=H10#H10\">",
"     \"Intracoronary stent restenosis\", section on 'Contact allergy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient satisfaction is high after hysteroscopic sterilization [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/23,25,38\">",
"     23,25,38",
"    </a>",
"    ]. Outcome measures for this method include correct placement of device and contraceptive efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Device placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral devices are placed successfully in most women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/16,23,24,54-56\">",
"     16,23,24,54-56",
"    </a>",
"    ]. The most important factor for correct bilateral micro-insert placement is adequate visualization of the tubal ostia. This was illustrated in a prospective multicenter study of Essure sterilization in which 469 women had presumed bilateral patent tubes (ie, no history of salpingectomy or radiographic evidence of tubal occlusion) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/24\">",
"     24",
"    </a>",
"    ]. During a first procedure, micro-inserts were successfully placed bilaterally in 94 percent and unilaterally in 5 percent. Among women with unilateral placement, 13 of 15 underwent successful placement in a second procedure. Good visualization of the tubal ostium was the only factor associated with successful placement; other factors that did not have an effect were: parity, type of anesthesia, premedication with nonsteroidal antiinflammatory medications, and concomitant procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Contraceptive efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy prevention with hysteroscopic sterilization varies by method employed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Micro-insert",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficacy of Essure micro-inserts appears to be similar to, or better than, other methods of sterilization. As an example, in the largest study, 64 pregnancies were reported after approximately 50,000 procedures and all involved protocol deviations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/57\">",
"     57",
"    </a>",
"    ]. It was concluded that most pregnancies can be avoided by performing the procedure in the proliferative phase of the menstrual cycle; using reliable contraception until tubal occlusion can be confirmed by hysterosalpingogram (HSG); and adhering to the HSG protocol with accurate reporting of the HSG results.",
"   </p>",
"   <p>",
"    At five-year follow-up, the cumulative risk of pregnancy was 2.6 per 1000 procedures. With the exception of unipolar cautery, which is no longer practiced due to complications, this pregnancy risk is lower than other methods reported in the United States Collaborative Review of Sterilization (CREST) study (",
"    <a class=\"graphic graphic_table graphicRef54215 \" href=\"UTD.htm?13/33/13851\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15018?source=see_link\">",
"     \"Surgical sterilization of women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common reasons for contraceptive failure of micro-insert sterilization are [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/41,42,57,58\">",
"     41,42,57,58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant at the time of placement",
"     </li>",
"     <li>",
"      Incorrect placement &mdash; unilateral or tubal or uterine perforation",
"     </li>",
"     <li>",
"      Noncompliance with postoperative instructions &mdash; failure to use contraception until confirmation of occlusion or failure to have follow-up imaging",
"     </li>",
"     <li>",
"      Misreading of imaging study used to confirm bilateral occlusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No device-related obstetric complications have been reported in women who have given birth after hysteroscopic sterilization [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/42,50\">",
"     42,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     PREGNANCY AFTER STERILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current methods of hysteroscopic sterilization are not reversible. Women who desire pregnancy after the procedure will require in vitro fertilization (IVF). While there are few data, it appears that micro-insert presence in the tubes does not diminish IVF success rates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. There are no data regarding IVF following polymer matrix insertion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=see_link&amp;anchor=H18#H18\">",
"     \"Reproductive surgery for female infertility\", section on 'Tubal reanastomosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15018?source=see_link&amp;anchor=H4#H4\">",
"     \"Surgical sterilization of women\", section on 'Regret after sterilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24219815\">",
"    <span class=\"h1\">",
"     POLYMER MATRIX (no longer available)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polymer matrix (Adiana) hysteroscopic sterilization device was available in the United States from 2009 to 2012, as noted above. Information about the device that is relevant to the care of women who had the device placed is included here.",
"   </p>",
"   <p>",
"    The polymer matrix device was placed by use of a low level of radiofrequency energy (resulting in a lesion within the superficial layer of cells in the tubal lumens that was 5 mm long and 500 microns deep) followed by placement of a 3.5 mm nonabsorbable silicone elastomer matrix in each tubal lumen. The device cannot be visualized with a radiograph.",
"   </p>",
"   <p>",
"    The only study regarding the efficacy of the polymer matrix was a prospective series of 645 women, as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/23\">",
"     23",
"    </a>",
"    ]. Among 553 women who had confirmed bilateral tubal occlusion and who completed follow-up, the pregnancy rate at one-year was 1.1 percent. Two-year follow-up data for 321 women showed a 1.8 percent pregnancy rate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/23/12665/abstract/57\">",
"     57",
"    </a>",
"    ]. With the exception of spring clip application, this pregnancy rate is higher than other methods reported in the United States Collaborative Review of Sterilization (CREST) study (",
"    <a class=\"graphic graphic_table graphicRef54215 \" href=\"UTD.htm?13/33/13851\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15018?source=see_link\">",
"     \"Surgical sterilization of women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/51/23346?source=see_link\">",
"       \"Patient information: Sterilization for women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/28/7620?source=see_link\">",
"       \"Patient information: Permanent sterilization procedures for women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hysteroscopic sterilization is performed by inserting a metal micro-insert into the interstitial portion of each fallopian tube. Three months after placement, correct device placement and bilateral tubal occlusion are confirmed with pelvic imaging. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hysteroscopic sterilization device'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Advantages of hysteroscopic sterilization compared with other approaches to female sterilization include: the ability to perform the procedure in an outpatient setting and without an incision. A disadvantage is the three-month waiting period until tubal occlusion is confirmed. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Comparison with other sterilization approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women who desire sterilization:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest a hysteroscopic approach rather than laparoscopy or laparotomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      However, laparoscopy is a reasonable option for patients who do not wish to use another method of contraception for several months postoperatively or who are planning a laparoscopy or laparotomy for reasons other than sterilization and can have a concomitant sterilization. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Comparison with other sterilization approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After the procedure, we suggest a hysterosalpingogram rather than a pelvic radiograph or ultrasound to confirm bilateral tubal occlusion. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Confirming occlusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications are rare and include: uterine or tubal perforation, expulsion of the device, and pelvic infection. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of pregnancy after hysteroscopic sterilization is approximately 0.1 percent with the micro-insert. Reasons for failure include: pregnancy at the time of insertion, incorrect placement, noncompliance with postoperative instructions, and misreading of imaging study used to confirm bilateral occlusion. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Contraceptive efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/1\">",
"      Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23 2010; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/2\">",
"      Liu Y, Wu Y, Chen X, et al. A five-year follow-up study on the efficacy and safety of female tubal sterilization by chemical instillation. Reprod Contracept 1999; 10:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/3\">",
"      Zipper J, Kessel E. Quinacrine sterilization: a retrospective. Int J Gynaecol Obstet 2003; 83 Suppl 2:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/4\">",
"      Shuber J. Transcervical sterilization with use of methyl 2-cyanoacrylate and a newer delivery system (the FEMCEPT device). Am J Obstet Gynecol 1989; 160:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/5\">",
"      Ligt-Veneman NG, Tinga DJ, Kragt H, et al. The efficacy of intratubal silicone in the Ovabloc hysteroscopic method of sterilization. Acta Obstet Gynecol Scand 1999; 78:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/6\">",
"      Cooper JM. Hysteroscopic sterilization. Clin Obstet Gynecol 1992; 35:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/7\">",
"      Qui&ntilde;ones GR, Alvarado AD, Ley EC. Tubal electrocoagulation under hysteroscopic control (three hundred and fifty cases). Am J Obstet Gynecol 1975; 121:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/8\">",
"      Brumsted JR, Shirk G, Soderling MJ, Reed T. Attempted transcervical occlusion of the fallopian tube with the Nd:YAG laser. Obstet Gynecol 1991; 77:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/9\">",
"      Valle RF, Carignan CS, Wright TC, STOP Prehysterectomy Investigation Group. Tissue response to the STOP microcoil transcervical permanent contraceptive device: results from a prehysterectomy study. Fertil Steril 2001; 76:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/10\">",
"      Mi&ntilde;o M, Arjona JE, Cord&oacute;n J, et al. Success rate and patient satisfaction with the Essure sterilisation in an outpatient setting: a prospective study of 857 women. BJOG 2007; 114:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/11\">",
"      Levie MD, Chudnoff SG. Office hysteroscopic sterilization compared with laparoscopic sterilization: a critical cost analysis. J Minim Invasive Gynecol 2005; 12:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/12\">",
"      Syed R, Levy J, Childers ME. Pain associated with hysteroscopic sterilization. JSLS 2007; 11:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/13\">",
"      Duffy S, Marsh F, Rogerson L, et al. Female sterilisation: a cohort controlled comparative study of ESSURE versus laparoscopic sterilisation. BJOG 2005; 112:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/14\">",
"      Franchini M, Cianferoni L, Lippi G, et al. Tubal sterilization by laparoscopy or hysteroscopy: which is the most cost-effective procedure? Fertil Steril 2009; 91:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/15\">",
"      Thiel JA, Carson GD. Cost-effectiveness analysis comparing the essure tubal sterilization procedure and laparoscopic tubal sterilization. J Obstet Gynaecol Can 2008; 30:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/16\">",
"      Cooper JM, Carignan CS, Cher D, et al. Microinsert nonincisional hysteroscopic sterilization. Obstet Gynecol 2003; 102:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/17\">",
"      Kraemer DF, Yen PY, Nichols M. An economic comparison of female sterilization of hysteroscopic tubal occlusion with laparoscopic bilateral tubal ligation. Contraception 2009; 80:254.",
"     </a>",
"    </li>",
"    <li>",
"     ww.essuremd.com/portals/essuremd/PDFs/TopDownloads/Essure IFU Oct 5 2011.pdf (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     file://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/ucm273626.htm (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/20\">",
"      Agostini A, Crochet P, Petrakian M, et al. Hysteroscopic tubal sterilization (essure) in women with an intrauterine device. J Minim Invasive Gynecol 2008; 15:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/21\">",
"      Mascaro M, Mari&ntilde;o M, Vicens-Vidal M. Feasibility of Essure placement in intrauterine device users. J Minim Invasive Gynecol 2008; 15:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/22\">",
"      Tatalovich JM, Anderson TL. Hysteroscopic sterilization in patients with a Mirena intrauterine device: transition from extended interval to permanent contraception. J Minim Invasive Gynecol 2010; 17:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/23\">",
"      Vancaillie TG, Anderson TL, Johns DA. A 12-month prospective evaluation of transcervical sterilization using implantable polymer matrices. Obstet Gynecol 2008; 112:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/24\">",
"      Panel P, Grosdemouge I. Predictive factors of Essure implant placement failure: prospective, multicenter study of 495 patients. Fertil Steril 2010; 93:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/25\">",
"      Scarabin C, Dhainaut C. [The ESTHYME study. Women's satisfaction after hysteroscopic sterilization (Essure micro-insert). A retrospective multicenter survey]. Gynecol Obstet Fertil 2007; 35:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/26\">",
"      Chudnoff S, Einstein M, Levie M. Paracervical block efficacy in office hysteroscopic sterilization: a randomized controlled trial. Obstet Gynecol 2010; 115:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/27\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 458: Hysterosalpingography after tubal sterilization. Obstet Gynecol 2010; 115:1343.",
"     </a>",
"    </li>",
"    <li>",
"     Concomitant Use with GEA - US.  file://www.essuremd.com/Home/LearningLibrary/Downloads/tabid/281/Default.aspx (Accessed on September 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/29\">",
"      Valle RF, Valdez J, Wright TC, Kenney M. Concomitant Essure tubal sterilization and Thermachoice endometrial ablation: feasibility and safety. Fertil Steril 2006; 86:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/30\">",
"      Hopkins MR, Creedon DJ, El-Nashar SA, et al. Radiofrequency global endometrial ablation followed by hysteroscopic sterilization. J Minim Invasive Gynecol 2007; 14:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/31\">",
"      Donnadieu AC, Deffieux X, Gervaise A, et al. Essure sterilization associated with endometrial ablation. Int J Gynaecol Obstet 2007; 97:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/32\">",
"      Carey, ET, El-Nashar, S, Creedon, DJ, et al. Feasibility of hysterosalpingography following a combined radiofrequency global endometrial ablation and hysteroscopic sterilization procedure (abstract). J Minim Invas Gynecol 2009; 16:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/33\">",
"      Basinski, CM, Price, P. Essure tubal sterilization combined with subsequent Novasure endometrial ablation: a retrospective analysis. J Minim Invas Gynecol 2009; 16:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/34\">",
"      Vilos, GA, Emanuel, MH, Fortin, C, Leyland, N, Abu-Rafea, B. Multicentre outpatient thermal balloon endometrial ablation (thermablate). J Minim Invas Gynecol 2009; 16:S69.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.essuremd.com/Portals/essuremd/PDFs/TopDownloads/CC-3032%2028FEB12F%20physician%20customer%20letter.pdf (Accessed on April 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/36\">",
"      Garza-Leal J, Hernandez L, Castillo NG, et al. Essure transcervical sterilization combined with Novasure endometrial ablation: A perihysterectomy saftey study (abstract). J Minim Invasive Gynecol 2008; 15:44S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/37\">",
"      Garza-Leal, J, Castillo, L, Hernandez, I, et al. Concomitant use of Adiana permanent contraception and NovaSure impedance controlled endometrial ablation: a peri-hysterectomy study (abstract). J Minim Invasive Gynecol 2009; 16:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/38\">",
"      Arjona JE, Mi&ntilde;o M, Cord&oacute;n J, et al. Satisfaction and tolerance with office hysteroscopic tubal sterilization. Fertil Steril 2008; 90:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/39\">",
"      Shavell VI, Abdallah ME, Diamond MP, et al. Post-Essure hysterosalpingography compliance in a clinic population. J Minim Invasive Gynecol 2008; 15:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/40\">",
"      Guiahi, M, Goldman, KN, Olson, CG. Retrospective Analysis of Hysterosalpingogram Confirmatory Test Follow-Up after Essure&reg; Hysteroscopic Sterilization; 4-Year Experience in a Community Setting (abstract). J Minim Invas Gynecol 2008; 15:78S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/41\">",
"      Veersema S, Vleugels MP, Moolenaar LM, et al. Unintended pregnancies after Essure sterilization in the Netherlands. Fertil Steril 2010; 93:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/42\">",
"      Veersema S, Vleugels MP, Timmermans A, Br&ouml;lmann HA. Follow-up of successful bilateral placement of Essure microinserts with ultrasound. Fertil Steril 2005; 84:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/43\">",
"      Langenveld J, Veersema S, Bongers MY, Koks CA. Tubal perforation by Essure: three different clinical presentations. Fertil Steril 2008; 90:2011.e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/44\">",
"      Thiel JA, Suchet IB, Lortie K. Confirmation of Essure microinsert tubal coil placement with conventional and volume-contrast imaging three-dimensional ultrasound. Fertil Steril 2005; 84:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/45\">",
"      Connor V. Contrast infusion sonography in the post-Essure setting. J Minim Invasive Gynecol 2008; 15:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/46\">",
"      Wittmer MH, Brown DL, Hartman RP, et al. Sonography, CT, and MRI appearance of the Essure microinsert permanent birth control device. AJR Am J Roentgenol 2006; 187:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/47\">",
"      Hurskainen R, Hovi SL, Gissler M, et al. Hysteroscopic tubal sterilization: a systematic review of the Essure system. Fertil Steril 2010; 94:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/48\">",
"      Thoma V, Chua I, Garbin O, et al. Tubal perforation by ESSURE microinsert. J Minim Invasive Gynecol 2006; 13:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/49\">",
"      Bradley, LD, Price, TM, Van Herendael, BJ, Cayuela, E. Long-Term Follow-Up of Hysteroscopic Sterilization with the Essure&reg; Micro-Insert (abstract). J Minim Invas Gynecol 2008; 15:14S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/50\">",
"      Moses AW, Burgis JT, Bacon JL, Risinger J. Pregnancy after Essure placement: report of two cases. Fertil Steril 2008; 89:724.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/51\">",
"      Hur HC, Mansuria SM, Chen BA, Lee TT. Laparoscopic management of hysteroscopic essure sterilization complications: report of 3 cases. J Minim Invasive Gynecol 2008; 15:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/52\">",
"      Beckwith AW. Persistent pain after hysteroscopic sterilization with microinserts. Obstet Gynecol 2008; 111:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/53\">",
"      Jansen NE, Vleugels MP, Kluivers KB, Vierhout ME. Bilateral cornual abscess after endometrial ablation following Essure sterilization. J Minim Invasive Gynecol 2007; 14:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/54\">",
"      Kerin JF, Cooper JM, Price T, et al. Hysteroscopic sterilization using a micro-insert device: results of a multicentre Phase II study. Hum Reprod 2003; 18:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/55\">",
"      Ubeda A, Labastida R, Dexeus S. Essure: a new device for hysteroscopic tubal sterilization in an outpatient setting. Fertil Steril 2004; 82:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/56\">",
"      Savage UK, Masters SJ, Smid MC, et al. Hysteroscopic sterilization in a large group practice: experience and effectiveness. Obstet Gynecol 2009; 114:1227.",
"     </a>",
"    </li>",
"    <li>",
"     Adiana Transcervical Sterilization System PMA P070022 Draft Panel Discussion Questions, p.2, December 14, 2007. www.fda.gov/ohrms/dockets/AC/07/questions/2007-4334%20q1%20FDA%20Draft%20Disc%20quest-Cytyc%20P070022.pdf. (Accessed on October 20, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/58\">",
"      Levy B, Levie MD, Childers ME. A summary of reported pregnancies after hysteroscopic sterilization. J Minim Invasive Gynecol 2007; 14:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/59\">",
"      Kerin JF, Cattanach S. Successful pregnancy outcome with the use of in vitro fertilization after Essure hysteroscopic sterilization. Fertil Steril 2007; 87:1212.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/23/12665/abstract/60\">",
"      Mijatovic V, Veersema S, Emanuel MH, et al. Essure hysteroscopic tubal occlusion device for the treatment of hydrosalpinx prior to in vitro fertilization-embryo transfer in patients with a contraindication for laparoscopy. Fertil Steril 2010; 93:1338.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3277 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-201.248.109.99-45DF552418-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12665=[""].join("\n");
var outline_f12_23_12665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACHES TO TRANSCERVICAL STERILIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HYSTEROSCOPIC STERILIZATION DEVICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COMPARISON WITH OTHER STERILIZATION APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patient counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Women using intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Timing and endometrial preparation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PREOPERATIVE SET-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Personnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CONCOMITANT OR SUBSEQUENT PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9272913\">",
"      Endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4673280\">",
"      - Prior to confirmation of tubal occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4673272\">",
"      - Subsequent to confirmation of tubal occlusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Routine postprocedure care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Confirming occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Post-procedure restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Tubal or uterine perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Device expulsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Pelvic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Device placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Contraceptive efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Micro-insert",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      PREGNANCY AFTER STERILIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24219815\">",
"      POLYMER MATRIX (no longer available)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3277\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3277|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/51/3888\" title=\"diagnostic image 1\">",
"      Hysterosc microinsert HSG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/35/37425\" title=\"diagnostic image 2\">",
"      Hysteroscopic microinsert HSG2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/13/28885\" title=\"diagnostic image 3\">",
"      Hysterosc microinsert ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3277|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/60/3010\" title=\"figure 1\">",
"      Hysterosc microins in tube",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3277|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/31/22013\" title=\"table 1\">",
"      Hysterosc steriliz protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/33/13851\" title=\"table 2\">",
"      Sterilization failure rates",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22951?source=related_link\">",
"      Hysteroscopy: Managing fluid and gas distending media",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=related_link\">",
"      Patient information: Care after gynecologic surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/28/7620?source=related_link\">",
"      Patient information: Permanent sterilization procedures for women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/51/23346?source=related_link\">",
"      Patient information: Sterilization for women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=related_link\">",
"      Reproductive surgery for female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15018?source=related_link\">",
"      Surgical sterilization of women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=related_link\">",
"      Uterine perforation during gynecologic procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_23_12666="Pyogenic granuloma 2";
var content_f12_23_12666=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52128%7EDERM%2F67395%7EDERM%2F52429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52128%7EDERM%2F67395%7EDERM%2F52429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma on the finger",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A rapidly growing, red, dome-shaped, friable papule with a collarette of scale is consistent with a pyogenic granuloma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher, GR, Ludwig, S, Baskin, MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A red, protruding vascular papule consistent with a pyogenic granuloma is present on the chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pyogenic granuloma: the epithelial \"collarette\" can be seen at the base of the lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12666=[""].join("\n");
var outline_f12_23_12666=null;
var title_f12_23_12667="NK deficiency syndromes";
var content_f12_23_12667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NK deficiency syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Responsible gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Deficiency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Infectious susceptibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ANKD",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Absence of CD56+ cells",
"       </td>",
"       <td>",
"        CMV, VZV, HSV, MAI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNKD",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Absence of CD56+/CD3- cells",
"       </td>",
"       <td>",
"        HPV, Trichophyton",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        FNKD",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        NK cytotoxicity, Cytokine responsiveness",
"       </td>",
"       <td>",
"        EBV, HSV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FCRG3A",
"       </td>",
"       <td>",
"        NK cytotoxicity",
"       </td>",
"       <td>",
"        HSV, VZV, EBV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12667=[""].join("\n");
var outline_f12_23_12667=null;
var title_f12_23_12668="Major clinical manifestations of GD at presentation";
var content_f12_23_12668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F85527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F85527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major clinical manifestations of Gaucher disease (all types) at presentation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical manifestation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"        <br/>",
"        (percent at presentation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Splenomegaly",
"       </td>",
"       <td class=\"centered\">",
"        All types",
"       </td>",
"       <td class=\"centered\">",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatomegaly",
"       </td>",
"       <td class=\"centered\">",
"        All types",
"       </td>",
"       <td class=\"centered\">",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenia",
"       </td>",
"       <td class=\"centered\">",
"        All types",
"       </td>",
"       <td class=\"centered\">",
"        68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia",
"       </td>",
"       <td class=\"centered\">",
"        All types",
"       </td>",
"       <td class=\"centered\">",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding",
"       </td>",
"       <td class=\"centered\">",
"        All types",
"       </td>",
"       <td class=\"centered\">",
"        Common",
"        <br/>",
"        (percent not reported)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteopenia",
"       </td>",
"       <td class=\"centered\">",
"        All types",
"       </td>",
"       <td class=\"centered\">",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone pain",
"       </td>",
"       <td class=\"centered\">",
"        All types",
"       </td>",
"       <td class=\"centered\">",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pathologic fractures",
"       </td>",
"       <td class=\"centered\">",
"        All types",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone crisis",
"       </td>",
"       <td class=\"centered\">",
"        All types",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Growth retardation",
"       </td>",
"       <td class=\"centered\">",
"        All types",
"       </td>",
"       <td class=\"centered\">",
"        36",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Charrow J, Andersson HC, Kaplan P, et al. The Gaucher Registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000; 160:2835.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12668=[""].join("\n");
var outline_f12_23_12668=null;
var title_f12_23_12669="Abnormal urine organic acids";
var content_f12_23_12669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Abnormal metabolites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Abnormal Metabolite(s)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Organic acidemias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylmalonic acidemia",
"       </td>",
"       <td>",
"        Methylmalonic &amp; methylcitric acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Propionic acidemia",
"       </td>",
"       <td>",
"        3-Hydroxypropionic acid, propionylglycine, methylcitric acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Isovaleric acidemia",
"       </td>",
"       <td>",
"        Isovalerylglycine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glutaric acidemia type I",
"       </td>",
"       <td>",
"        Glutaric, 3-hydroxyglutaric, &amp; dicarboxylic acids &amp; acylglycine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3-Methylglutaconic aciduria",
"       </td>",
"       <td>",
"        3-Methylglutaconic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2-Hydroxy-3-methylbutyryl-CoA dehydrogenase deficiency",
"       </td>",
"       <td>",
"        2-Hydroxy-3-methylblutyric acid, tiglyglycine, 2-ethylhydracrylic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2-Hydroxyglutaric aciduria",
"       </td>",
"       <td>",
"        2-Hydroxyglutaric acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Disorders of ketogenesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medium chain acyl-CoA dehydrogenase (MCAD) deficiency",
"       </td>",
"       <td>",
"        Hexanoylglycine &amp; suberylglycine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3-ketothiolase deficiency",
"       </td>",
"       <td>",
"        2-Hydroxy-3-methylbutyric acid, tiglyglycine, 2-methyl-3-hydroxyacetoacetic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3-Hydroxy-3-methylglutaryl(HMG)-CoA lyase deficiency",
"       </td>",
"       <td>",
"        3-Hydroxy-3-methylglutaric, 3-methylglutaric &amp; 3-methylglutaconic acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Canavan disease",
"       </td>",
"       <td>",
"        N-acetylaspartic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glutaric acidemia type II (Multiple acyl-CoA dehydrogenase deficiency)",
"       </td>",
"       <td>",
"        Glutaric &amp; 2-hydroxyglutaric acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mevalonate kinase deficiency",
"       </td>",
"       <td>",
"        Mevalonic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maple syrup urine disease",
"       </td>",
"       <td>",
"        2-Hydroxyisovaleric, 2-hydroxy-3-methylvaleric, &amp; 2-ketoisocaproic&nbsp;acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phenylketonuria",
"       </td>",
"       <td>",
"        Phenylpyruvic &amp; phenyllactic acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fumarase deficiency",
"       </td>",
"       <td>",
"        Fumaric acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glutathione synthetase deficiency",
"       </td>",
"       <td>",
"        5-Oxoproline (pyroglutamic acid)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Biotinidase deficiency&bull;",
"       </td>",
"       <td>",
"        3-Hydroxyisovaleric acid, methylcitric acid, 3-methylcrotonylglycine, propionylglycine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Holocarboxylase synthetase deficiency&bull;",
"       </td>",
"       <td>",
"        3-Hydroxyisovaleric acid, methylcitric acid, 3-methylcrotonylglycine, propionylglycine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glycerol kinase deficiency",
"       </td>",
"       <td>",
"        Glycerol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ethylmalonic encephalopathy",
"       </td>",
"       <td>",
"        Ethylmalonic &amp; methylsuccinic acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Disorders of uncertain consequence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3-methylcrotonyl-CoA carboxylase deficiency",
"       </td>",
"       <td>",
"        3-methylcrotonylglycine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Short chain acyl-CoA dehydrogenase deficiency",
"       </td>",
"       <td>",
"        Ethylmalonic acid, butyrylglycine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Other abnormal metabolites may be seen in these disorders but these listed are the most characteristic for the diagnosis.",
"     <br>",
"      &bull; Diagnosis by urine organic acid analysis is unreliable.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of V Reid Sutton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12669=[""].join("\n");
var outline_f12_23_12669=null;
var title_f12_23_12670="Calculation vascular resistance";
var content_f12_23_12670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Calculation of systemic and pulmonary vascular resistance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 170px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Or mean pulmonary artery wedge pressure (mmHg).",
"     <br>",
"      &bull; Use measured cardiac output if no shunt is present.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12670=[""].join("\n");
var outline_f12_23_12670=null;
var title_f12_23_12671="AC followed by TH regimen";
var content_f12_23_12671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) for HER2-positive* breast cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: AC is given every 21 days for four cycles; paclitaxel (T) and trastuzumab (H) are given every seven days of a 28 day cycle for three cycles. Following completion of T, H is given weekly for a total treatment duration of 52 weeks",
"        <sup>",
"         &Delta;",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doxorubicin",
"        </strong>",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with normal saline (NS) to a final concentration of 2 mg/mL and administer as an IV bolus over three to five minutes into a free flowing IV infusion of NS or 5 percent dextrose in water (D5W). The presence of local erythematous streaking along the vein as well as facial flushing may be signs that administration is too rapid. If needed, doxorubicin can be further diluted after reconstitution in NS or D5W and given as a slow IV infusion administered over 15 to 60 minutes",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cyclophosphamide",
"        </strong>",
"       </td>",
"       <td>",
"        600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 to 500 mL NS or D5W and administer over 30 to 60 minutes. Rapid infusions may produce nasal burning or congestion that is relieved by slowing the rate.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Following AC, administer:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Paclitaxel",
"        </strong>",
"       </td>",
"       <td>",
"        80 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL NS or D5W to a final concentration of 0.3 to 1.2 mg/mL and administer over one hour; special tubing needed",
"        <sup>",
"         &loz;",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Days 1, 8, 15, and 22",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Trastuzumab",
"        </strong>",
"       </td>",
"       <td>",
"        4 mg/kg IV loading dose, followed by 2 mg/kg",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS and administer over 90 minutes for the loading dose and over 30 minutes for subsequent doses.",
"        <strong>",
"         DO NOT",
"        </strong>",
"        mix with D5W, and",
"        <strong>",
"         DO NOT",
"        </strong>",
"        infuse as an IV push or bolus.",
"       </td>",
"       <td>",
"        Weekly for 52 weeks",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days thereafter) and void frequently to reduce the risk of hemorrhagic cystitis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Paclitaxel may cause severe hypersensitivity reactions. Premedication regimen should include dexamethasone (either 20 mg orally twelve and six hours before, or 20 mg IV 30 minutes before drug administration) plus both an H1 (diphenhydramine 25 to 50 mg IV) and an H2 receptor antagonist (ranitidine 50 mg or famotidine 20 mg IV) 30 to 60 minutes prior to paclitaxel administration. Severe infusion reactions (eg, skin rash, flushing, dyspnea, urticaria, back pain, hypotension, chest pain, tachycardia) occur primarily during the first and second infusions, typically within the first hour after the start of the infusion. Further information on infusion reactions, including management, is available. Trastuzumab may also cause infusion reactions. These can be severe, though most are mild; they typically occur during or within 24 hours of the first infusion. The most common symptoms are fever, chills, nausea, headache, abdominal pain, and dyspnea; less often are vomiting, dizziness, rash, rhinitis, or hypotension. Most clinicians do not routinely premedicate prior to the first trastuzumab dose.",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Trastuzumab infusion should be discontinued for anaphylaxis (bronchospasm, hypotension, angioedema). Further information on infusion reactions and their management is available. Refer to UpToDate topics on \"Infusion reactions to systemic chemotherapy\" and \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Doxorubicin is a vesicant and can cause significant tissue damage if an extravasation occurs. For peripheral infusions, the IV line should be recently placed into a large, intact vein, with good blood return established immediately prior to starting the infusion. The IV or catheter site should be continuously monitored throughout drug administration infusion. If extravasation occurs, apply ice to the site and consider use of dexrazoxane. Paclitaxel can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Not applicable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Dose adjustment is not necessary for doxorubicin or paclitaxel in renal impairment. The need for cyclophosphamide dose reduction in renal insufficiency is controversial. For patients with preexisting hepatic impairment, dose adjustments in doxorubicin, cyclophosphamide, and paclitaxel may be needed. The available data suggest that disposition of trastuzumab is not altered based on serum creatinine (&le;2 mg/dL). Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\". For patients with preexisting hepatic impairment, dose adjustments in doxorubicin, cyclophosphamide, and paclitaxel may be needed. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiac issues:",
"        </strong>",
"        A baseline assessment of LVEF is recommended, with periodic reassessment during therapy. The risk of doxorubicin-associated cardiac dysfunction is related to cumulative dose. The risk for cardiotoxicity is increased in patients with underlying heart disease, when anthracyclines are used concurrently with other cardiotoxic agents (including paclitaxel and trastuzumab) or radiation, and in patients previously treated with mediastinal or chest wall irradiation. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines",
"        <sup>",
"         [2]",
"        </sup>",
"        . Trastuzumab is associated with cardiotoxicity, and reassessment of LVEF prior to therapy (after completion of AC) is indicated. Information on use of trastuzumab according to baseline cardiac evaluation is available. Refer to UpToDate topics on \"Cardiotoxicity of anthracycline-like chemotherapy agents\" and \"Cardiotoxicity of trastuzumab\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Pulmonary issues:",
"        </strong>",
"        Trastuzumab has been associated with serious pulmonary toxicity (including acute respiratory distress syndrome [ARDS] and interstitial pneumonitis) and should be used with caution in patients with preexisting pulmonary disease",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment with AC and paclitaxel (or every three weeks if dosing paclitaxel every three weeks).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Serum electrolytes and liver and renal function tests prior to each treatment cycle of AC and paclitaxel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in neurologic function prior to each treatment cycle of paclitaxel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess cardiac function prior to AC and prior to initiation of trastuzumab.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess cardiac function prior to trastuzumab and at 3, 6, 9, 12, and 18 months after starting trastuzumab.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; During treatment with AC and paclitaxel, assess line site periodically during infusion of chemotherapy for signs and symptoms of extravasation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Patients should be closely monitored for infusion reactions, especially during the first two courses of trastuzumab. Standing orders should be in place to allow immediate intervention without waiting for the physician to arrive.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Subsequent cycles should be delayed until the absolute neutrophil count is greater than 1000/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count greater than 100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . If there is more than a three week delay in treatment, a dose reduction of 25 percent is recommended",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        For patients who develop severe neuropathy (grade 3 or 4) that persists for a week or longer, the dose of paclitaxel should be reduced by 20 percent for subsequent courses of paclitaxel; hold if severe toxicity persists after dose reduction. Refer to UpToDate topic on \"Neurologic complications of non-platinum chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for hepatic or renal dysfunction:",
"        </strong>",
"        Guidelines for managing doxorubicin, cyclophosphamide, and paclitaxel in patients who have changes in kidney or liver function during therapy are addressed in detail separately. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiotoxicity:",
"        </strong>",
"        Guidelines for managing trastuzumab in patients with symptomatic cardiac dysfunction or asymptomatic changes in LVEF during therapy are addressed in detail separately. Refer to UpToDate topic on \"Cardiotoxicity of trastuzumab\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Pulmonary toxicity:",
"        </strong>",
"        Discontinue trastuzumab if patients develop ARDS, interstitial pneumonitis, or pulmonary fibrosis. Refer to UpToDate topics on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\" and \"Taxane-induced pulmonary toxicity\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there are other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; LVEF: left ventricular ejection fraction; ARDS: acute respiratory distress syndrome; CBC: complete blood count.",
"     <br>",
"      * High levels of HER2 overexpression, as determined by either 3+ immunohistochemical staining (IHC) or positive fluorescence in situ hybridization (FISH), are used to select patients for therapy with trastuzumab. Refer to UpToDate topic on \"HER2 and predicting response to therapy in breast cancer\".",
"      <br>",
"       &Delta; Trastuzumab can also be administered as a 4 mg/kg loading dose week 1, then 2 mg/kg weekly for a total of 12 weeks (concurrent with paclitaxel), followed one week later by 6 mg/kg infused over 30 to 90 minutes every three weeks to complete a total 52 weeks of therapy.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.",
"        <br>",
"         &sect; Paclitaxel can be administered weekly (80 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         ) for 12 weeks, or it can be given as a dose of 175 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         every 21 days for four cycles",
"         <sup>",
"          [1]",
"         </sup>",
"         .",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Romond EH, et al. N Engl J Med 2005; 353:1673.",
"      </li>",
"      <li>",
"       Adriamycin (doxorubicin hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).",
"      </li>",
"      <li>",
"       Herceptin (trastuzumab) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_23_12671=[""].join("\n");
var outline_f12_23_12671=null;
